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3.1 List of candidate residues for mutagenesis to increase the tolerance of the
CpI FeFe-hydrogenase for CO. The symbol X indicates that the residue
has also been previously tested/proposed [1, 2] for disrupting the
diffusion network of the competing inhibitor O2 in this enzyme (This




1.1 The protein-protein interaction (a) between a protein and a peptide (Protein
Data Bank; PDB:1BXL), and (b) between two proteins (Protein Data
Bank; PDB:2B4J). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Locations of metal clusters in [FeFe]-hydrogenase are highlighted. The
protein-backbone is shown as ribbons, and metallic clusters are shown as
space-filling. The active-site domain of the protein is shown in blue
ribbons, and the non-active-site domain is shown in red ribbons. . . . . . . . . . . . 5
1.3 (a) Small-molecule structure with R1 and R2 functional groups (inset in box)
along with the chemical structures of all small-molecules studied. [4] (b)
A cartoon representation of the RGS4-Gαi1 complex (PDB code 1AGR)
is shown. Each of the 9 α-helices of RGS4 is colored and labeled, and the
location of four cysteine residues are shown by their Cα-atoms as orange
spheres with the C95 residue labeled. The Gαi1-subunit is shown in
transparent white ribbons, and the loops of Gαi1 in the proximity of
RGS4 are highlighted in black ribbons. (c) Sequence alignment of RGS4,
RGS8, and RGS19. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
1.4 The Structure of Phosphodiesterase 4 (PDE4), and studied inhibitors
(roflumilast, zardaverine, and IBMX are shown in green, yellow, and
blue, respectively) overlayed in the catalytic domain of PDE4. The
helices of PDE4 are labeled and colored. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.1 (a) The locations of 497 unique centers (the positions of the center-of-mass
of O2) chosen after TAMD sampling are highlighted. The
protein-backbone is shown as white ribbons and the extracted centers are
shown as spheres. The centers are colored from blue to red, based on
their distance to the H-cluster. (b) The running-average of mean forces
(kcal/mol.Å) for three Cartesian directions for one representative center
(blue, X-direction; red, Y-direction; green, Z-direction) are shown from a
1 ns (panel b) and 5 ns (panel c) mean-force calculation. . . . . . . . . . . . . . . . . 23
2.2 A snapshot of an MD simulation domain is shown. The H-cluster of
[FeFe]-hydrogenase and ions (green) are shown as space-filling, and water
molecules are shown as gray wireframe. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
xiv
3.1 Isosurfaces of the 3D-PMF map of O2 inside [FeFe]-hydrogenase are shown
in top panels. Energy levels are represented at (a) 3 kcal/mol, (b) 12
kcal/mol, and (c) 17 kcal/mol with respect to the global free-energy
minimum in proximity of the H-cluster. The local minima are
represented by red spheres. The backbone of protein is shown as ribbons,
the isosurfaces are shown as black mesh, and the H-cluster is shown as
sticks. In bottom panels, the proximal area of the central cavity (green
surface), channel A (red surface) and B (blue surface) [5], water pathway
(pink surface) [6], and the proton transport pathway (orange surface) [7]
are shown in surface representations as a front-view (d), a side-view (e),
and a back-view (f). The local minima are represented by black spheres
and labeled. The protein backbone is rendered as ribbons, and the
H-cluster is shown as sticks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2 (a) Pathways of O2 migration inside [FeFe]-hydrogenase, values of the PMF
along each MFEP and local minima, are indicated by color. The
pathways are represented as curved lines and the local minima as
spheres. (b) The connection between local minima along pathways are
shown by black arrows. The local minimum 0 corresponding to the
G-site is shown as a blue sphere, and the local minimum 1 corresponding
to the Xe-site is shown as a green sphere. The bottom panels show the
PMF profiles along MFEPs between local minima 1 and 2 (panel c),
local minima 2 and 3 (panel d), local minima 2 and 20 (panel e), local
minima 0 and 9 (panel f), local mlocal minima 0 and 1 (panel g), and
local minima 0 and 2 (panel h). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
3.3 (a) Front and back views of MFEPs for CO diffusion are depicted on the
structure of the FeFe-hydrogenase along with the positions of all minima
(indicated by spheres). (b) The MFEPs for CO diffusion from the other
local minima to the local minimum 7 are shown. (c) The MFEPs for CO
diffusion within 0-18 Å (leftmost panel), 18-25 Å (middle panel), and
over 25 Å (rightmost panel) of the local minimum 7 are shown. The
locations of the energy barriers are shown by transparent magenta
spheres in panels b and c (This figure was created by my co-author Yong
Liu. [3]). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
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3.4 The α carbon-atoms of several candidate residues investigated by earlier
studies (panel a) and proposed in this work (panel b) are shown. (a) The
residue P324 is located near the H-cluster and the G-site. The residues
I197 [8, 9], F417 [10], A321 [11], and V423 [11] are experimentally shown
to alter O2 diffusion in [FeFe]-hydrogenase. The hydrophobic residues
A426, A427 and V423 are located in the proximity of the Xe-site. The
residues F493 and A427 are along the pathway to the Xe-site. The
residues I276, A272, V423, F493 and A427 are proposed for mutation in
the patent application of King et al. [12] (b) Potential candidate residues
for mutations to alter the oxygen-diffusion kinetics in [FeFe]-hydrogenase
(A321 has been tested in study of Ghirardi et al. [11]) from our work.
The residues at the local minima are shown as blue spheres, and near the
energy barriers are shown as pink spheres. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
3.5 Locations of the minima for CO (filled spheres) and O2 (wireframe spheres)
diffusion in the CpI FeFe-hydrogenase are shown. The global minimum
for both gases are shown in black filled or wireframe spheres and are
labeled (G for CO and G-O2 for O2). The Xenon cavity is shown as a
pink sphere and labeled as Xe. For CO, colors of other minima are
consistent with Fig. 3.3: red (0-4 kcal/mol), green (4-8 kcal/mol), blue
(8-12 kcal/mol), and cyan (over 12 kcal/mol). For O2, colors of minima
indicate the following energy ranges: red (0-12 kcal/mol), green (12-16
kcal/mol), and blue (over 16 kcal/mol) (This figure was created by my
co-author Yong Liu [3]). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
4.1 (a) Small-molecule structure with R1 and R2 functional groups (inset in box)
along with the chemical structures of all small-molecules studied and the
mechanism of reaction to form an adduct with a cysteine residue on the
RGS4 [4]. (b) A cartoon representation of the RGS4-Gαi1 complex
(PDB code 1AGR) is shown. Each of the 9 α-helices of RGS4 is colored
and labeled, and the location of four cysteine residues are shown by their
Cα-atoms as orange spheres with the C95 residue labeled. The
Gαi1-subunit is shown in transparent white ribbons, and the loops of
Gαi1 in the proximity of RGS4 are highlighted in black ribbons. (c, d, e)
Cartoon representations of RGS4 conformations are shown for the
wild-type apo-RGS4, and in its conformationally changed models
(Models 1 and 2), respectively. Highlighted in cartoon representations are
α4-helices as cyan cartoons along with the C95 residues as space-filling.
The residue C95 is buried in the wild-type RGS4 structure but it is
accessible in Models 1 and 2. For each model, the structure of RGS4
(except the α4-helix) is rendered in a white surface representation. . . . . . . . . 57
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4.2 Docked initial conformations of TDZD compounds 1, 2, and 3 in Model 1
(panels a, b, and c) and Model 2 (panels d, e, and f) are shown. In all
snapshots, the protein backbone is shown in red ribbons as well as white
transparent surfaces, while compounds, along with the cysteine residue
C95, are shown in green space-filling representations. . . . . . . . . . . . . . . . . . . . . 58
4.3 Docked initial conformations of non-TDZD compounds 4 and 5 in Model 1
(panels a and b) and Model 2 (panels c and d) are shown. Coloring and
labeling schemes are identical to Fig. 4.2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.4 Root-mean-squared-fluctuation (RMSF) per residue are shown for Model 1
(panels a and b) and Model 2 (panels c and d) of RGS4. The RMSF
values are reported from two independent 1 µs long simulation runs (Run
1 and Run 2) for each model, where simulations were conducted with
TDZD analogues (compounds 1, 2, and 3 in Fig. 4.1a) covalently-bound
to the C95 residue of RGS4. As a baseline reference, the RMSF values of
the RGS4 structure without any compound (apo-form; black traces) are
also shown from our previous work [13]. The vertical bars labeled α1
through α9 demarcate the locations of residues in 9 α-helices of RGS4. . . . . . 61
4.5 The histograms of RMSD-averages computed based upon Models 1 and 2
are shown.Panels a and b show data from two independent runs of Model
1, and panels c and d show data from two independent simulations of
Model 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.6 The side-chains of aromatic residues in the vicinity of covalently-docked
compound 1 are shown at various time-points from two independent
simulations of Model 1 (panels a and b). The compound 1 is
covalently-linked to residue C95, and neighboring residues are labeled
and shown in green sticks. The protein backbone in all snapshots is
shown in a white transparent cartoon. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.7 The histograms of the buried surface area (BSA) between the α5-α6 helical
pair and the rest of RGS4 are shown for Model 1 (panels a and b) and
Model 2 (panels c and d). Data are shown for simulations of each model
conducted with TDZD congeners (compounds 1, 2, and 3). The vertical
dotted lines in panels indicate the values of BSA in the RGS4 crystal
structure (PDB: 1AGR). The BSA traces for apo-RGS4 computed from
a simulation reported in our previous work [13] are also shown (black
traces). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
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4.8 The histograms of average distances between the centers of mass of residues
involved in five salt-bridge-forming residue pairs are shown from two
independent simulations of Model 1 and Model 2 for three TDZD
compounds. The data for an apo-RGS4 simulation from our previous
work [13] are also shown (black histograms). The Cα-atoms of all
residues involved in salt-bridges are shown and labeled as red/blue
spheres on the RGS4 structure (inset in circle). . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.9 The data from RMSF (panel a/d), BSA (panel b/e), and salt-bridging
interactions (panel c/f) are shown from two simulations of each
non-TDZD compound in Model 1 (compound 4, yellow trace; compound
5, magenta trace). Other details in panels a/d, b/e, and c/f are similar
to Figs. 4.4, 4.7, and 4.8, respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
4.10 Data similar to those presented in Fig. 4.9 are shown from Run3 for
compounds 4 and 5 in which diffusion of each compound out of the
protein pocket was observed. The left-panels show data for parts of
trajectories when compounds still reside within the protein, and the
right-panels show data for the remaining parts of trajectories when
compounds have diffused out of the pocket. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.11 (a and b) Free energy profiles are plotted against the collective variable
(CV) for structural transitions (between open and closed states) in RGS4
when three TDZD compounds are docked in distinct pockets created in
Models 1 and 2. For each model, thermodynamically favorable
conformations of RGS4 bound to TDZD compounds are also shown as
cartoons in panels a and b. (c) For compound 2 in Model 2, highlighted
as cartoons are conformations of RGS4 showing spontaneous diffusion of
compound 2 (CCG-203769; Fig. 4.1a) from its initially-docked position
on the protein surface to within the α4-α7 helical bundle. The circle in
panel c denotes the combined location of covalently-linked residue C95
and compound 2. For all panels, the protein backbone in snapshots is
depicted in white ribbons except helices α4 through α7 that are uniquely
colored as in Fig. 4.1b (This figure was created by my co-author Hossein
Mohammadiarani [14]). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
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4.12 (a) A schematic highlighting the proposed mechanism of binding of TDZD
small-molecules to RGS4 is shown. In this scheme, the exposure of C95
(orange circle labeled C) in the apo-RGS4 conformation (panels 1 and 2)
allows initial covalent recognition (panel 3) of small-molecules (orange
circle labeled L flanked by filled/empty circles indicating R1 and R2
functional groups) and a subsequent migration of compounds to the core
of the α4-α7 helical bundle causing allosteric structural perturbations in
helices (panel 4), especially in residues in the RGS/Gα protein-protein
interface. (b) Previously proposed mechanism [15] for the exposure of
C95 in the apo-RGS4 conformation (panels 1 and 2) and subsequent
binding of compounds causing allosteric structural perturbations (panel
3). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
4.13 (a) The structures of the single-cysteine RGS4 construct (RGS4 C95) and
three compounds used in the flow cytometry protein-protein interaction
assay are shown. (b) Inhibition of the RGS4 C95/Gα protein-protein
interaction by compounds 1, 2 and 3 over a range of concentrations is
shown (This figure is provided by my co-author Vincent Shaw [14]). . . . . . . . 76
5.1 (a) Alignment of RGS19, RGS4, and RGS8 sequences in α4-α7 helix bundle.
Charged residues that make interhelical contacts are indicated in red and
blue. Structural alignments of α4-α5 (b and e), α5-α6 (c and f), and
α6-α7 (d and g) helix pairs are shown, with highlighted residues in panel
a rendered as sticks. RGS19 (PDB 1CMZ) is in green, RGS4 (PDB
1AGR) is in yellow, and RGS8 (PDB 2ODE) is in cyan (This figure was
created by my co-author Vincent Shaw [16]). . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
5.2 Thermal stability was determined by differential scanning fluorimetry. A)
The L118D mutation in RGS19 increased melting temperature by 7 ◦C
compared to WT. B) The E84L mutation in RGS8 decreased melting
temperature by 8 ◦C. C) The RGS4 D90L mutation introduced a
biphasic melt curve and increased melting temperature by 5 ◦C. For each
pair, derivative melt curves are shown on the left and melt temperatures
are shown on the right. Error bars represent SD. n=3. Analyzed by
1-way ANOVA with Sidak’s Multiple Comparisons test (This figure is
provided by my co-author Vincent Shaw [16]). ****p < 0.0001 . . . . . . . . . . . 86
5.3 Change in RMSF per residue (∆RMSF) between wild-type RGS proteins
and RGS proteins with mutation in the α4-α5 salt bridge forming
residue. (a) L118D in RGS19 (b) E84L in RGS8 and (c) D90L in RGS4.
Data represent differences in RMSF from two independent MD
simulations of the mutated and unmutated forms of RGS proteins. . . . . . . . . 87
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5.4 (a) Dynamic cross-correlation matrix calculated for the Cα atoms of (a)
RGS19/RGS19 L118D, (b) RGS8/RGS8 E84L, (c) RGS4/RGS4 D90L.
Horizontal dotted lines indicate the regions of the α4 helix, while vertical
solid lines indicate the regions of the α5 helix for each protein. The color
scheme ranges from anticorrelation (-1.0, blue), no correlation (0, green),
and positive correlation (+1.0, red). Values are the average for the two
independent simulation runs of each protein. . . . . . . . . . . . . . . . . . . . . . . . . . . 90
5.5 Difference in % deuterium incorporation (∆%DI) between mutated and
unmutated proteins in RGS19 L118D (A), RGS8 E84L (B), and RGS4
D90L (C) fragments, as measured by HDX. Red arrows indicate
fragments containing mutated residue, and black arrows indicate
fragments containing conserved α4 cysteine. Kinetics of deuterium
incorporation in these fragments for individual constructs are shown
below. n=3. Error bars represent SD. Analyzed by 2-way ANOVA with
Sidak’s multiple comparisons test (This figure is provided by my
co-author Vincent Shaw [16]). *p < 0.05, **p < 0.01, ****p < 0.0001 . . . . . 91
5.6 Potency of inhibition of CCG-50014 against α4 is altered in salt bridge
mutants of RGS proteins. (A) RGS4 IC50: 8.8 µM, RGS4 D90L IC50:
2.2 µM. (B) RGS8 IC50: 29 µM, RGS8 E84L IC50: 4.6 µM (C) RGS19
IC50: 7.0 µM, RGS19 L118D IC50: 1.1 µM. n=3 (This figure is provided
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6.1 Interactions of five key Cα-atoms of the 32 residues that interact with
ligands in (a) human PDE4D and (b) C. elegans PDE4 binding pocket.
The Zn and Mg ions are shown as gray and green spheres, respectively.
The three Asp residues coordinating with Zn and Mg ions are
highlighted by purple spheres. The Gln and Phe/Tyr residues are shown
as red and blue spheres, respectively. The protein backbone is
represented as ribbons, the Cα-atoms of residues of the binding pocket
and ions are shown as space-filling. (c) Changes in total non-bonded
interaction energy and its components for C. elegans PDE4 relative to
human PDE4D are shown for selected residues in the binding pocket
(labeled 1-5 in panel a and b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
6.2 The traces of root-mean-squared-deviation (RMSD) vs. simulation time (ns)
for PDE4D and C. elegans PDE4. (a and b) Two independent simulation
runs for complexes of human PDE4D and C. elegans PDE4 with IBMX,
zardaverine, or roflumilast. (c) RMSD traces of three independent
simulation runs of apo-PDE4D and apo-C. elegans PDE4. . . . . . . . . . . . . . . 101
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6.3 Probability (P) distributions of interatomic distances between ligand (O4
atom in roflumilast or zardaverine, or O6 atom in IBMX) and binding
pocket residues. a) shows measurements of d1 [between the oxygen atom
on the ligand and the Nδ atom on Gln535(human)/Gln282(C. elegans)]
and of d2 [between the oxygen atom of the ligand and the C4 atom of
Phe506 (human)/O atom on the side chain of Tyr253(C. elegans)]. b)
illustrates the distributions for distance d1 for C. elegans PDE4 (red)
and human PDE4D (yellow). c) shows the distributions for the distance
d2 for C. elegans PDE4 (blue) and human PDE4D (cyan). Vertical
dotted lines in panels b and c indicate the distances in the crystal
structures of inhibitors bound to human PDE4D. . . . . . . . . . . . . . . . . . . . . . . 102
6.4 Root-mean-squared-fluctuation (RMSF) per residue (top panel) and the
change in RMSF (∆RMSF) per residue (bottom panel) are shown for (a)
human PDE4D and (b) C. elegans PDE4 complexes with IBMX,
zardaverine, and roflumilast. The superimposed structures for human
PDE4D/C. elegans PDE4 along with superposition of IBMX,
zardaverine, and roflumilast ligands (sticks) are shown at the top. The
colored helices and vertical bars labeled α1 through α16 highlight the
location of residues in the 16 helices in the catalytic domain. The
Val334/81 and Met439/186 residues for human/C. elegans PDE4 are
shown by red and blue spheres, respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . 104
6.5 Dynamic cross correlation matrices calculated for the Cα atoms of human
PDE4D and C. elegans PDE4 complexed with IBMX (a), zardaverine
(b), and roflumilast (c). Residues in the α14 and α15 helices are shown
by areas between dashed-lines and solid-lines, respectively. Red
tick-marks on the axes represent the 32 residues in the binding site (as
depicted in Fig. 6.1a-b). The color scheme ranges from anticorrelation
(-1.0, blue), no correlation (0, green), and positive correlation (+1.0, red).
Values are the average for the two independent simulation runs. . . . . . . . . . . 109
6.6 Dynamic cross correlation matrices calculated for the Cα atoms of human
PDE4D and C. elegans PDE4 in their apo state. Color scheme is the
same as for Fig. 6.5. Panels a-c represent three independent
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6.7 Key salt-bridging interactions are shown based upon the first set of MD
simulations of human PDE4D and C. elegans PDE4 with IBMX (a),
zardaverine (b), and roflumilast (c). Three conserved salt-bridges are
labeled in blue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
6.8 Data similar to Fig. 6.7 are shown for a second set of MD simulations with
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6.9 Data similar to Fig. 6.7 are shown for three independent sets of MD
simulations of apo human PDE4D and apo C. elegans PDE4. . . . . . . . . . . . . 113
6.10 C. elegans PDE4 catalytic domain illustrating three conserved salt-bridges.
Residues participating in each salt-bridge are colored and labeled. The
three inhibitors are shown as sticks. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
6.11 Enzyme activity was tested over a range of inhibitor concentrations with 1
µM cAMP substrate 323 concentration. The dose-response relationship
was fit to a 3-parameter logistic equation to obtain the 324 IC50 and the
standard error of the mean for the indicated number of experiments
(This figure was created by my co-author Kevin Schuster). . . . . . . . . . . . . . . 119
A.1 The locations of centers are shown as blue points, and the mean-forces at
each point are shown as red arrow. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
A.2 The reconstructed 3D free energy surfaces are shown. The lower isosurfaces
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E.1 The effect of F417Y mutation on the PMFs along the pathway 1-0 (see Fig
3.2) in [FeFe]-hydrogenase. (a and b) Snapshots highlighting the location
of the wildtype F417 residue and the mutant Y417 residue along the
pathway 1-0 (yellow curve). Three points (in the collective variable
space) chosen to map the PMF are labeled and depicted as blue spheres
in panel a. The approximate locations of the Xe-site and the G-site are
marked by Xe and G, respectively. The H-cluster in each panel is labeled
and highlighted in a stick representation. (c) The PMF values (kcal/mol)
calculated with respect to the first point are shown for the WT protein
by blue filled squares, and for the mutated protein by black filled
squares. The increase in the free-energy value of the second point closest
to the mutated residue is showing a higher energy-barrier of oxygen
transition around Y417 toward the H-cluster in the mutated protein. . . . . . 205
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E.2 Energy barriers (kcal/mol) between local minima in the 3D PMF map
(Figure 3.2 in the main article). The value on the entry i j is the free
energy barrier when going from local minimum i to local minimum j.
The empty cells indicate negligible energy barriers or minima pairs that
are not connected. The G-site and the Xe-site are shown by local
minimum 0, and local minimum 1, respectively (Figure 3.2b). . . . . . . . . . . . . 206
E.3 Histogram of the standard deviation of each mean-force over the last 10% for
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E.5 Major energy barriers (kcal/mol) along MFEPs between minima pairs
(MFEPs are shown in Fig. 3.3) . The value on the entry i j is the free
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F.1 The traces of root-mean-squared-deviation (RMSD) vs. simulation time (µs)
for 4 helices in the α4-α7 helical bundle of RGS4 are shown from two
independent simulation runs (Run1, panel a; Run2, panel b) for
complexes of RGS4 with TDZD compounds 1 (cyan trace), 2 (green
trace), and 3 (magenta trace). The black traces show data for an
apo-RGS4 simulation from our previous work [13]. . . . . . . . . . . . . . . . . . . . . . 212
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F.3 The traces of buried surface area (BSA) between the α5-α6 helices and the
rest of RGS4 vs. simulation time (µs) are shown from two independent
simulation runs for each Model (Models 1 and 2). The BSA traces are
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F.4 Snapshots at various time-points for conformational evolution of complexes
of non-TDZD compounds 4 (panel a) and 5 (panel b) with RGS4 (Model
1). In each panel, snapshots from three independent simulation runs are
shown for each compound. Coloring and labeling schemes are identical to
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rest of RGS4 vs. simulation time (µs) are shown from three independent
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each panel highlights the BSA-value in the crystal structure of RGS4
(PDB: 1AGR). The symbols (×) on the BSA traces mark the locations
of time-points in Run3 of each compound (panel c) after which
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G.1 The traces of root-mean-squared-deviation (RMSD) vs. simulation time (µs)
for (a) RGS4 D90L, (b) RGS8 E84L, and (c) RGS19 L118D.Two
independent simulation runs for each structure are presented, and the
wild-type runs are presented from our previous work [13]. . . . . . . . . . . . . . . . 220
G.2 The salt-bridge interaction within the α4-α7 bundle of helices in
single-cysteine structures of RGS4, RGS8, and RGS19 from MD
simulations and potency of CCG-50014 inhibition of single-cysteine RGS
proteins from our previous work [13] (This figure was created by my
co-author Vincent Shaw). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 221
xxiv
H.1 The nonbonded interaction energy analysis between residues in the inhibitor
binding pocket of PDE4D and C. elegans PDE4 for the first simulation
run. See Fig. 6.1a and 6.1b for depictions of the binding pocket and the
32 residues analyzed with bound (a) IBMX, (b) zardaverine, and (c)
roflumilast. Amino acid residues in blue text denote residues that differ
between human and C. elegans PDE4 sequences. . . . . . . . . . . . . . . . . . . . . . . 222
H.2 The nonbonded interaction energy analysis between residues in the inhibitor
binding pocket of PDE4D and C. elegans PDE4 for the second
simulation run. (a) IBMX, (b) zardaverine, and (c) roflumilast. Amino
acid residues in blue text denote residues that differ between human and
C. elegans PDE4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223
H.3 Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of
Q369/Q282 (red dashed line, labeled 2) and the O6 oxygen of IBMX
bound to human PDE4D or C. elegans PDE4 obtained from two
independent MD simulation runs, (a) run 1 and (b) run 2. . . . . . . . . . . . . . . 224
H.4 Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of
Q369/Q282 (red dashed line, labeled 2) and the O4 oxygen of
zardaverine bound to human PDE4D or C. elegans PDE4 obtained from
two independent MD simulation runs, (a) run 1 and (b) run 2. . . . . . . . . . . . 225
H.5 Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of
Q369/Q282 (red dashed line, labeled 2) and the O4 oxygen of roflumilast
bound to human PDE4D or C. elegans PDE4 obtained from two
independent MD simulation runs, (a) run 1 and (b) run 2. . . . . . . . . . . . . . . 226
I.1 Shown is the journal cover image [17] related to work described in chapter 4
and in Ref. [14]. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
xxv
Abstract
Computational Studies of Protein-Inhibitor Interactions
In this thesis work, I conducted large-scale molecular dynamics (MD) simulation stud-
ies of interactions of enzymes and signaling proteins with inhibitory ligands. Specifically,
I have studied three classes of proteins: the first part of my thesis reports studies on the
hydrogen-producing [FeFe]-hydrogenase enzyme, the second part reports on studies of reg-
ulatory proteins from the G-protein coupled receptor (GPCR) family, and the third part
reports on studies of the phosphodiesterase (PDE) enzyme family.
In the first part, I studied the problem of [FeFe]-hydrogenase sensitivity to the presence
of inhibitory gases oxygen (O2) and carbon monoxide (CO) that cause irreversible damage
to the active site of this enzyme. Therefore, a detailed knowledge of the diffusion pathways
of these inhibitory gases is necessary to develop strategies for designing novel enzymes that
are tolerant to these gases. Specifically, I studied the diffusion pathways of O2 and CO in the
CpI [FeFe]-hydrogenase from Clostridium pasteurianum. I used several enhanced sampling
and free-energy simulation methods to reconstruct a three-dimensional free-energy surface
for diffusion of each gas which revealed free-energy minima forming an interconnected net-
work of pathways. I discovered multiple pathways of minimal free-energy as diffusion portals
for O2 and CO, and observed that the global minimum in the free-energy surface is located
in the vicinity of the active site metal cluster, the H-cluster. Among potential residues that I
propose as candidates for future mutagenesis studies to increase the tolerance of this enzyme
to both inhibitory gases, 11 residues are shared between O2 and CO. I hypothesize that these
shared candidate residues are potentially useful for designing new variants of this enzyme
that are tolerant to both inhibitory gases.
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In the second part, I have studied the interplay of protein conformational dynamics and ef-
fects of small-molecule inhibitors in a class of signaling proteins, known as the Regulators of
G protein signaling (RGS) proteins, that negatively modulate signaling in GPCRs. Recently
discovered thiadiazolidinone(TDZD) compounds that target cysteine residues have shown
different levels of specificities and potencies for several known RGS proteins, thereby sug-
gesting intrinsic differences in dynamics of these proteins upon binding of these compounds.
I characterized the effect of binding of several small-molecule inhibitors on perturbations and
dynamical motions in RGS4.
Specifically, I studied two conformational models of RGS4 in which a buried cysteine residue
is solvent-exposed due to side-chain motions or due to flexibility in neighboring helices. I
found that TDZD compounds with aromatic functional groups perturb the RGS4 structure
more than compounds with aliphatic functional groups. Moreover, small-molecules with aro-
matic functional groups but lacking sulfur atoms only transiently reside within the protein
and spontaneously dissociate to the solvent. I further probed the salt-bridges forming across
isoforms of RGS proteins, resulting in a hypothesis that differences in salt-bridges between
a pair of helices in RGS proteins are responsible for differences in flexibility and potency
among isoforms.
In the final part of my thesis, I evaluated differences in binding interactions of phospho-
diesterase 4 (PDE4) inhibitors within the PDE4 catalytic domain. From residues within 5 Å
of the ligand binding site, five residues revealed significant differences in non-bonded inter-
action energies that could account for the differential binding affinities of inhibitors. I found
one site (Phe506 in human PDE4; Tyr253 in the C. elegans PDE4 catalytic domain) that
alters the binding conformation of roflumilast and zardaverine (human PDE 4 inhibitors)
into a less energetically favorable state. These results support the feasibility of designing the
next-generation of anthelmintics/nematicides that could selectively bind to nematode PDEs.
Overall, my thesis has resulted in enhancement of detailed mechanistic insights into several
protein and inhibitory ligand interactions that are potentially useful in the developement of





The past decade has seen many advances in molecular understanding of regulatory systems
critical in physiology and pathology, and protein-protein interactions (PPIs) (Fig. 1.1) signify
a key objective space for pharmacological intervention. Recent genomics advances found that
there are up to 10000 disease related proteins [18], and yet only approximately 400 proteins
have been explored for therapeutic development. The majority of these proteins are the G
protein-coupled receptors (GPCRs), enzymes, ion channels, and nuclear hormone receptors
[19].
Figure 1.1: The protein-protein interaction (a) between a protein and a peptide (Protein
Data Bank; PDB:1BXL), and (b) between two proteins (Protein Data Bank; PDB:2B4J).
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Most of these disease related proteins exert their functions via interactions with other pro-
teins (Fig. 1.1), and recent developments demonstrate that PPIs can be modulated with
small-molecule drugs and peptides [19]. To enhance development of novel therapeutic com-
pounds, a molecular understanding of the structure and dynamics of interacting proteins is
essential.
1.2 Protein-Ligand Interactions
Protein functions are usually coupled to binding of small molecules such as substrates or
ligands. These ligands often interact with endogenous ligand-binding sites of their target
proteins. The modulation of a target protein by a ligand has been extensively explored for a
diverse range of objectives in drug discovery [19]. The interaction of a ligand with a protein
is a complex biophysical event, as the surface of a protein constitutes a multitude of polar
and hydrophobic sites that represent challenges to understanding the interaction mechanism
of a ligand with the target protein.
1.3 Classification of ligands
Ligands modulate proteins and PPIs via three broad mechanisms ([18]): (1) orthosteric in-
hibition, (2) allosteric regulation, and (3) interfacial binding. The orthosteric ligands bind
target proteins at the overlapping areas in PPIs, directly inhibiting the formation of macro-
molecular complexes. The allosteric inhibitors bind to their target protein at a site distinct
from the macromolecular interface. The interfacial inhibitors bind to a pocket at the inter-
nal space or macromolecular interface often transiently formed, and cause a nonproductive
conformation of the protein/protein complex. In this thesis, I studied three categories of
ligands, small-molecule interfacial inhibitors, orthosteric inhibitors and allosteric inhibitors.
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1.3.1 Small-Molecules Inhibitors
Small-molecule inhibitors have been extensively explored in modulation of many diseases
related to proteins [20]. These inhibitors could be as simple as small gas molecules O2 and
CO, that are known to inhibit enzymes with metallic clusters. Most proteins exert their
functions through interactions with other proteins, and they often lack obvious druggable
pockets for small molecules.
Although PPIs are essential for many aspects of cellular functions and provide vast potential
for drug development, targeting PPIs with small molecules is challenging for two main rea-
sons. Firstly, the interacting areas between proteins typically contain numerous polar and
hydrophobic interactions distributed across a large interface. Unless the interaction hotspot
can be identified, a small molecule with a reduced contact area with a protein has difficulty in
achieving effective binding due to lower interactions. Secondly, the protein-protein interfaces
are typically featureless. The lack of pockets limits the site of binding to only limited areas
of a small molecule; such binding is much less effective than binding with multiple areas in
a deeper pocket. Despite these difficulties, there has been a growing interest in identifying
small-molecule inhibitors against PPIs [21].
1.3.2 Allosteric Inhibitors
These small-molecule ligands bind to target proteins at sites distinct from the macromolec-
ular interface. Ligand binding induces changes in either the static conformation or the
dynamic properties of the target protein and hinders the macromolecular interaction in an
allosteric (distant) manner. In this thesis, I studied thiadiazolidinone (TDZD) compounds
that have been successfully exploited to modulate the activity of their target proteins al-
losterically.
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1.4 Background of Major Proteins Studied
In this thesis, I have studied three essential classes of proteins that are affected by ligands:
(i) [FeFe]-hydrogenase, (ii) Regulators of G-protein signaling (RGS) proteins, and (iii) Phos-
phodiesterase 4 (PDE4) enzyme. The hydrogen-producing [FeFe]-hydrogenase is a promising
source of renewable H2. RGS proteins are clinically significant drug targets. PDE4 enzymes
are drug targets for the development of nematicides. In this thesis, I explored these three
classes of proteins and their interactions with inhibitory compounds.
1.4.1 FeFe-hydrogenase
Biological H2 production from [FeFe]-hydrogenase, found in photosynthetic microorganisms,
is an attractive alternative source of renewable energy in future [22, 23, 24]. Among such
microorganisms, green algae and cyanobacteria are potential sources of H2 production be-
cause they have a maximum solar to hydrogen (STH) conversion efficiency [11, 25, 26]. The
hydrogenase family is broadly classified into [NiFe]-hydrogenase and [FeFe]-hydrogenase,
based upon the metal-cluster present in the active-site [27, 28]. In comparison to [NiFe]-
hydrogenase, [FeFe]-hydrogenase is primarily responsible for H2 production, but is signif-
icantly inhibited by O2 [29, 30]. In this work, I have focused on CpI [FeFe]-hydrogenase
from Clostridium pasteurianum. Fig. 1.2 shows the crystal structure (PDB code 1FEH) of
the CpI [FeFe]-hydrogenase containing 574 amino-acid residues, and six metal clusters: four
[Fe4S4] metal clusters, three of which are ligated to four cysteines, distal metal cluster that
is ligated to three cysteines and one histidine, and one surface cluster [Fe2S2] that is ligated
to four cysteines.
The central metal cluster, which is known as the H-cluster, consists of [2Fe]-subclusters with
ligation to carbonyl and cyanide groups [31]. Hydrogen production in this enzyme takes
place at the H-cluster buried inside the protein [32]. In [FeFe]-hydrogenase, the H-cluster
is a complex structure consisting of Fe2(CO)3(CN)2(dithiomethylamine), which is covalently
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Figure 1.2: Locations of metal clusters in [FeFe]-hydrogenase are highlighted. The protein-
backbone is shown as ribbons, and metallic clusters are shown as space-filling. The active-site
domain of the protein is shown in blue ribbons, and the non-active-site domain is shown in
red ribbons.
bound to an accessory metal cluster [Fe4S4] [33, 34, 35]. The side of the protein that harbors
the H-cluster (blue ribbons in Fig. 1.2), is designated as the active-site domain, and the side
of the protein that harbors other metal clusters, is designated as the non-active-site domain
(red ribbons in Fig. 1.2).
A major obstacle to achieving the goal of sustained H2 production is the inactivation of this
hydrogenase by oxygen [25, 26]. Although both NiFe and FeFe hydrogenases are sensitive
to inactivation by O2, [NiFe]-hydrogenases capable of naturally resisting the inactivation
by O2 with different metallic clusters were recently found [36, 37]. Recently, success has
also been achieved in improving the O2 sensitivity of [NiFe]-hydrogenase [38, 39, 40], but
no similar progress has been made on H2-producing [FeFe]-hydrogenase. It is thought that
the inactivation of [FeFe]-hydrogenase by O2 consists of diffusion of O2 from the solvent into
the enzyme interior, getting to the H-cluster buried in the core of the protein-matrix, and
subsequently binding to the H-cluster [5, 41, 42].
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Although the exact mechanism of inactivation of the H-cluster after binding of O2 is not
well understood, X-ray absorption measurements show that binding of O2 to the distal Fe
(Fed) in the H-cluster can subsequently damage the [Fe4S4] accessory cluster next to the H-
cluster [43, 44, 45, 46, 47]. It has been proposed that possible formation of reactive oxygen
upon O2 binding to Fed of the H-cluster and its diffusion toward the [Fe4S4] accessory-cluster
damages this cluster (cluster 1 in Fig. 1.2) [43, 48]. However, Swanson et al. [49] describe
a rather complex mechanism for degradation of the H-cluster, including the formation of
a reversible state before its full degradation. Aside from the H-cluster, Liebgott et al.
[50] have shown that by altering the structure of [NiFe]-hydrogenase using a site-directed
mutagenesis approach, the diffusion rate of O2 can be slowed by orders of magnitude, thereby
slowing the inactivation rate. This is accomplished by replacing the amino acids along known
gas diffusion channels with bulky amino acids, likely blocking the possible O2 diffusion
path within the protein [50]. Similarly, Nienhaus et al. [51, 52] show that CO diffusion in
myoglobin is altered by mutations of amino acids along CO-diffusion paths.
The presence of gas channels in [FeFe]-hydrogenase for O2 and H2 has been investigated both
computationally and experimentally. The existence of two main gas channels in the active-
site domain of the [FeFe]-hydrogenase has been proposed [5, 11, 53, 25]. Kubas et al. [10]
investigated the rate of O2 diffusion along these two main channels [10]. A major limitation
of these investigations has been a narrow understanding of O2 diffusion pathways within
the other parts of [FeFe]-hydrogenase, and interactions of these diffusion channels with each
other. Moreover, computational studies for gaining insights into ligand diffusion mechanisms,
such as O2 diffusion in [FeFe]-hydrogenase, is still an active area of research [54]. In fact,
Bingham et al. [55] have reported that the mutations in an area away from the two main gas
channels affect O2 diffusion noticeably, indicating the potential presence of other gas channels
in [FeFe]-hydrogenase or an allosteric communication between O2 binding sites. Although,
both Lautier et al.’s [6] and Ghirardi et al.’s [11] mutagenesis investigations suggest that O2
is possibly using the two main channels, the likelihood of the presence of other pathways
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for O2 within the protein was highlighted [6]. Indeed, a network of interconnected diffusion
pathways have been found for ligand diffusion in various proteins [56, 57, 58], clearly showing
the presence of key residues or reaction sites along the predicted pathways, and elucidating
the interconnected nature of diffusion pathways of ligands in proteins. Therefore, a better
understanding of gas diffusion in [FeFe]-hydrogenase is needed to develop strategies for its
functional modification. Thus, a detailed mapping of diffusion pathways of CO and O2 in
the FeFe-hydrogenase is not only needed for resolving these questions, but also for developing
approaches to enhance the tolerance of the FeFe-hydrogenase to inhibitory gases.
1.4.2 Regulators of G-protein signaling (RGS)
GPCRs are membrane proteins of profound clinical relevance [59, 60, 61, 62, 63], as they
mediate key roles in many cellular reactions to neurotransmitters and extracellular ligands
[64]. Signaling by GPCRs is negatively modulated by a family of proteins known as RGS
proteins that serve as a critical node in controlling various cellular responses [65, 66, 67,
68]. The mechanism of action of RGS proteins is to bind to activated (GTP-bound) G
protein α-subunits (Gα) and accelerate the rate of GTP-hydrolysis, resulting in conversion
of GTP to GDP and deactivation of Gα-subunits. By this mechanism, RGS proteins rapidly
dampen signaling by GPCRs, and therefore inhibitor candidates targeting RGS/Gα protein-
protein interaction are potentially useful to enhance signaling by GPCRs [69]. Inhibiting
protein-protein interactions, such as the one between an RGS protein and a Gα subunit,
is particularly challenging [70, 71, 72, 73], because of the lack of suitable binding pockets
for small-molecules at the RGS/Gα protein-protein interface. Although progress has been
made recently in the development of small molecules as covalent allosteric protein modifiers
[74, 75, 76, 77], application of small-molecule ligands for the inhibition of RGS proteins and
protein-protein interactions is an active area of research [78, 65, 79, 80, 81, 82, 70, 83, 84,
85, 4].
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Specifically, high-throughput screens have revealed several classes of small molecule inhibitors
acting through covalent modification of cysteine thiols on the RGS4 protein [85, 84, 86, 87],
which is a well-characterized member of the R4 subfamily [66]. Among them, the thiadi-
azolidinone (TDZD) inhibitor CCG-50014 and its congeners (Fig. 1.3a) have shown high
potency (measure of the concentrations of a drug at which it is effective) and specificity
(the degree to which the effects of a drug are due to the one pharmacological action) [4].
CCG-203769 is one of the congeners of CCG-50014 with two aliphatic side-chains, but with
substantially improved solubility [4]. RGS4 is highly expressed in the striatum [88, 89], regu-
lating synaptic plasticity in response to dopamine signaling [90, 91], and has been associated
with Parkinson’s disease [92]. The effectiveness of CCG-203769 on RGS4 has been demon-
strated through in-vivo studies, by reducing bradykinesia in a raclopride model of certain
Parkinson’s-like motor deficits in mice [93]. Furthermore, RGS4 has also been implicated in
cancer [94, 95, 96], heart rate control in the sinoatrial node [97], suppression of the anticon-
vulsant action of adenosine [98], and opioid receptor signaling [99].
Structurally, RGS proteins are defined by a conserved ∼120 residue-long box-domain with
nine α-helices [100]. The crystal structure of RGS4 bound to Gαi1 (PDB code 1AGR) is
shown in Fig. 1.3b [101], highlighting the RGS domain with each helix distinctly colored.
The crystal structure of RGS4 reveals the location of four cysteine residues (highlighted by
orange spheres in Fig. 1.3b), three of which are solvent-exposed and one cysteine residue
(labeled C95 in Fig. 1.3b) is buried. The C95-residue is also a conserved residue among
many RGS proteins, thereby making it an attractive target for covalent modification. Al-
though other cysteines in RGS4 play an important role in potent inhibition of RGS4 by
covalent inhibitors [84], these residues are not conserved among all inhibited RGS proteins.
Therefore, an understanding of the actions of TDZDs at C95 will be broadly applicable to
other RGS proteins. Importantly, TDZD compounds can allosterically inhibit the RGS/Gα
protein-protein interaction via the conserved and buried cysteine residue C95 [84, 85, 102].
Moreover, the activity of RGS4 is regulated allosterically by endogenous lipid modulators
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Figure 1.3. (a) Small-molecule structure with R1 and R2 functional groups (inset in box)
along with the chemical structures of all small-molecules studied. [4] (b) A cartoon repre-
sentation of the RGS4-Gαi1 complex (PDB code 1AGR) is shown. Each of the 9 α-helices
of RGS4 is colored and labeled, and the location of four cysteine residues are shown by their
Cα-atoms as orange spheres with the C95 residue labeled. The Gαi1-subunit is shown in
transparent white ribbons, and the loops of Gαi1 in the proximity of RGS4 are highlighted
in black ribbons. (c) Sequence alignment of RGS4, RGS8, and RGS19.
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at a site far from the Gα interaction interface but near the C95 residue, also known as
the “B-site” (the region marked by a circle in Fig. 1.3b) [65]. This allosteric site is also a
promising drug target as many physiological regulators of RGS4 directly interact with the
B-site [103, 104].
Figure 1.4. The Structure of Phosphodiesterase 4 (PDE4), and studied inhibitors (roflu-
milast, zardaverine, and IBMX are shown in green, yellow, and blue, respectively) overlayed
in the catalytic domain of PDE4. The helices of PDE4 are labeled and colored.
1.4.3 Phosphodiesterase 4 (PDE4)
The efficacy of and resistance to anthelmintic/nematicidal compounds for controlling
parasitic nematodes is a growing concern in the fields of medicine, veterinary medicine, and
agriculture [105, 106]. I have studied the human and nematode PDE4 enzyme for targeting
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nematode PDEs for the development of nematicides. The class I PDE superfamily in verte-
brates consists of eleven PDE families that share a conserved signature motif in the catalytic
domain [107]. The crystal structures of the catalytic domains of almost all the PDE fami-
lies have been solved, providing atomic-level details on the enzymatic and pharmacological
properties of enzymes in this superfamily [108].
The catalytic domain is made up of ∼330 amino acids whose secondary structure consists
of 16 α-helices (Fig. 1.4). These α-helices create three subdomains [109] which form a deep
catalytic pocket at their center. The active site is composed of two sub-pockets, which bind
two divalent metal ions and the substrate, respectively [108]. Zinc and magnesium ions are
stabilized by conserved His and Asp residues in the metal binding pocket [108]. For example,
the structure of the human PDE4 catalytic domain is stabilized by interactions with divalent
cations and Asp and His residues of the metal binding pocket as well as with conserved Gln
and Phe residues in the hydrophobic pocket. The invariant Gln residue of PDEs have been
shown to be critical for substrate and inhibitor binding [108].
1.5 Thesis Outline
In Chapter 2, I introduce details of all computational methods and software packages used in
my thesis work. These include the basics of molecular dynamics (MD) simulations, and other
related computational techniques. Chapter 3 describes studies of inhibitory gases O2 and
CO in FeFe-hydrogenase. Chapter 4 contains the results of studies of allosteric inhibitors for
the RGS4 protein. Chapter 5 contains the results of studies on coupling of protein dynamics
and salt-bridging interactions among RGS proteins. Chapter 6 provides structural studies
of inhibitors on human and nematode PDE4. Each chapter begins with a brief introduction
describing the background information. The introduction of each chapter is followed by
results and discussion. The usage of “we” in this thesis refers to work done in collaboration
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with other researchers and their contributions have been acknowledged throughout the thesis.
Appendices A through D contain samples of computer scripts and codes used in this thesis,
appendix E through H provides supporting information for chapters 3 to 6, respectively, and
appendix I highlights a cover image related to the work described in chapter 4. My brief





In this chapter, I describe specific methods in detail including classical MD and enhanced
sampling MD techniques. The software used are: VMD (Visual Molecular Dynamics) [110],
NAMD (NAnoscale Molecular Dynamics) [111], MD-TASK [112], ICM [113], and CHARM-
MGUI (CHARMM is an acronym for Chemistry at HARvard Molecular Mechanics) [114].
The analysis scripts were implemented in MATLAB (stands for MATrix LABoratory), TCL
(Tool Command Language), and Linux bash scripting. The computations were performed
on local supercomputing resources at UNH (Premise and Trillian), and Comet (San Diego
Supercomputer Center).
2.2 Molecular Dynamics Simulation
Statistical mechanics bridges macroscopic observations with microscopic details using sta-
tistical theories combined with classical physics concepts rooted in thermodynamics and
Newton’s laws [115, 116, 117]. In this context, an ensemble is the group of all microscopic
states that correspond to one macroscopic state. In other words, macroscopic properties
are statistical averages over multiple microstates of the system, also known as ensemble av-
erages. In statistical mechanics, different kinds of ensembles exist which are characterized
by fixed values of thermodynamic variables such as total number of particles N , volume V ,
temperature T , total energy E, or chemical potential µ [118]. In my thesis, all simulations
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were carried out either in the NVT ensemble or in the NPT ensemble. These two ensembles
are more commonly compared to experimental settings.
In my thesis work, I used MD simulations as a main tool to study complex interactions
between biomolecules and small-molecule inhibitors. Given the expensive nature of quantum
mechanical calculations, MD simulations provide a more practical way to study complex
biomolecules while retaining classical molecular models based on quantum calculations [119,
120, 121].
MD simulations are rooted in numerical techniques for solving equations of motion for a
large number of atoms. The basics of underlying equations of motion originate from classical
physics. The source of a force calculation in classical physics is a potential energy function
that plays a key role in describing the behaviour of a many-body system. The potential
functions account for both bonded and non-bonded interactions. The typical form of the
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The first term in the energy function accounts for bond stretches where kb is the bond
force constant and (b − b0) is the net displacement from equilibrium. The second term in
the equation accounts for angles where kθ is the angle force-constant and (θ − θ0) is the
angular deviation from equilibrium for three bonded atoms. The third term is for dihedrals
(also known as torsion angles) where kφ is the dihedral force-constant, n is the multiplicity
of the function, φ is the dihedral angle and δ is the phase shift. The fourth term accounts
for impropers, that is out of plane bending, where kω is the force constant and (ω − ω0) is
the out of plane angle deviation. The Urey-Bradley component (cross-term accounting for
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angle bending using 1,3 nonbonded interactions) comprises the fifth term, where ku is the
respective force constant and u− u0 is the distance between the 1,3 atoms in the harmonic
potential.
Nonbonded interactions between pairs of atoms (i, j) are represented by the last two terms.
The electrostatic interactions are represented by a Coulombic potential where qi represents
the charge of an atom, ε0 is the permittivity of free space, and rij is the distance between the
centers of mass of two atoms. The van der Waals forces are represented by a Lennard-Jones
potential function. In this equation, εij represents the energy well depth, σij is the hard
sphere radius [122]. There are no special terms to represent hydrogen bonding, as they are
treated as a sum of van der Waals and electrostatic interactions. For a potential function
used in an MD simulation, the above parameters are computed based on quantum-mechanical
calculations and optimized against experimental data [111].
In this thesis, I have used the CHARMM force-field with the CMAP correction [122, 123]
for all the MD simulations. CHARMM is the most common and a widely used force-field
for proteins, peptides, lipids, and small molecule ligands [124]. All small-molecules used in
this thesis and their force-fields were parameterized using the Multipurpose Atom-Typer for
CHARMM (MATCH) tool [125].
2.2.1 Components of an MD Simulation
2.2.1.1 Langevin Equation
To improve the dynamical stability of the system in an MD simulation, the equation of
motion is modified to a partially stochastic Langevin equation, which is given by:





F (r) = −∇U(r)
(2.2)
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where M is the mass of a particle, v = ṙ is the velocity, v̇ is the acceleration, F is the
force, U is the potential energy, r is the position vector, γ is the friction coefficient, kB is
the Boltzmann constant, T is the temperature, and R(t) is a univariate Gaussian random
process. The typical values of friction coefficient are 5 ps−1 or 10 ps−1. The second term
is for dissipative forces, and the last term adds fluctuations for stochasticity which crudely
mimics molecular collisions and viscosity in the realistic cellular environment.
2.2.1.2 Numerical Integration
For evolving the system in time, the equation of motion for each atom is numerically
integrated. The complexity and stochastic nature of biological systems work against the
convergence and stability of an integration algorithm.
The time-step (∆t∼1-2 fs) also increases the cost of numerical integration significantly.
The numerical integration algorithm also needs to maintain the accuracy of the system
properties, e.g., temperature and pressure, while being efficient even with the existence of
fluctuations in the system [111]. The Brünger-Brooks-Karplus (BBK) method [126], the
extension of velocity-Verlet algorithm [121], is the common scheme used in MD simulation
packages. The BBK method obtains the position and velocity of each particle through the
following recurrence relation:
rn+1 = rn +
1− γ∆t/2








where rn is the position vector, γ is the friction coefficient, ∆t is the time-step, M is
the mass of a particle, F is the force, kB is the Boltzmann constant, T is the temperature,
and Zn is a group of Gaussian random variables with a mean of zero and a variance of one.
In the BBK method, only one random variable is needed for each degree of freedom. This
method has a global error proportional to ∆t2 [127].
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2.2.1.3 Choice of integration time-step ∆t
The time step is an important parameter in an MD simulation for numerical integration
of differential equations for progress of the system. It is important because it determines the
extent of accuracy and convergence in MD simulations. On one hand, larger values of ∆t
will lead to instabilities in the integration scheme, but on the other hand, smaller values of
∆t will lead to limited exploration of the phase space and will increase the computational
cost. The choice of time-step needs to be adjusted to satisfy the numerical stability of
simulation, and convergence of the numerical integration scheme [128]. A suitable value
for ∆t in MD simulations of proteins for which the bonds to hydrogen atoms are fixed is
2 fs, and if the bonds to hydrogen atoms are not fixed, the suitable value for ∆t is 1 fs.
The implementation of a multiple-time-stepping algorithm could double the computational
efficiency [111, 128]. Multiple-time-stepping algorithms compute slow-varying-forces such as
long range electrostatics forces less frequently than fast-varying-forces such as Lennard-Jones
and short range electrostatic [128]. The limitation of this algorithm is in conserving energy
within a simulation system, which makes this scheme inapplicable to the NVE ensemble. In
this thesis, I have not used the NVE ensemble and used only the NPT or NVT ensembles in
MD simulations.
2.2.1.4 Initial conditions, minimization, temperature control, and pressure con-
trol
In an MD simulation, the initial coordinates of each atom in the system must be spec-
ified. As in a finite time-scale MD simulation, trajectories are highly dependent on initial
configurations. As expected, the initial configuration of proteins and other biomolecules
should be near a stable state of the system. The main repository for the initial configura-
tions of different proteins used in this thesis was the Protein Data Bank (PDB)1, which is
1http://www.rcsb.org/pdb/home/home.do
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the data repository for 3D structures of biomolecules determined by X-ray crystallography,
Nuclear Magnetic Resonace (NMR), and other approaches. In addition to initial coordinates
of the system, for solving the differential equations of motion, the initial values of all veloc-
ities should also be assigned. In an MD simulation, initial velocities to each atom from a







where v is the velocity, m is the particle mass and kBT is the product of Boltzmann’s
constant and the temperature. Based on the ergodic hypothesis in MD runs.
In MD simulations, boundary conditions of physical systems could be defined in three
possible ways: (i) vacuum, (ii) a reflecting wall, and (iii) periodic boundary conditions
(PBC). The simplest case for BC is vacuum, but the global properties computed will not be
representative of the condensed phase [129]. In the case of reflecting wall BC, for keeping
the atomic particles inside the simulation box, solid boundaries with a potential are applied
[130]. In PBC, a common practice in MD simulations and which is used in this thesis, par-
ticles are isolated in a simulation box that is infinitly replicated by periodic translations in
all dimensions [129]. In two-dimensions, each unit cell has eight nearest neighbors, while
in three-dimensions each unit cell would have 26 nearest neighbors. An atom or a particle
can leave the simulation box from one side, and consequently, it is replaced by an image of
the particle which enters from the opposite side of the unit cell, in doing so conserving the
number of particles in a simulation box, which is requirment of the NVT and NPT ensembles
used in this thesis.
Prior to an MD simulation, the initial configuration of the system obtained from PDB
may need preparation to add often missing hydrogen atoms or missing atoms in residues. In
most cases, the preparation of the system could include incorporating mutations, solvation,
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and ionization of the system. Upon preparation of the desired system for an MD simulation,
by using steepest descent or conjugate gradient schemes [131] the system arrangement in
space energy-minimized. In this thesis, for all pre-simulation systems, I used the conjugate
gradient method for minimization.
The temperature control for an MD simulation can be applied by a Langevin thermostat
where additional damping and random forces are introduced in the system. In this method,
the temperature of the system is maintained at the chosen value by frequently adjusting the
momenta of all atoms in the system. Other techniques used in MD schemes are the Ander-
sen thermostat [132] and the Berendsen thermostat. For pressure control, the Nosé-Hoover
barostat algorithms were used [133, 134, 135].
2.3 Software Packages for Biomolecular Simulations
2.3.1 MD Simulation
In my thesis, I have used NAMD (versions 2.11-2.12) as the primary software tool to
carry out MD simulations. NAMD is a parallel MD simulation code designed for large-scale
simulations of biomolecular systems [111]. NAMD is capable of effectively using hundreds of
processors on computational nodes in supercomputing clusters, and can be further deployed
on GPU architectures with a significant reduction in computation time. MD simulations of
very large systems of up to ∼64 million atoms are possible with NAMD [136]. The NAMD
package contains several efficient techniques to accurately control temperature and pressure,
and numerically integrating Newton’s equations of motion. NAMD is an open source code
package that is available2 to academic researchers, and its features can be modified by Tcl/Tk
scripting (Tk is the standard GUI for Tcl).
2http://www.ks.uiuc.edu/Research/namd/
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2.3.2 Modeling and Analysis
In this thesis, I primarily used NAMD’s companion software VMD (version 1.9) [110]
for visualization and analysis. VMD was used for preparing input files for NAMD, and for
extracting different properties from MD trajectories. VMD is a versatile software that can
run from a simple laptop up to GPU clusters, and it is able to perform parallel computations
for computationally intensive tasks.
In this thesis, I used MATLAB (versions 2016-2018) for various calculations, optimiza-
tions, and creating data plots. The numerous built-in functions, various toolboxes, and
libraries make MATLAB a unique tool for computational science researchers. I have pro-
vided all MATLAB codes in this thesis in Appendix A.
I used the MD-TASK package [112] for calculating dynamic cross correlation (DCC)
maps. I calculated the DCC maps of each system based on the Cα atoms of residues using
the MD-TASK package3 [112]. These maps are reported in Fig. 5.4 (chapter 5), and Fig. 6.5
and Fig. 6.6 (chapter 6). Each cell value (Cij) in the matrix of the DCC map was calculated







Where ∆ri represents the displacement from the mean position of atom i, and <> de-
notes the time average over the whole trajectory. The positive values of Cij show correlated
motion between residues i and j, moving in the same direction, whereas negative values of
Cij show anti-correlated motion between residues i and j, moving in the opposite direction.
3https://md-task.readthedocs.io/en/latest/home.html
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I also used Linux-based operating systems (openSUSE and Ubuntu) for working with
all local software packages, managing and deploying simulations on clusters, shell scripting
for analyzing data, and scripting. In Linux, bash shell is the terminal language for various
command line operations from simple tasks to analyzing data and for parallel calculations.
I have provided all useful bash codes in Appendix B and C. I used MobaXterm (version 9.4)
and Cygwin64 software for remotely accessed Linux-based workstations and supercomputing
clusters.
I used CHARMM-GUI4 and the MATCH web server5 to produce both the topology and
parameter files for small molecules. An important utility program termed catdcd (version
4.0) which is a built-in feature in VMD, was used for concatenating trajectory files and se-
lecting the desired segments of trajectories (Appendix D).
2.4 Advanced Sampling Methods
In a conventional MD simulation, due to a large number of degrees of freedom, the ex-
plored conformational space of biomolecules in limited [137]. Therefore, several enhanced
sampling methods have been developed to overcome the limitations of conventional MD sim-
ulations. Enhanced sampling methods such as temperature accelerated MD (TAMD) and
metadynamics are methods to accelerate sampling and overcome free-energy barriers for en-
hancing conformational exploration [111, 138, 139, 137]. In this thesis, I used metadynamics
and TAMD for enhanced sampling MD simulations in conjunction with a suite of methods,
called the single-sweep, for the free-energy reconstruction, and for finding the interconnected




methods are described in the following.
2.4.1 TAMD Algorithm
TAMD is a method of enhanced sampling to explore the physical free-energy landscape
[140], and has been successfully applied to a number of systems [142, 143, 144, 15]. TAMD
algorithm begins by defining an extended version of the physical system in which new vari-
ables, z, are coupled to the physical variables via collective variables (CV), θ(x)[145, 140].
The new total potential (U) contains, in addition to the physical energy (V (x)), a term that
couples CVs (θ(x)) to new z-variables, thus






Here, m is the number of CVs, κ is a spring constant and is an adjustable parameter. The
new variables z are assigned a fictitious mass (M) and a fictitious temperature (T̄ ) which is
different from that of the physical system. The evolution of the extended system is governed
by the following dynamical equations:
Mẍ = −∇xV (x)− κ
m∑
j=1
(θj(x)− zj)∇xθj(x) + thermostat at β−1 (2.7)
γ̄ż = κ(θ(x)− z) +
√
2β̄−1γ̄ηz (2.8)
where γ̄ is the artificial friction coefficient, β̄ is the inverse of the artificial temperature (β̄ =
1/(kBT̄ ), where kB is the Boltzmann’s constant), β is the inverse of the physical temperature
(β = 1/(kBT )), and ηz is the white-noise associated with the Langevin evolution of the new
variables.
2.4.1.1 Free-energy Reconstruction
The exploration of the protein interior space via TAMD results in a dense cloud of
ligand positions (Fig. 2.1). In this thesis, I have used the single-sweep method [141] for
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reconstructing the free-energy landscape in CVs that are TAMD-explored positions of the
center-of-mass of O2 and CO. This method has been successfully used as an efficient way of
computing multidimensional free-energies [141]. Out of a large number of explored positions,
it is necessary to choose a unique set of positions, namely centers, covering various areas of
the protein. For estimating the mean-force required to keep the ligand at those positions,
these centers are chosen along the trajectory based on a distance criterion: beginning with
the value z1 as the first center, a new point is added to the set when its distance from all
other members of the set exceeds a prescribed cut-off distance. In the end, a large number
of centers (∼300-700) are harvested (Fig. 2.1a). Each chosen location is referred to as a
“center”, and the kth center is indexed as zk.
Figure 2.1: (a) The locations of 497 unique centers (the positions of the center-of-mass of
O2) chosen after TAMD sampling are highlighted. The protein-backbone is shown as white
ribbons and the extracted centers are shown as spheres. The centers are colored from blue
to red, based on their distance to the H-cluster. (b) The running-average of mean forces
(kcal/mol.Å) for three Cartesian directions for one representative center (blue, X-direction;
red, Y-direction; green, Z-direction) are shown from a 1 ns (panel b) and 5 ns (panel c)
mean-force calculation.
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Here, κ is the spring constant, zk is the position vector of the kth center, t is the number
of time increments in the trajectory and θ is the center-of-mass of the single molecule as
a CV [58, 146]. The mean-force for each center was computed by using an MD simulation
with CVs restrained at the center using a coupling constant of 10 kcal/mol·Å2. The Cα
atoms of 3 residues were restrained using a spring constant of 2.0 kcal/mol·Å2 to orientally
restrained the protein during each force calculation, as has been employed in other appli-
cations [57, 58]. The solvent centers around protein were chosen and (Fig. 2.1a) for which
mean-forces were nearly negligible. The simulation for all centers are independent of each
other, and therefore are independently distributed among different computing nodes [56].
Each mean-force calculation lasts for 1 ns, after which the convergence of mean-force values
was observed (Fig. 2.1b). For some selected centers that needed more than 1 ns for force
convergence, calculations were continued up to 5 ns (Fig. 2.1c). The histogram of standard
deviation computed over the last 10% of each force calculation represent the convergence of
mean-forces by delta function at origin (Fig. E.4).
Given the harvested centers and their computed respective mean-forces, the global re-
construction of the free-energy surface (FES), A(z), was carried out as a linear combination





akϕσ(| z − zk |) + C (2.10)
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Here ϕσ is a Gaussian with a width of σ, K is the total number of centers, ak’s are coefficients
in expansion, and C is a constant for adjusting the height of A(z). The optimization method
based on the least-square fitting was used for obtaining the optimal values of σ and ak








ak′∇zϕσ(| zk − zk′ |) + f(zk) |2 (2.11)
2.4.1.2 Minimum free-energy pathways (MFEP)
Following the reconstruction of the free-energy surface, the minimum free-energy path-
ways (MFEP), as pathways of the single molecule diffusion on the FES, can be determined
using the zero-temperature string method (ZTS) [149]. These MFEPs are identified as the
diffusion pathways of ligands inside the protein [150]. The diffusion pathways are the net-
work of MFEPs that interconnect local minima and the solvent portals. Given an analytical
approximation of the free-energy landscape, obtained from the PMF reconstruction step, the
ZTS method gives MFEPs as the steepest-descent paths from saddle points on the recon-
structed FES [151, 149]. This optimization method starts from an initial guess for a curve on
the FES, and in a two-step iterative algorithm finds the optimal pathways; in the first step,
the points that were obtained by discretizing the line were allowed to move based on the
steepest descent on the FES landscape, while the second reparametrization step kept the dis-
tances between the points uniform [151, 152]. MFEPs are the most probable pathways that
one can take on the FES between two local minima [151, 152]. Since the three-dimensional
FES has been reconstructed and it is available analytically, the ZTS method was employed
without requiring further MD simulations [56].
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2.4.2 Metadynamics Simulations
Metadynamics is an enhanced sampling method for faster exploration of conformational
space in a specified set of collective variables (CVs) by augmenting the force-field with a














where ξi is the current value of the CV and ξi(t′) is the value of the CV at time t′. Vmeta is
constructed as a sum of Ncv-dimensional repulsive Gaussian functions with a chosen height
(W ) and width (δ). The Gaussian functions can be added at a desired frequency τG. The
three main parameters in metadynamics that control the efficiency and accuracy of the free
energy reconstruction from converged metadynamics potential (Vmeta) [139] are W , δ, and
τG. The metadynamics method has been successfully applied to study many biophysical
problems including computational drug design [155, 138, 156, 157, 158, 159, 160].
2.5 Procedures for MD Simulations
Three steps for carrying out MD simulations in NAMD are (i) solvation and ionization of the
initial configuration, (ii) simulating the system using the MD software, and (iii) analyzing
output files. These steps are described below.
All biomolecular systems are found in an aqueous environment with ions, and hence the
prepared systems of biomolecules need to be solvated with water and neutralized by adding
ions to mimic the physiological environment. The number of added water molecules need to
be adjusted, as more water molecules are added the size of the system will increase, thereby
increasing the computational cost. The solvate plugin in VMD provides the tool for solvation
of the system prior to an MD simulation. The autoionize plugin in VMD provides a tool
for adding ions to the solvated system. In this thesis, MD simulations of all systems were
carried out using NAMD. The generated trajectories were visualized and analyzed by the
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VMD software. In this thesis, I also used MATLAB and python based MD-TASK package
for futher analyzing trajectory data.
Figure 2.2: A snapshot of an MD simulation domain is shown. The H-cluster of [FeFe]-
hydrogenase and ions (green) are shown as space-filling, and water molecules are shown as
gray wireframe.
2.6 Computational Resources
The computational resources used in this thesis are as the following: (i) Lennard is a local
linux workstation assigned to me in our laboratory at the University of New Hampshire
equipped with 20 processors (model name : Intel(R) Xeon(R) CPU E5-2630 v4 @ 2.20GHz),
2 GB RAM, and a 2 TB internal hard-drive; (ii) the Trillian cluster, which was acquired
through an NSF Major Research Instrumentation (MRI) grant, with cost sharing from the
UNH Space Science Center ,Senior Vice Provost for Research, the College of Engineering and
Physical Sciences (CEPS), and the Research Computing Center (RCC). This supercomputer
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has 132 compute nodes, each with 2 AMD 16 core ’Abu Dhabi’ 2.4 GHz CPUs, for a total
of 4,224 cores; (iii) the Premise cluster which is made up of 37 compute nodes connected
together using 56 Gb FDR Infiniband networking, each node has two 12-core CPUs, all nodes
have at least 128GB of main memory. Ten nodes have NVIDIA K80 GPUs which I used
mainly in MD simulations because of the higher performance compared to non-GPU com-
pute nodes. The entire cluster shares 225TB of usable Lustre storage; and (iv) the Extreme
Science and Engineering Discovery Environment (XSEDE) which is a powerful collection of
integrated digital resources and services such as supercomputers, visualization and storage
systems, collections of data, software, networks, and expert support that scientists, engineers
around the world use to advance solving complex problems.
Comet is a dedicated XSEDE cluster, which was designed by Dell using Intel’s Xeon Pro-
cessor E5-2600 v3 family, with two processors per node and 12 cores per processor running
at 2.5GHz. Each compute node has 128 GB (gigabytes) of traditional DRAM and 320 GB
of local flash memory. Since Comet is designed to optimize capacity for modest-scale jobs,
each rack of 72 nodes (1,728 cores) has a full bisection InfiniBand FDR interconnect from
Mellanox, with a 4:1 over-subscription across the racks. There are 27 racks of these com-
pute nodes, totaling 1,944 nodes or 46,656 cores. In addition, Comet has four large-memory
nodes, each with four 16-core sockets and 1.5 TB of memory, as well as 36 GPU nodes, each
with four NVIDIA GPUs (graphic processing units). The GPUs and large-memory nodes
are for specific applications such as visualization, and MD simulations.
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CHAPTER 3
STUDIES ON DIFFUSION PATHWAYS OF INHIBITORY
GASES IN [FeFe]-HYDROGENASE
3.1 Abstract
The H2 production potential of [FeFe]-hydrogenase, a hydrogen-producing enzyme from green
algae, is reported to be promising for economical and large-scale production of H2 as an alter-
native source of renewable energy. The production of hydrogen takes place at the catalytic
center buried in the enzyme core. Unfortunately, binding of O2 and CO to the catalytic
center of the enzyme irreversibly inactivates it, essentially blocking hydrogen production.
Therefore, a better understanding of the mechanism of O2 and CO entry/exit is necessary to
develop strategies for designing oxygen-tolerant enzymes. In this work, I have investigated
the pathways and diffusion channels of O2 and CO gases in [FeFe]-hydrogenase. Through
exhaustive mapping of O2 and CO diffusion channels, I computed a full thermodynamic
map of preferred binding locations of O2 and CO gases within the enzyme interior, which
showed that O2 and CO can enter and exit the enzyme through multiple pathways along
which are key residues that are known to perturb binding rates of O2 and CO binding. The
global minimum for each gas in the free-energy landscape is located near the H-cluster, a key
metallic center within the enzyme. Along O2 and CO diffusion channels, I further identified
several residues that could be potential candidates for mutations to increase the tolerance
of [FeFe]-hydrogenase to both inhibitory gases.
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3.2 Background
Enzymes use their active sites to exquisitely perform essential processes in living organisms
by catalyzing chemical transformations. Given that the active sites are buried within the
protein matrices, ligand migration between the solvent and the active site is an indispensable
process for chemical reactions to occur. This observation hints at the existence of ligand en-
try/exit channels through which the activity of enzymes can be modulated by altering ligand
diffusion (e.g. limiting the diffusion of inhibitory gases) [161, 162]. Although permanent
diffusion channels may not exist in flexible structures of enzymes, transient thermal fluctu-
ations throughout the protein matrix can potentially lead to the formation of a network of
metastable pockets that can serve as conduits for site-to-site hopping of ligands.
Described in this chapter are studies on the thermodynamics of ligand diffusion pathways in
the FeFe-hydrogenase, an enzyme of the hydrogenase superfamily, that is reported to be a
key source of biological hydrogen production due to its ability to catalyze proton reduction
and/or H2-oxidation under optimal conditions [163, 164, 165, 166, 167, 168, 169]. The
crystal structure of the CpI FeFe-hydrogenase from Clostridium pasteurianum revealed a
deeply-buried active site (the H-cluster) with three 4Fe4S and one 2Fe2S accessory metal-
clusters [170, 171]. The H-cluster is comprised of one Fe4S4 subcluster and one 2Fe subcluster
with a vacant site on Fed (distal) which can bind different ligands [167] including inhibitory
gases CO and O2 that can severely hamper the enzymatic activity of the FeFe-hydrogenase.
Specifically, it has been suggested that O2 attacks and irreversibly deactivates the H-cluster,
while CO can compete with O2 for binding to the H-cluster and prevent inhibition by O2
when the enzyme is oxidizing H2 or is at the resting state (no reaction) [172, 173, 174].
Regardless, CO can still irreversibly deactivate the enzyme during H2-production [174]. Im-
portantly, both CO and O2 attack the same site, the Fed of the 2Fe subcluster of the H-cluster
[175, 176, 177]. Moreover, with CO binding to the active site, O2 cannot access the active
site, and previous studies have suggested a faster binding rate for CO than O2 [178, 175].
30
Since accessing the active site requires channels connecting to the solvent, several possible
scenarios can be hypothesized to explain the phenomenon of the protective effect and inhi-
bition by CO: (a) CO diffuses faster than O2 if both gases compete for the same diffusion
pathway; (b) CO migrates along shorter diffusion pathways if each gas has an independent
pathway; and/or (c) CO has a higher binding-affinity for Fed than O2. Therefore, a detailed
mapping of diffusion pathways of CO and O2 in the FeFe-hydrogenase is not only needed for
resolving these questions, but also for developing approaches to enhance the tolerance of the
FeFe-hydrogenase to inhibitory gases.
Furthermore, to improve the tolerance of hydrogenase enzymes to inhibitory gases, mutations
in specific amino-acid residues have been carried out. For example, the rates of CO and H2
diffusion in another enzyme of the hydrogenase family, D. fructosovorans NiFe-hydrogenase,
can be decreased after mutations of two residues (V74 and L122) [175, 178]. However, it
is highly challenging to rationally choose residues for mutations among a large number of
residues (e.g. 574 residues in the CpI FeFe-hydrogenase), especially without the knowledge
of diffusion channels and the location of the free-energy barriers along them. This is evident
in an experimental study on mutations of seven residues in the CpI FeFe-hydrogenase (C299,
F417, V423, A427, A431, I461, and F493), where none of the residues showed any strong
effect on the kinetic performance of this hydrogenase although some of these residues (A427,
A431, I461, F493) are located in the pathway A [176]. This suggests the existence of ad-
ditional pathways for gas diffusion in the FeFe-hydrogenase. Indeed, my previous study [1]
disclosed an exhaustive mapping of the diffusion network of O2 in the CpI FeFe-hydrogenase
showing several new pathways to access the active site besides those previously suggested.
We also suggested several new candidate residues lining diffusion pathways of O2 whose mu-
tations have the potential to significantly disrupt the O2 diffusion network, as these residues
are located in the vicinity of the free-energy barriers. However, no studies on the exhaustive
mapping of the diffusion pathways of the competing inhibitor CO in the FeFe-hydrogenase
have been carried out so far although pathways of CO diffusion in structurally-unrelated
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NiFe-hydrogenase have been studied [179].
Hypothesis: An interconnected network of migration pathways exists for inhibitory
gases throughout CpI [FeFe]-hydrogenase.
Therefore, I have studied the pathways and diffusion channels of O2 and CO in CpI
[FeFe]-hydrogenase by employing a judicious combination of enhanced sampling and free-
energy reconstruction methods [56]. By finding the three dimensional free-energy of O2 and
CO binding within the enzyme, and interconnected network of diffusion pathways of both
inhibitory gases, unique insights into O2 and CO diffusion in [FeFe]-hydrogenase have been
obtained. The results show that, the global minimum in the free-energy landscape is in the
proximity of the H-cluster binding site (location where O2 bind to the H-cluster), and another
local minimum is in the proximity of the Xe-binding site (an experimentally found location
for xenon presence [180]). The work shows the presence of numerous interconnected path-
ways of O2 and CO diffusion toward the H-cluster beyond the two main channels, providing
enhanced information on other areas of protein affecting O2 diffusion. Moreover, along each
pathway, energy barriers and local minima in the free-energy surface can be readily found.
The important residues along the obtained pathways are prime candidates for guiding and
designing [FeFe]-hydrogenase tolerant to both inhibitory gases.
3.3 Methods
3.3.1 System Setup
I carried out all MD simulations (section 2.2) using the CHARMM force-field for proteins,
ions, water, and metal clusters [122, 181, 182]. I prepared a fully-solvated and ionized simu-
lation domain using the initial coordinates for all protein atoms from the crystal structure of
the FeFe-hydrogenase (PDB code 1FEH), solvating with explicit water (TIP3P) molecules,
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Figure 3.1: Isosurfaces of the 3D-PMF map of O2 inside [FeFe]-hydrogenase are shown in
top panels. Energy levels are represented at (a) 3 kcal/mol, (b) 12 kcal/mol, and (c) 17
kcal/mol with respect to the global free-energy minimum in proximity of the H-cluster. The
local minima are represented by red spheres. The backbone of protein is shown as ribbons,
the isosurfaces are shown as black mesh, and the H-cluster is shown as sticks. In bottom
panels, the proximal area of the central cavity (green surface), channel A (red surface) and
B (blue surface) [5], water pathway (pink surface) [6], and the proton transport pathway
(orange surface) [7] are shown in surface representations as a front-view (d), a side-view (e),
and a back-view (f). The local minima are represented by black spheres and labeled. The
protein backbone is rendered as ribbons, and the H-cluster is shown as sticks.
and ionizing with NaCl. After an initial energy minimization of this system for 1000 steps,
the box-volume was equilibrated by conducting a 1-ns long molecular dynamics (MD) sim-
ulation in the NPT ensemble, where the temperature was controlled at 310 K using the
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Langevin thermostat and the pressure was controlled using the Nosé-Hoover barostat. An
integration time-step of 1 fs, periodic boundary conditions, the particle-mesh Ewald sum-
mation (with a grid spacing of 1 Å) for long-range electrostatics, and a cutoff distance of
10 Å for van der Waals interactions was used. For exhaustive exploration of gas diffusion
using enhanced sampling methods, I created several initial systems, each differing only in the
initial position of gas molecule, which was chosen to span various locations throughout the
enzyme matrix. Each of these systems was MD equilibrated for 1 ns in the NPT ensemble
using the protocol described above. The coordinates from the end of the MD trajectories of
these equilibrated systems were used as initial conditions for TAMD simulations (vide infra).
3.3.2 TAMD Simulations
I applied TAMD (section 2.4.1) for exhaustively exploring the gas-accessible interior vol-
ume of the FeFe-hydrogenase by using the Cartesian coordinates of the center-of-mass of each
gas as the three-dimensional CV-space. In TAMD simulations, β̄−1 values ranging between
2 kcal/mol and 7 kcal/mol, a spring constant κ of 200 kcal/mol·Å2, and a fictitious friction
coefficient γ̄ of 50 ps−1 were used. Starting from each of the initial locations of each gas, 30
independent 1-ns long TAMD simulations were performed resulting in a total of ∼ 300−600
ns of simulation time for exhaustive sampling of each gas diffusion.
3.3.3 Free-energy Surface Reconstruction and Minimum Free Energy Pathways
To reconstruct the 3D-FES of O2 and CO diffusion in the FeFe-hydrogenase, we used the
single-sweep method [141, 56] in which mean-forces are computed at CV positions sampled
by TAMD (section 2.4.1). Specifically, it is necessary to choose distinct CV positions, also
termed unique centers, throughout the protein matrix. Due to the rotation and translation
of the protein, all TAMD trajectories were aligned to a common reference structure for ex-
tracting centers. Out of all gas positions sampled by TAMD, we chose several unique centers
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(Fig. 2.1a). The centers were chosen by beginning with the first center (z1) and adding
new centers such that the distance of each new center from all previous centers exceeds a
prescribed cutoff distance.
To compute the mean-force at each of the k centers, fk, we launched a set of new MD
simulations in which the center-of-mass of O2 and CO is harmonically restrained about the
CV-value at the chosen center. We conducted restrained MD simulations by using a spring
constant κ of 10 kcal/mol·Å2. Each of these simulations generally lasted for 1 ns within
which we observed the convergence of the mean-force (Fig. 2.1b), but some centers required
simulations up to 5-ns long for the convergence of the mean-force (Fig. 2.1c). We show
the convergence of all mean-force calculations by plotting the histogram of the standard
deviation of each mean-force calculation computed over the last 10% of each restrained MD
trajectory. This histogram reveals the behavior of a delta function centered at the origin
indicating convergence (Fig. E.4).
Using converged mean-forces at all centers, we globally reconstructed the free-energy sur-
face A(z) (section 2.4.1.1) as a linear combination of Gaussian radial basis functions by
obtaining the optimized parameters (coefficients, ak; and the Gaussian width, σ) via a least
square fitting procedure per equation [141]. We further studied the 3D-FES using the zero-
temperature string (ZTS) method [183, 184, 185, 186] (section 2.4.1.2) and found MFEPs
between all pairs of minima as the steepest descent paths from saddle points on the analyti-
cally reconstructed free-energy hypersurface, A(z). Therefore, MFEPs are the most probable
pathways between pairs of minima on A(z) and are identified as the diffusion pathways for
O2 and CO inside the enzyme. We also note that the application of the ZTS method does not
require any additional MD simulations since the analytical functional form of the 3D-FES
is available from equation.
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3.4 Results
3.4.1 Mean Force Estimation and PMF Map Reconstruction for O2
The centers were selected as described in Chapter 2 (Section 2.4, Fig 2.1a). The converged
mean-force values for 497 centers (chapter 2) were used for the reconstruction of the free-
energy landscape of O2 diffusion (inside the [FeFe]-hydrogenase), as a linear combination of
radial basis functions using the single-sweep method [56]. In Figures 3.1a to 3.1c, I show
isosurfaces of the 3D-PMFs, obtained from single-sweep calculations for O2, at three energy
levels of 3, 12, and 17 kcal/mol with respect to the global energy minimum in the free-energy
landscape. The obtained 3D-PMF of O2 binding sites on scale of the entire protein elucidates
the detailed physical insight of O2 transport in this protein. The global minimum in the PMF
is located in the vicinity of the active-site pocket of the [FeFe]-hydrogenase (local minimum
0 in Figures 3.1d to 3.1f), and I found a free-energy difference of ∼18.5 kcal/mol between
the global minimum and the solvent space.
In addition to global minimum, we identified 22 other local minima within the protein
matrix (Figures 3.1d to 3.1f). I observed a local minimum in the proximity of the only
known Xe-binding site [187] that is near the central cavity [5] and next to the H-cluster
(local minimum 1 in Figures 3.1d to 3.1f). The relative free-energy difference for this local
minimum is ∼13.31 kcal/mol with respect to the global minimum. I further observe local
minima 2 and 20 (Figures 3.1d to 3.1f) within a previously identified water pathway [6]
(pink surface in Figures 3.1d to 3.1f) that extends from the solvent to the central cavity [6]
(green surface in Figures 3.1d to 3.1f). The local minimum 2 is in the proximity of S320
(with a free-energy of 11.72 kcal/mol), and the local minimum 20 is in the proximity of the
surface-exposed K571 (with a free-energy of 13.76 kcal/mol). Several other local minima are
located throughout the protein matrix with a large number of them in the active-site domain
(Figure 3.1).
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3.4.2 Diffusion Pathways of O2 in [FeFe]-hydrogenase
I characterized diffusion pathways of O2 in [FeFe]-hydrogenase by computing MFEPs
between pairs of local minima located in the 3D-PMF (see methods section for details). In
Figures 3.1a to 3.1c, I show the locations of all local minima by red spheres. The MFEPs
are relatively dense in the vicinity of the H-cluster in the active-site domain of the protein,
and in the non-active-site domain, I find MFEPs only near the protein surface (Figure 3.2a).
The pathways to the Geminate-site (G-site, a location near the global minimum indicated
by 0/0-G in Figure 3.2a,b) are largely originating in the lower side of the active-site domain
via the central cavity (green surface in Figures 3.1d to 3.1f), in the water pathway [6] (pink
surface in Figures 3.1d to 3.1f), and in the upper-part of the active-site domain.
In Figure 3.2a, I show the diffusion pathways of O2 within the [FeFe]-hydrogenase with
color-coded values of the free-energy. The global minimum, located next to the H-cluster,
is shown by a blue sphere, on the side of the distal Fe-site of the H-cluster [49]. The local
minimum corresponding to the Xe-binding site inside [FeFe]-hydrogenase is designated as
minimum 1, and the MFEP that connects the Xe-site to the G-site is shown by a pathway
between minima 0 and 1 (Figure 3.2a), and the barrier of this MFEP is in the proximity of
A272. The local minimum 2 and 20 are in the proximity of S320 and K571, respectively;
both have MFEPs to the G-site (Figure 3.2a). The energy barrier of the MFEP between the
local minimum 2 and the G-site is in the proximity of A321.
The local minimum 9 is in the proximity of cluster 1, and the MFEP between the G-site
and local minimum 9 shows a pathway for O2 with access both to the H-cluster and to
the adjacent [Fe4S4] cluster. The local minima 7, 8, and 19 with free-energy values of 11.86,
12.18, and 8.88 kcal/mol are located within the active-site domain, and the pathway between
them has access to the H-cluster from the local minimum 7, and has access to cluster 1 from
the local minimum 19. The access of O2 to the local minima 7, 8, and 19 from pathways
originating in the active-site domain is more likely due to lower energy barriers (Figure 3.2a).
The Xe-site has access to the local minima 2 and 4 (Figure 3.2a) with the energy barriers
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Figure 3.2: (a) Pathways of O2 migration inside [FeFe]-hydrogenase, values of the PMF
along each MFEP and local minima, are indicated by color. The pathways are represented
as curved lines and the local minima as spheres. (b) The connection between local minima
along pathways are shown by black arrows. The local minimum 0 corresponding to the G-site
is shown as a blue sphere, and the local minimum 1 corresponding to the Xe-site is shown
as a green sphere. The bottom panels show the PMF profiles along MFEPs between local
minima 1 and 2 (panel c), local minima 2 and 3 (panel d), local minima 2 and 20 (panel e),
local minima 0 and 9 (panel f), local mlocal minima 0 and 1 (panel g), and local minima 0
and 2 (panel h).
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of 7.72 and 0.76 kcal/mol, indicating that it is easier for O2 to enter the Xe-site from the
local minimum 4 than from the local minimum 2. The local minimum 6 is located within
the channel B (blue surface in Figures 3.1d to 3.1f), as described by Cohen et al. [5], and
it is connected to local minima 2 and 4 with energy barriers along MFEPs of 1.57 and 1
kcal/mol, suggesting that the energy barriers are lower along the pathway 6-4-1 than the
pathway 6-2-1.
The energy barrier for O2 entering the G-site from the Xe-site (pathway 1-0) is 3.6
kcal/mol, whereas the energy barrier from the local minimum 2 to the G-site (pathway 2-0)
is 7.29 kcal/mol, suggesting that it is easier for O2 to access the H-cluster from the Xe-
site than from the local minimum 2. The sum of energy barriers along three pathways to
the H-cluster starting from local minimum 6, pathways 6-4-1-0, 6-2-0, and 6-2-1-0 are 5.36,
8.86, and 12.89 kcal/mol, suggesting that it is unlikely for O2 to take pathway 6-2-1-0 in
comparison to pathways 6-2-0 and 6-4-1-0 (Figure 3.2b). The local minimum 3 is located
within the channel A (red surface in Figures 3.1d to 3.1f), as identified by Cohen et al.[5],
and it is connected to the local minimum 2 with an energy barrier of 4.33 kcal/mol along
the MFEP. The two pathways to the H-cluster starting from the local minimum 3, pathways
3-2-0 and 3-2-1-0, have energy barriers of 11.62 and 15.65 kcal/mol, suggesting that O2
diffusion is less likely along the pathway 3-2-1-0 than the pathway 3-2-0 to the H-cluster
(Figure 3.2b). A table of energy barrier values between local minima is reported in Table
E.5.
The free-energy profiles for MFEPs between local minima 0 and 1, local minima 1 and 2,
local minima 2 and 3, local minima 0 and 2, local minima 0 and 9, and local minima 2 and
20 (Figure 3.2c to 3.2h) are showing the change in PMF values as O2 is migrating along the
pathway between them, and all PMFs are shown with respect to the global minimum at the
G-site (indicated by 0 in Figure 3.2b). The pathways on the upper side of the H-cluster, e.g.,
pathway 7-8-19-9, are suggesting the existence of a O2 circulation network with relatively
low-energy barriers around the H-cluster; however O2 migration is less likely to direct to
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pathways in the non-active-site domain due to higher energy barriers, e.g., energy barrier of
the pathway 9-12 is 11.96 kcal/mol, suggesting that it is unlikely for O2, after entering the
protein from the active-site domain, to access the non-active-site domain versus entering the
protein from the active-site domain to access the H-cluster.
The local minima 21 and 22 with free-energy of 16.91 and 18.21 kcal/mol, respectively, are
located in the solvent. These PMF values are showing an estimate of the free-energy values
in the solvent and suggest an oxygen diffusion gradient toward the protein interior. The
local minimum 22 is connected to the local minimum 3 that has access to the H-cluster via
channel A (Figures 3.2b) [5]. The local minimum 21 is connected via an MFEP to the local
minimum 0 or the G-site with an energy barrier of 1.8 kcal/mol which is in the proximity of
F570, suggesting that this particular pathway potentially provides the easiest access route
for O2 to the H-cluster. This pathway is located between the channel B [5] and the water
pathway [6]. The local minimum 20 with an energy of 15.34 kcal/mol is located within the
water pathway, and is connected to the local minimum 2 and the G-site with energy barriers
of 1.04 and 3.5 kcal/mol, indicating that it is less likely for O2 to migrate along pathways
20-2-1-0 or 20-2-0 than the pathway 20-0. The pathway 9-0 is in the proximity of residues
K358 and E361, defining the water-based proton transfer pathway [188, 7] (orange surface in
Figures 3.1d to 3.1f). The free-energy profile of O2 diffusion along this pathway is shown in
Figure 3.2f indicating an energy barrier of 4 kcal/mol along this MFEP. The local minimum
10 with a free-energy value of 14 kcal/mol is connected to the local minimum 9. Via this
pathway, O2 entry from the local minimum 10 could be directed to the proximity of cluster
1 and to the H-cluster, suggesting that the pathway 10-9-0 could be another access route for
O2 to access the H-cluster, and similarly, the pathway 13-5-1-0 shows another possible route
to the H-cluster.
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Figure 3.3: (a) Front and back views of MFEPs for CO diffusion are depicted on the structure
of the FeFe-hydrogenase along with the positions of all minima (indicated by spheres). (b)
The MFEPs for CO diffusion from the other local minima to the local minimum 7 are shown.
(c) The MFEPs for CO diffusion within 0-18 Å (leftmost panel), 18-25 Å (middle panel),
and over 25 Å (rightmost panel) of the local minimum 7 are shown. The locations of the
energy barriers are shown by transparent magenta spheres in panels b and c (This figure was
created by my co-author Yong Liu. [3]).
3.4.3 Network of CO Diffusion Pathways
We located an MFEP for each pair of local minima using the zero-temperature string
(ZTS) method [183, 184, 185] (section 2.4.1.2). The ZTS-algorithm begins with an initial
guess for a curve connecting the chosen minima pair on the analytically-reconstructed 3D-
FES. This initial guess is then iteratively optimized via a discretized parameterization scheme
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by keeping points along the curve equidistant on each iteration while allowing points to move
on the basis of the steepest descent on the 3D-FES. Therefore, MFEPs are the pathways
of minimal free-energy for CO diffusion in the FeFe-hydrogenase, which are assumed as the
most likely diffusion channels for CO.
We show the network of these pathways in Fig. 3.3a, where one can visualize the color-
coded free-energy values along with the MFEPs between local minima pairs (depicted as
spheres). Consistent with the 3D-FES, we found that the MFEPs of CO diffusion along
previously proposed hydrophobic pathways have high free-energy values (over 8 kcal/mol),
which are shown as blue curves. We also observed that the MFEPs interconnect multiple local
minima between the solvent-space and the H-cluster. We present a center-by-center matrix of
energy barriers between all pairs of local minima in Appendix E. We find that major energy
barriers along MFEPs originating from the global minimum to neighboring local minima are
∼10 kcal/mol, and these barriers are higher than the energy barriers of reverse MFEPs. This
suggests a preference for CO diffusion toward the global minimum. Previous studies have
suggested that CO binds the Fed of the 2Fe subcluster of the H-cluster, thereby competing
with the binding of O2 [174, 178, 175]. To explore the CO diffusion pathways connecting the
solvent region and the H-cluster, we present the MFEPs of CO diffusion between the local
minimum 7 (which is located in the vicinity of the Fed of the 2Fe subcluster of the H-cluster,
an area known as the geminate site) and other neighboring minima (Fig. 3.3b and 3.3c).
The locations of the major energy barriers along MFEPs are indicated by magenta spheres
(Fig 3.3c).
Within 18 Å of the H-cluster, we identified 12 local minima, including the global min-
imum: 5 minima with the free-energy values lower than 4 kcal/mol (red/black spheres), 3
minima with the free-energy values in the range of 4 to 8 kcal/mol (green spheres), 3 minima
with the free-energy values in the range of 8 to 12 kcal/mol (blue spheres), and 1 minimum
with a free-energy value of 18.20 kcal/mol (cyan sphere).
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The energy barriers for pathways 2-7 and 5-7 are 2.45 kcal/mol and 5.23 kcal/mol, re-
spectively. The pathways 3-7, 23-7, and 24-23-7 have energy barriers of 9.29 kcal/mol, 3.61
kcal/mol, and 7.58 kcal/mol, respectively. The pathways 17-7 and 35-7 share a part of their
MFEPs, but the major energy barriers are located at distinct positions, in the vicinity of
the residue F328 for the pathway 17-7 vs. the residue D273 for the pathway 35-7. The
MFEP originating at the minimum 30 passes through the minimum 26 before arriving at the
minimum 7. Therefore, the pathways 30-7 and 26-7 share the same major energy barrier of
2.49 kcal/mol. The pathway 43-7 passes through the local minimum 35 as well as the global
minimum (G), and both MFEPs 43-7 and G-7 have the same major energy barrier of 14.62
kcal/mol. This suggests that a deep local minimum with high energy barriers of CO escape
could trap CO.
Within 18 to 25 Å of the H-cluster, we found 20 additional distinct local minima, most
of which are located at or near the surface of the enzyme and likely serve as local reservoirs
for CO as it enters from the solvent. The local minima 4, 6, 8, 9, and 10 have free-energy
values lower than 4 kcal/mol (relative to the global minimum). The pathways 6-7 and 9-7
share part of their MFEPs as well as the location of the major energy barrier in the vicinity
of the residue A230, but the values of the free-energy barriers for each pathway are distinct,
9.29 kcal/mol (pathway 6-7) and 8.15 kcal/mol (pathway 9-7). Also, the pathways 6-7 and
9-7, respectively, pass through the minima 3 and 23, two minima located within 18 Å of
the H-cluster (left panel; Fig. 3.3c). Similarly, the pathway 4-7 passes through the local
minimum 5 and shares a part of its MFEP with the pathway 19-7 as well as the location
of the major energy barrier in the vicinity of the residue V352, but the value of the energy
barrier for each pathway is different, 5.23 kcal/mol for the pathway 4-7 (same value as for the
pathway 5-7) and 8.15 kcal/mol for the pathway 19-7. Even though the pathways from the
local minima 8, 37, 38, and 39 to the minimum 7 merge in the pathway 17-7, the locations of
the major energy barriers along the MFEPs of 8-7, 37-7, and 38-7 are different. Specifically,
the barriers along pathways 8-7, 37-7, and 38-7 are located near residues F348, I567, and
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A331, respectively. The energy barrier for the pathway 39-7 is in the vicinity of residues
S323 and Q325. Since the pathway 29-7 passes through the local minimum 35, the location
of the energy barrier is same as for the pathway 35-7. Several other pathways show shared as
well as unique features: the pathways 10-7, 41-7, 32-13-7 and 18-5-7 merge into the pathway
2-7, but the location of the energy barrier for each pathway is different, and the pathways
31-13-30-26-7, 36-26-7, 42-30-26-7, and 44-26-7 merge into the pathway 26-7, but the energy
barriers for 31-13-30-26-7 and 36-26-7 are located in the unshared parts of their MFEPs
and the energy barriers for 42-30-26-7 and 44-26-7 are located in the shared part 26-7. The
pathway 36-7 passes through the global minimum and has the same value for the major
energy barrier with the same location as the pathway G-7.
We observed 13 local minima at a distance over 25 Å from the Fed of the H-cluster,
most of which are located in the non-active-site domain of the enzyme (rightmost panel in
Fig. 3.3c). Among these 13 minima, two (12 and 40) are located in the solvent region near
the enzyme surface and show MFEPs reaching to the minimum 7: the pathways 12-19-5-7,
19-5-7, 4-5-7, and 5-7 all arrive at the minimum 7 and along which the major energy bar-
rier of 5.23 kcal/mol is shared, and the pathway 40-7 passes through the local minimum
43 as well as the global minimum to arrive at the local minimum 7. The MFEPs of sev-
eral other minima in the non-active-site domain merge at the local minimum 2, but each
MFEP has a different location and magnitude of the energy barrier (see Tables E.5 and E.6).
3.5 Discussion
In this chapter, we have presented details on characterizing O2 and CO diffusion channels and
their underlying thermodynamics via a combination of several state-of-the-art computational
methods [145, 140, 141, 150]. The 3D-PMF for O2 binding shows a preference for O2 diffusion
into the protein interior relative to the solvent. The preference for protein environment by
O2 has been similarly observed in the earlier work of Cohen et al. [5]. The global minimum
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Table 3.1: List of candidate residues for mutagenesis to increase the tolerance of the CpI
FeFe-hydrogenase for CO. The symbol X indicates that the residue has also been previously
tested/proposed [1, 2] for disrupting the diffusion network of the competing inhibitor O2 in
this enzyme (This table was created by my co-author Yong Liu [3]).








G302 42-26, 31-26 X
S323 39-7, 25-7 X
Q325 39-7, 25-7
V352 19-7, 4-7 X








in the free-energy is close to the residue P324 and the H-cluster (Figure 3.4a), in the vicinity
of an area termed as the G-site (Geminate) [10]. The G-site is a location one step away
from covalent binding of O2 to the H-cluster that irreversibly inactivates the protein. The
noticeable difference in the free-energy between the global minimum and other local minima
would make it difficult for O2 to leave the global minimum to other areas of the protein
matrix, thus making binding to the H-cluster highly likely, because this is the only path
from the G-site that leads to a lower free-energy, as also highlighted in previous studies
[10, 5]. All local minima with energies close to the global minimum are in the active-site
domain of the protein, whereas those local minima in the non-active-site domain of the
protein have energy values closer to those in the solvent.
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Figure 3.4: The α carbon-atoms of several candidate residues investigated by earlier studies
(panel a) and proposed in this work (panel b) are shown. (a) The residue P324 is located
near the H-cluster and the G-site. The residues I197 [8, 9], F417 [10], A321 [11], and V423
[11] are experimentally shown to alter O2 diffusion in [FeFe]-hydrogenase. The hydrophobic
residues A426, A427 and V423 are located in the proximity of the Xe-site. The residues F493
and A427 are along the pathway to the Xe-site. The residues I276, A272, V423, F493 and
A427 are proposed for mutation in the patent application of King et al. [12] (b) Potential
candidate residues for mutations to alter the oxygen-diffusion kinetics in [FeFe]-hydrogenase
(A321 has been tested in study of Ghirardi et al. [11]) from our work. The residues at the
local minima are shown as blue spheres, and near the energy barriers are shown as pink
spheres.
3.5.1 O2 Pathways in the Vicinity of the Xe Site
In crystallographic studies, Xe as a probe (similar to O2) has been observed to prefer
hydrophobic environments in the protein, but it is more electron rich than O2, so it can
readily be detected by the crystallographic methods [180]. We observed a local minimum
close to the only experimentally known Xe-binding site in this [FeFe]-hydrogenase [187]; as
expected, this local minimum is located in a mostly hydrophobic environment of the protein,
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e.g., A426, A427, and V423 (Figures 3.4a). The Xe-binding site is reported to be blocked
by the side-chains of A427 and F493 in CpI hydrogenase [6]. We found that the computed
pathway to this local minimum is well aligned with the side-chains of A427 and F493, along
the pathway 1-2. This local minimum is in the proximity of A426 (Figure 3.4a). Importantly,
another experimental study on [FeFe]-hydrogenase found that the mutation A426L makes
the Xe-binding site smaller [6].
3.5.2 O2 Diffusion in Water and Proton-Transport Pathways
The location of two local minima (the local minimum 2 and 20) within the proposed water
pathway [6], shows that O2 and water may both use this pathway, as has been suggested
by Lautier et al. [6]. The local minimum 2 and 20 are in the proximity of S319 and K571,
respectively. In agreement with previous experimental and theoretical work, both residues
are found to have contact with stabilized water molecules [170, 33]. Several theoretical
and experimental studies show that surprisingly, hydrophobic ligands can occupy and use
hydrophilic channels as well. In a previous computational study, MD simulations have
revealed that water molecules occupy a Xe-binding site in myoglobin [189], and another
study shows that the local minimum of 3D-PMF of water in myoglobin corresponds with the
Xe-binding sites [57]. It is therefore interesting to note that Xe or O2 displace water molecules
under pressure in protein crystals [180, 190]. Indeed, another theoretical study on catalase
using MD simulations found that O2 and water share the same channel [191]. The presence of
pathways in the vicinity of water pathway [6] and the proton-transport [188, 7, 192] pathway
in [FeFe]-hydrogenase suggest the existence of possible common pathways between water and
gas molecules to access the active-site, as also observed in [NiFe]-hydrogenase by Sumner et
al. [193].
3.5.3 O2 MFEPs Near the G Site and the Xe Site
The O2 migration pathways in [FeFe]-hydrogenase show the areas within the protein
through which the access of O2 is most likely. Notably, there is only one pathway found
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between the Xe-binding site and the G-site located within the central cavity. The residue
A272 is found along the energy barrier of this pathway (Figure 3.4b), and its substitution
is proposed in a patent application by King et al. [12] for increasing oxygen tolerance of
[FeFe]-hydrogenase. Furthermore, this MFEP is in the proximity of areas of a key transition
path to the G-site, as described by Kubas et al. [10], because they found that the mutation
F417Y decreases the kinetic rate constant of O2 transition by 100-fold along this path [10].
We observed an increase in the free-energy barrier of oxygen transition in this area by F417Y
mutation (see Figure E.1).
3.5.4 O2 MFEP to the Accessory Metal Cluster
The MFEPs of O2 diffusion within the protein matrix core could reveal information
about the mechanism of [FeFe]-hydrogenase active-site inhibition by O2. The pathway 9-
0 (Figure 3.2a) shows a migration path of O2 from the [Fe4S4] cluster to the H-cluster.
This MFEP shows that the direction of O2 diffusion path from cluster 1 to the G-site is
thermodynamically more favorable, which correlates well with the experimental study by
Stripp et al. [43]. It is suggested that O2 reacting with the H-cluster produces reactive
oxygen species (ROS), that either binds, presumably, at the distal Fe-site of the H-cluster
[49] or migrates along a short-path to oxidize cluster 1 [43, 194]. Stripp et al. [43] suggested
that ROS very likely is a superoxide that is more potent oxidant than O2 with a higher
energy to overcome the energy barriers to leave the H-cluster space for cluster 1 [43], and it
is possible that superoxide could potentially migrate along this MFEP for O2 between the
G-site and cluster 1.
3.5.5 MFEPs and Experimental Understanding of O2 Pathways
Many experimentally tested residues that are known to impact O2 access to the H-cluster
are located along our observed pathways (Figure 3.4a) [55, 11, 6]. Using the site-directed
mutagenesis, Stapleton et al. [8, 9] found only residue I197 to measurably decrease O2
inhibition of CpI [FeFe]-hydrogenase by a single mutation to V197 [55]. We find that I197
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is located along pathways 9-15, 9-16, and 9-17 in the upper-side of the H-cluster that are
connected to the local minimum 9 in the proximity of cluster 1, suggesting that the mutation
of I197 is impacting the pathways forming a circulation network of O2 on the upper side of
the the H-cluster by limiting the access of O2 to the active-site of the protein. Ghirardi et
al. [195], using an E. coli expression system, made mutations (A321I and V423L) in CpI
[FeFe]-hydrogenase that were effective in altering O2-access to the H-cluster [11]. Pathways
3-2-1-0 and 3-2-0 are located in the proximity of the channel A [5] toward the H-cluster, and
pathways 6-2-1-0, 6-4-1-0, and 6-2-0 are located in the proximity of the channel B [5] toward
the H-cluster (Figures 3.2b). The residue A321 is located along the pathway 2-0 with an
energy barrier of 7.29 kcal/mol, consistent with the work of Ghirardi et al. [11], and V423
is located near the pathway 1-0; thus either of these site mutations can impact pathways
within the central cavity [5], where pathways from both channels merge. By looking at the
full network of pathways, we can find pathways 1-5 and 20-2, that both have accessibility
to the solvent other than pathways within the channels A and B. Therefore, the single
mutations of V423 and A321 could affect multiple O2 pathways to the H-cluster. In fact,
such an unintended effect of these mutations is hypothesized by Ghirardi et al. [11], but is
confirmed by our network of O2 pathways within the protein.
The interconnected network of MFEPs shows that it is more likely for O2 to diffuse along
channel B than channel A. As there are three possible pathways from the channel B to the
H-cluster, and 2 possible pathways from the channel A to the H-cluster, and the energy
barriers of these 5 pathways show that the lowest overall energy barriers are along pathways
in the channel B. Channel B is a dynamic pathway, first discovered by a theoretical study
of O2 diffusion in [FeFe]-hydrogenase [5], and given the presence of many pathways to the
H-cluster from the channel B, residues in the channel B along the MFEPs, such as A321
and A564, are prime candidates for mutations (Figure 3.4b). However, a patent application
protecting the redesign of [FeFe]-hydrogenase by incorporating bulky amino-acids suggested
residues that are concentrated near the central cavity and the channel A [12], neglecting
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residues in the channel B. This disparity is also noted by Lautier et al. [6]. Nevertheless,
we find many residues along MFEPs, the mutations of which are suggested in the patent
application by King et al. [12]: A272 is along the pathway 0-1, I276 is along the pathway
4-1, V423 is near the Xe-site, and A427 and F493 are along the pathway 2-1 toward the
Xe-site (Figure 3.4a).
The presence of pathways 20-2-0 and 20-0 (within the water pathway [6]) to the H-cluster
corroborates with the proposal [6] that O2 is likely using this hydrophilic channel to access
the active-site of [FeFe]-hydrogenase (Figures 3.2b). Although the local minimum 20, close
to K571, is located within the water channel, we note that only pathway 20-2 is along the
suggested water pathway, and the pathway 2-0 is located in the central cavity. The pathway
20-0 is partially located in an area between the channel B [5] and the water pathway [6].
The pathway 21-0 is perhaps the easiest access route to the H-cluster for O2 located between
the channel B [5] and the water pathway [6].
3.5.6 Potential Candidate Residues for Future Mutations along O2 MFEPs
The proximity of the pathway 21-0 to these channels might cause the mutations of residues
(in the channel B and the water channel) to affect this pathway indirectly, i.e., allosterically.
The energy barrier of this pathway is located close to the surface-exposed F570, making
this residue a good candidate for mutations to disrupt the O2 diffusion along this pathway.
Similarly, O2 diffusion along pathway 13-5-1-0 could be hindered by mutations of residues
along energy barriers of pathways 5-1 and 1-0. In a similar fashion, for pathway 10-9-0,
the residues close to energy barriers are suitable choices for mutations. All such candidate
residues are shown in Figure 3.4b. Our work suggests the existence of multiple pathways for
O2 to access the H-cluster beyond previously known channels A and B, such as the presence
of pathways in the vicinity of the water pathway [6] and the proton transport [188, 7], and
pathways in other areas of the active-site domain. The construction of a systematic network
of migration pathways of O2 along MFEPs provides unique physical insight into the complex
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nature of ligand diffusion in [FeFe]-hydrogenase, and shows that it is highly informative for
the purpose of identifying candidate residues (Figures 3.4b) for future experimental studies
by mutagenesis or other methods.
Figure 3.5: Locations of the minima for CO (filled spheres) and O2 (wireframe spheres)
diffusion in the CpI FeFe-hydrogenase are shown. The global minimum for both gases are
shown in black filled or wireframe spheres and are labeled (G for CO and G-O2 for O2). The
Xenon cavity is shown as a pink sphere and labeled as Xe. For CO, colors of other minima
are consistent with Fig. 3.3: red (0-4 kcal/mol), green (4-8 kcal/mol), blue (8-12 kcal/mol),
and cyan (over 12 kcal/mol). For O2, colors of minima indicate the following energy ranges:
red (0-12 kcal/mol), green (12-16 kcal/mol), and blue (over 16 kcal/mol) (This figure was
created by my co-author Yong Liu [3]).
3.5.7 CO MFEPs to the active site
The MFEPs of CO diffusion from other minima to the local minimum 7 could potentially
disclose the mechanism of CO access to the active site. In Fig. 3.3, we show the MFEPs
from 44 distinct minima to the local minimum 7 as well as the locations of major barriers
along MFEPs. The major energy barriers range between 2.45 kcal/mol and 16.68 kcal/mol,
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among which the the pathways 2-7 and 41-7 have the lowest free-energy barriers and the
pathway 28-7 has the highest free-energy barrier.
Among thermodynamically favored local minima at the surface of the enzyme (those with
free-energy values below 4 kcal/mol relative to the global minimum), the pathway 10-2-7 has
the lowest energy barrier of 4.15 kcal/mol, although the pathway 4-5-7 also has a comparable
energy barrier of 5.23 kcal/mol. However, the exit route for CO from the H-cluster requires
overcoming a barrier of at least 5.04 kcal/mol, which is the energy barrier along the reverse
MFEP 4-5-7. The lower energy barriers along the MFEP 4-5-7 for CO entry/exit from the
enzyme make this pathway a highly likely route for CO diffusion between the solvent and
the H-cluster.
3.5.8 Comparisons between CO and O2 diffusion in the enzyme matrix
In our study of O2 diffusion in the CpI FeFe-hydrogenase, we identified 23 minima in-
cluding the global minimum, which are shown in Fig. 3.5 in a wireframe representation [1].
We observe that two local minima of O2 partially overlapped with the local minima 2 and 5
of CO diffusion, indicating that CO and O2 may reside within the enzyme matrix at shared
locations. The global minimum for both inhibitory gases CO and O2 are located near the ac-
tive site, which suggests a high-affinity for both gases surrounding the active site. The global
minimum for CO is located near the residue F417, where F417Y mutation was previously
shown to decrease the kinetic rate constant for O2 diffusion [10, 1].
Although some common features can be found, CO diffusion and O2 diffusion in the CpI
FeFe-hydrogenase differ in many aspects. For example, no local minimum for O2 is found in
the immediate neighborhood of the H-cluster, but for CO, the local minimum 7 is situated
at a distance of 2.75 Å from the H-cluster. This suggests that CO likely has easier and faster
access to the active site than O2, as has been previously suggested [196, 175]. This is further
reinforced by the fact that, on comparing the 3D-FES for CO in this work with that of O2
from our previous work [1], we find overall lower free-energy barriers for CO diffusion (with
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respect to the global minimum for CO) than for O2 diffusion (with respect to the global
minimum for O2), even though the free energy difference (∆F) between the global minimum
and the solvent space for each gas are comparable, 18.81 kcal/mol (CO) and 18.5 kcal/mol
(O2).
However, in the regions of the enzyme with two hydrophobic pathways, we find that O2
diffusion is thermodynamically favored over CO diffusion, because five local minima (four
shown in green wireframe spheres and one shown as a red wireframe sphere near the Xe
cavity in Fig. 3.5) with relatively lower free-energy values of O2 diffusion are located along
hydrophobic pathways.
Even though there exists a local minimum in the vicinity of the Xe cavity for both CO
and O2, the Xe cavity is located in the lower free-energy region of the 3D-FES for O2 while
CO diffusion in the vicinity of the Xe cavity requires overcoming higher free-energy barriers.
The Xe cavity is surrounded by three hydrophobic residues (F493, A427, and A431) which
may stabilize apolar gases over polar gases [176], indicating that O2 is more likely to be
found in the Xe cavity. These differences can also be explained by the observation that CO
is a polar molecule with a van der Waals volume of 16.20 cm3/mol, while O2 is an apolar
molecule with a van der Waals volume of 13.00 cm3/mol [197]. The effect of the size of
gases on diffusion pathways has been demonstrated in previous MD simulations of H2 and
O2 diffusion in the CpI FeFe-hydrogenase, where H2 with a smaller van der Waals radius was
shown to diffuse in a broader region of the protein matrix and on shorter timescales [198].
Furthermore, CO was shown as a better ligand for binding to electron-rich metals compared
with O2 [199]. This is consistent with the observation that CO reacts much faster than O2
with the FeFe-hydrogenase based on electrochemical studies [175, 174, 196, 200].
3.5.9 Candidate residues for mutations
To prevent inhibitors (e.g. CO and O2) from binding to the Fed of the 2Fe subcluster
of the H-cluster, mutagenesis of protein residues is an approach to alter diffusion pathways.
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Based on the pathways and thermodynamics of CO diffusion, we propose key candidate
residues for mutations to disrupt or block the diffusion of CO (Table 3.1). These 19 residues
are located in the vicinity of the energy barriers of the targeted MFEPs for CO diffusion.
For example, the residue S323 is located near the energy barrier for the pathway 39-7 and
is along the previously proposed water pathway [176]. Similarly, the residue K358 is in the
proximity of the energy barrier of the pathway 5-7, and is also one of the residues defining
the water-based proton-transfer pathway [1, 188, 7]. We hypothesize that replacing this
residue with mutants having larger side-chains could disrupt the CO diffusion along multiple
MFEPs ( 5-7, 4-7, 19-7, and 28-7). The presence of MFEPs for CO in the vicinity of the
proton-transport pathway [192, 7, 188] as well as the water pathway [176] also suggests the
existence of shared pathways between water and gas molecules [193, 57].
Among the proposed 19 residues to disrupt CO diffusion within the enzyme, 11 have been
experimentally studied or computationally proposed (marked as Xin Table 3.1) to decrease
the rate of O2 diffusion inside the CpI FeFe-hydrogenase [8, 11, 1]. For example, both I197 [9]
and V423 [11] have been experimentally studied to alter the diffusion rate of O2. The other
9 residues have been proposed to block O2 diffusion [1], among which A228, M295, G302,
V352, and K358 are located in the proximity of energy barriers for O2 diffusion. This result
indicates that mutagenesis of common residues may decrease the diffusion rates of CO and
O2 in the CpI FeFe- hydrogenase. We speculate that mutations of I416, V423, and A426
may have a weaker effect on decreasing the rate of CO diffusion because these three residues
are located in the enzyme region with higher free-energy values for CO diffusion.
3.6 Conclusion
In this work, [FeFe]-hydrogenase is investigated using the single-sweep/string method of
Maragliano et al. [56] to map the migration pathways of O2 and CO diffusion in this enzyme.
In the reconstructed free-energy map, local minima are notably found near the active-site,
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the H-cluster, and a Xe-binding site. By assuming that the diffusion of O2 and CO in-
side this protein is following the pathways of minimal free-energy, we found that there are
multiple interconnected O2 and CO migration pathways from the solvent to the H-cluster.
The overall network of pathways shows that O2 and CO transport in [FeFe]-hydrogenase
is not limited to previously known pathways [5, 6], and O2 is able to access the H-cluster
for inactivation via several alternative routes. Our results provide an enhanced view of gas
diffusion in [FeFe]-hydrogenase and suggest new residues (Figure 3.4b), mutations of which
could increase oxygen tolerance. Furthermore, 11 of the proposed residues were also found
in CO studies. These findings will guide future experimental studies to increase CO and O2
tolerance of hydrogenases, as recently the more tolerant mutant of [FeFe]-hydrogenase found
by mutation of residue found in the neighborhood of proposed residues [201].
3.7 Publications
The work described in this chapter has resulted in the following journal articles:
• Mohammadi, M., Vashisth, H. (2017). Pathways and Thermodynamics of Oxygen
Diffusion in [FeFe]-Hydrogenase. J. Phys. Chem. B, 121(43), 10007-10017.
• Liu, Y., Mohammadi, M., Vashisth, H. (2018). Diffusion network of CO in FeFe-
Hydrogenase. J. Chem. Phys., 149(20), 204108.
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CHAPTER 4
STUDIES ON TDZD (ALIPHATIC VS. AROMATIC)
INHIBITORS OF RGS4
4.1 Abstract
RGS proteins play a pivotal role in regulation of GPCR signaling and are therefore be-
coming an increasingly important therapeutic target. Recently discovered thiadiazolidinone
(TDZD) compounds that target cysteine residues have shown different levels of specificities
and potencies for the RGS4 protein, thereby suggesting intrinsic differences in dynamics of
this protein upon binding of these compounds. In this work, we investigated the effect of
binding of several small-molecule inhibitors on dynamical motions in RGS4. Specifically, we
studied two conformational models of RGS4 in which a buried cysteine residue is solvent-
exposed due to side-chain motions or due to flexibility in neighboring helices. We found
that TDZD compounds with aromatic functional groups perturb the RGS4 structure more
than compounds with aliphatic functional groups. Moreover, small-molecules with aromatic
functional groups but lacking sulfur atoms only transiently reside within the protein and
spontaneously dissociate to the solvent.
4.2 Background
We have previously reported [102] an open-state model of RGS4 (shown as Model 1 in
Fig. 4.1d) which is conformationally different from apo-RGS4 (shown as Model 1 in Fig. 4.1c).
In this model, the flexibility in the α5-α6 helical pair facilitates access to the buried C95
residue for covalent-docking of the inhibitor CCG-50014 (compound 1 in Fig. 4.1a). On
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inhibitor binding, we found that the the α5-α6 helical pair remains perturbed and only par-
tially relaxes toward the closed conformation of these helices in the apo-RGS4 structure.
However, in the absence of inhibitor we observed that the protein largely reverts to a confor-
Figure 4.1. (a) Small-molecule structure with R1 and R2 functional groups (inset in box)
along with the chemical structures of all small-molecules studied and the mechanism of reac-
tion to form an adduct with a cysteine residue on the RGS4 [4]. (b) A cartoon representation
of the RGS4-Gαi1 complex (PDB code 1AGR) is shown. Each of the 9 α-helices of RGS4 is
colored and labeled, and the location of four cysteine residues are shown by their Cα-atoms
as orange spheres with the C95 residue labeled. The Gαi1-subunit is shown in transparent
white ribbons, and the loops of Gαi1 in the proximity of RGS4 are highlighted in black
ribbons. (c, d, e) Cartoon representations of RGS4 conformations are shown for the wild-
type apo-RGS4, and in its conformationally changed models (Models 1 and 2), respectively.
Highlighted in cartoon representations are α4-helices as cyan cartoons along with the C95
residues as space-filling. The residue C95 is buried in the wild-type RGS4 structure but it is
accessible in Models 1 and 2. For each model, the structure of RGS4 (except the α4-helix)
is rendered in a white surface representation.
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Figure 4.2. Docked initial conformations of TDZD compounds 1, 2, and 3 in Model 1
(panels a, b, and c) and Model 2 (panels d, e, and f) are shown. In all snapshots, the protein
backbone is shown in red ribbons as well as white transparent surfaces, while compounds,
along with the cysteine residue C95, are shown in green space-filling representations.
mation similar to apo-RGS4. While we conducted only short time-scale (∼40 ns) molecular
dynamics (MD) simulations in that work, parallel NMR HSQC results [15] identified several
significant perturbations in residues surrounding the inhibitor binding site. Given the short
time-scale of our earlier simulations, it is unclear to what extent the α5-α6 helical pair will
remain perturbed by bound ligand in longer time-scale simulations. Moreover, differences
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Figure 4.3. Docked initial conformations of non-TDZD compounds 4 and 5 in Model 1
(panels a and b) and Model 2 (panels c and d) are shown. Coloring and labeling schemes
are identical to Fig. 4.2.
in the degree of helical perturbations by CCG-50014 and its congeners with smaller side-
chains [4] (Fig. 4.1a) remain unknown as those small-molecules were not studied previously
in the context of our open-state model (Model 1).
Furthermore, using µs time-scale MD simulations combined with hydrogen-deuterium ex-
change (HDX) studies of three RGS proteins (RGS4 and its homologues RGS8 and RGS19)
[13, 202], we not only observed signatures of flexibility and partial unfolding in helices, but
also found that the side-chains of buried cysteine residues (C95 in RGS4) are transiently ex-
posed to solvent while apo proteins largely maintain a closed conformation. In our previous
work [13], we did not carry out simulation studies of RGS proteins with inhibitors, but we
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hypothesized that inhibitors could potentially access the otherwise buried C95 residue in the
cysteine-exposed closed conformation of RGS4 (Model 2 in Fig. 4.1e).
Hypothesis: Binding of aromatic and aliphatic TDZD analogues to buried and con-
served cysteine residue results in allosteric perturbations.
To determine whether ligand access to the buried cysteine residue (C95) was through
large conformational changes (Model 1) or through small local fluctuations in the side-chain
of C95 (Model 2), we here performed enhanced MD investigations of the mechanisms of
interactions of 5 small-molecules (3 TDZD compounds with aromatic/aliphatic functional
groups and 2 non-TDZD analogues lacking sulfur atoms; Fig. 4.1a) with the C95 residue of
RGS4. We further performed a flow cytometry-based assay [72] to measure concentrations of
three TDZD compounds needed to inhibit the RGS4/Gα protein-protein interaction (specif-
ically, the interaction between Gα and an RGS4 construct containing only a single-cysteine
residue, RGS4 C95). Taken together, these studies highlight the role of cysteine exposure
and global protein dynamics in recognition of TDZD compounds by RGS4, and suggest new
venues for designing non-covalent small-molecules targeting RGS proteins.
4.3 Methods
MD Simulations
We performed two sets of classical all-atom and explicit-solvent MD simulations for
RGS4/small-molecule complexes using the NAMD software [203] and the CHARMM force-
field with the CMAP correction [122, 123] (section 2.2). We used VMD for system creation
and post-simulation analysis [204]. All small-molecules used in this work are reported in
Fig. 4.1a, and their force-fields were parameterized using the Multipurpose Atom-Typer
for CHARMM (MATCH) tool [125]. The first set of simulations was for studying small-
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molecule analogues in complex with an open-state conformation of RGS4 (Model 1; Fig.
4.1d) [102], and the second set of simulations was for small-molecule analogues in complex
with a closed-state conformation of RGS4 (Model 2; Fig. 4.1e) [13].
For simulations of Model 1, the open-state conformation of RGS4 that was reported in
our earlier work [102] was used here as an initial state for docking of small-molecules. For
specifically understanding the effect of binding of thiadiazolidinone (TDZD) and non-TDZD
compounds in a binding pocket in the proximity of the cysteine residue C95 (Fig. 4.1b),
a single-cysteine mutant of RGS4 was created, where all cysteine residues (three in total)
except C95 were mutated to Ala. Following our previous protocol [102], the open-state con-
Figure 4.4. Root-mean-squared-fluctuation (RMSF) per residue are shown for Model 1
(panels a and b) and Model 2 (panels c and d) of RGS4. The RMSF values are reported
from two independent 1 µs long simulation runs (Run 1 and Run 2) for each model, where
simulations were conducted with TDZD analogues (compounds 1, 2, and 3 in Fig. 4.1a)
covalently-bound to the C95 residue of RGS4. As a baseline reference, the RMSF values
of the RGS4 structure without any compound (apo-form; black traces) are also shown from
our previous work [13]. The vertical bars labeled α1 through α9 demarcate the locations of
residues in 9 α-helices of RGS4.
61
Figure 4.5. The histograms of RMSD-averages computed based upon Models 1 and 2 are
shown.Panels a and b show data from two independent runs of Model 1, and panels c and d
show data from two independent simulations of Model 2.
formation of mutated RGS4 was then used to create 5 docked complexes with 5 compounds
(Fig. 4.1), where each TDZD compound is covalently bound to C95 and non-TDZD com-
pounds are non-covalently docked in the same pocket where TDZD compounds are covalently
docked (Fig. 4.2a, b, c, and Fig. 4.3a, b). For simulations of Model 2, a protocol similar to
Model 1 was followed where the initial state of RGS4 was a closed-conformation in which the
key cysteine residue (C95) is surface-exposed (Fig. 4.1e) per our earlier work [13]. The dock-
ing of compounds in Model 2 was further facilitated by the Internal Coordinate Mechanics
(ICM) software [113] to obtain their energetically favorable conformations (Fig. 4.2d, e, f,
and Fig. 4.3c, d).
We solvated all systems for Model 1 and Model 2 using explicit TIP3P water molecules [205],
ionized using NaCl, and added all hydrogen atoms. Each solvated and ionized system was
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Figure 4.6. The side-chains of aromatic residues in the vicinity of covalently-docked com-
pound 1 are shown at various time-points from two independent simulations of Model 1
(panels a and b). The compound 1 is covalently-linked to residue C95, and neighboring
residues are labeled and shown in green sticks. The protein backbone in all snapshots is
shown in a white transparent cartoon.
then energy minimized for ∼500-1000 cycles via conjugate-gradient optimization, and equi-
librated via MD simulations, conducted with a time-step (∆t) of 2-fs, for 1 µs in the NPT
ensemble where the Langevin thermostat with a damping coefficient of 5 ps−1 was used for
temperature control and the Nosé-Hoover barostat was used for pressure control. Periodic
boundary conditions were used throughout, non-bonded interactions were accounted with a
cut-off of 10 Å where smooth switching was initiated at 8 Å, and long-range electrostatic
interactions were handled using the Particle Mesh Ewald (PME) method. For each system,
two (for TDZD compounds) or three (for non-TDZD compounds) independent MD simula-
tions were carried out. In addition to classical MD simulations, we used metadynamics as
an enhanced sampling method (section 2.4.2) to compare thermodynamics of conformational
changes between open and closed-states in apo-RGS4 and RGS4/small-molecule complexes.
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For metadynamics simulations, we used an eigenvector as a CV [206] that was computed
based upon the atomic coordinates of the backbone Cα atoms of all residues in α4 through
α7 helices. The eigenvector choice of a CV is a projection of the coordinates of a group of
atoms (or more precisely, their deviations from the reference coordinates) onto a linear trans-
formation between two end-states: open and closed conformations of RGS4. The vector is
normalized, therefore the CV is 0 when the backbone Cα atoms are at the coordinates of the
closed conformation of RGS4 and the CV is 1 when they are at the coordinates of the open
conformation of RGS4. All metadynamics simulations were carried out with a time-step of
2-fs, and with W , δ, and τG values of 0.05 kcal/mol, 0.025 Å, and 2 ps, respectively. Overall,
we carried out 7 metadynamics simulations: one simulation for apo-RGS4 (∼0.25 µs long),
and 3 simulations (∼0.15−0.45 µs long) each for Models 1 and 2 when bound to compounds
1, 2, and 3 (Fig. 4.1a), respectively.
4.4 Results and Discussion
To understand the effect of binding of small-molecules in each conformational model of RGS4
(Model 1 and Model 2; Fig. 4.1d,e), we docked TDZD as well as non-TDZD compounds
(Fig. 4.2 and Fig. 4.3) in binding pockets created near the C95 residue and conducted sev-
eral independent µs time-scale MD simulations.The initial conformational state of RGS4 for
docking was chosen to either represent flexibility in helices (open-state; Model 1) [102] or
cysteine-exposure (closed-state; Model 2) [13]. For each model, we performed two sets of
independent simulations (each 1 µs long) for TDZD congeners having aromatic and aliphatic
side-chains (compounds 1, 2, and 3 in Fig. 4.1a) covalently-docked at the residue C95 on
the α4 helix (highlighted in cyan in Fig. 4.1d,e). We first describe results on various con-
formational metrics used to characterize the subsequent structural perturbations by three
covalently-linking TDZD compounds in each model of RGS4.
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Additionally, for two non-covalent TDZD analogues lacking sulfur atoms (compounds 4
and 5 in Fig. 4.1a), we performed three sets of independent simulations (each 1 µs long)
for Model 1 where we hypothesized that non-covalently-docked compounds can transiently
reside within the protein due to local interactions. While for Model 2, where compounds
4 and 5 are non-covalently-docked on the protein surface near the exposed cysteine residue
C95, our preliminary simulation analyses revealed that compounds 4 and 5 can quickly
and spontaneously diffuse into the solvent (vide infra). Therefore, we did not perform long
time-scale simulations of these two non-TDZD compounds for Model 2. In the following,
we describe various conformational metrics used to characterize the subsequent structural
perturbations in each model of RGS4.
We performed several µs-timescale unbiased MD simulations of RGS4 in the open-state
conformational model (Model 1) with three covalently-docked (at C95) TDZD congeners
(having aliphatic and aromatic side-chains), and two non-TDZD analogues lacking sulfur
atoms (Fig. 4.1a). As shown in Fig. 4.1b, the residue C95 is located on the α4 helix
(highlighted in cyan) surrounded by α5-α7 helices (highlighted in green, magenta, and yellow,
respectively), making it completely buried in the crystal structure of RGS4, but mostly
accessible in the open-state model of RGS4 (Model 1 in Fig. 4.1c).
4.4.1 Simulations of covalently-bound TDZD inhibitors
Root-mean-squared-fluctuation/deviation (RMSF/RMSD) analyses: To resolve
residue-level perturbations on binding of TDZD compounds (1, 2, and 3) in each model of
RGS4, we calculated RMSF per residue from two independent sets of simulations for each
model (cyan, green, and magenta traces in Fig. 4.4) and compared these values with RMSF
per residue values of apo-RGS4 from our previous work (black traces in Fig. 4.4) [13]. In
addition to higher fluctuations expected in free terminal helices (α1 and α9), we observed
in both simulations of Model 1 (panels a and b in Fig. 4.4) that all compounds induced
significant perturbations (∼4-8 Å higher than in apo-RGS4) in helices α5 and α6, and in
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the α5-α6 interhelical loop which directly contacts the Gα-subunit in the RGS4/Gα complex
(Fig. 4.1b). Moreover, the RMSF values show that compound 1 (with aromatic functional
groups) perturbs the α5-α6 interhelical loop more than compounds 2 and 3 (with aliphatic
functional groups) (cyan vs. green and magenta traces in Fig. 4.4a,b). The perturbations
in this interhelical loop also appear to propagate to structural motifs flanking this loop,
namely the C-terminus of the α5 helix and/or the N-terminus of the α6 helix. For compound
1 in comparison to compounds 2 and 3, we also observed marginally higher perturbations
in the α3-α4 interhelical loop, another structural region of RGS4 that is known to directly
contact the Gα-subunit in the RGS4/Gα complex (Fig. 4.1b). However, in Model 2 (panels
c and d in Fig. 4.4), where all three compounds are covalently-docked on the protein surface
(Fig. 4.2), we observed no significant perturbations in any structural motif of RGS4 as the
RMSF values are comparable to apo-RGS4.
We further report that the Cα-RMSD traces for helices α4 through α7 (Figs. F.1 and
F.2) and their average RMSD from both simulations (Fig. 4.5), measured relative to the
crystallographic conformation of apo-RGS4 (PDB: 1AGR), highlight that all compounds
induce greater perturbations when covalently-docked in Model 1 in comparison to Model 2.
Also, compounds with aromatic functional groups (compound 1) induce larger perturbations
than compounds with aliphatic functional groups (compound 2 and 3). The fluctuations of
residues located at the interaction site with the Gα subunit was shown in our previous work
to result in significant weakening of the RGS/Gα protein-protein interaction in the presence
of compound 1 (CCG-50014) [102]. As also observed here, this was largely attributed to
structural rearrangements of the α5-α6 helical pair and the loop connecting them. Specif-
ically, we observed significant allosteric perturbations in two residues (T124 and E126) of
the α5-α6 interhelical loop in which we previously reported perturbations on binding of
compound 1 based upon NMR HSQC data [102]. We also observed ring-ring interactions
(Fig. 4.6) between compound 1 and the side-chains of neighboring aromatic residues some
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of which (e.g. F91) were reported as highly perturbed on binding of compound 1 in our
previous work [102].
Figure 4.7. The histograms of the buried surface area (BSA) between the α5-α6 helical
pair and the rest of RGS4 are shown for Model 1 (panels a and b) and Model 2 (panels
c and d). Data are shown for simulations of each model conducted with TDZD congeners
(compounds 1, 2, and 3). The vertical dotted lines in panels indicate the values of BSA in
the RGS4 crystal structure (PDB: 1AGR). The BSA traces for apo-RGS4 computed from a
simulation reported in our previous work [13] are also shown (black traces).
Buried Surface Area (BSA) analysis: To further investigate conformational changes
on binding of compounds in each model of RGS4, we measured the BSA between the α5-α6
helical pair and the rest of the RGS4 structure from two independent simulations (Fig. 4.7).
In simulations of Model 1 (Fig. 4.7 a, b), we observed that compound 1 produces a greater
shift in the peaks of the BSA-histograms than do compounds 2 and 3 compared to the
BSA value in the crystal structure (vertical dotted lines labeled x-ray in Fig. 4.7) or in the
apo-RGS4 simulation (black traces in Fig. 4.7 a, b). The BSA traces for all compounds in
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Model 1show deviations from the BSA values in the crystallographic or apo-RGS4 simulation
indicating that the α5 and α6 helices only partially relax toward their closed conformation in
the crystal structure. In both simulations of compound 2 with aliphatic functional groups,
the BSA tracesshow a gradual increase in the BSA toward crystallographic values indicating
a nearly complete closure of the α5-α6 helical pair. In simulations of Model 2, the peaks
of the BSA-histograms (Fig. 4.7 c, d) and the BSA traces show no significant deviation
from the crystal structure values, thereby indicating a closed conformation of RGS4 when
bound to TDZD compounds. Consistent with RMSD/RMSF trends, these results show that
the binding of compounds in Model 1 perturbs the RGS4 structure significantly more than
their binding in Model 2. Furthermore, in Model 1, the α5-α6 helical pair, which is critical
for RGS/Gα binding, only partially relaxes toward the crystallographic conformation in
simulations of compound 1, but significantly recovers in 1 µs simulations of compound 2.
This suggests that the compounds with aliphatic functional groups (compounds 2 and 3),
when covalently-docked within the α4-α7 helical bundle, are more easily accommodated than
those with aromatic functional groups (compound 1).
Salt-bridging interactions: The α4-α7 helical bundle in RGS4 has several charged
amino-acids (K, R, D, and E) that likely form stable or intermittent salt-bridges due to
electrostatic interactions. To understand the ability of TDZD compounds to perturb in-
teractions between charged residues and thereby between helices, we investigated potential
perturbations in several salt-bridge forming residue pairs: D90-K125 (α4-α5), E97-K110 (α4-
α5), K99-D150 (α4-α7), E126-R134 (α5-α6), and D130-K155 (α6-α7). In Fig. 4.8, we show
histograms of average distances between the center-of-mass of these residue pairs from sim-
ulations with compounds (cyan, green, magenta bars) and without compounds (black bars;
apo-RGS4). On comparing these data for Model 1, we observed that all compounds per-
turb salt-bridges between the helical pairs α4-α5 (D90-K125/E97-K110), α5-α6 (E126-R134),
and α6-α7 (D130-K155), but only compound 1 perturbs the α4-α7 salt-bridge (K99-D150)
marginally higher than compounds 2 and 3; perturbations by compounds 2 and 3 are compa-
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Figure 4.8. The histograms of average distances between the centers of mass of residues
involved in five salt-bridge-forming residue pairs are shown from two independent simulations
of Model 1 and Model 2 for three TDZD compounds. The data for an apo-RGS4 simulation
from our previous work [13] are also shown (black histograms). The Cα-atoms of all residues
involved in salt-bridges are shown and labeled as red/blue spheres on the RGS4 structure
(inset in circle).
rable to apo-RGS4. For salt-bridges between the helical pairs α4-α5 (D90-K125) and α6-α7
(D130-K155), compound 1 perturbs salt-bridges more than compounds 2 and 3 in both
simulations of Model 1 (Fig. 4.8 a,b). The α5-α6 salt-bridge (E126-R134) is also perturbed
more by compound 1 in comparison to compound 2 in both simulations (Fig. 4.8 a,b), and
in comparison to compound 3 in the second simulation (Fig. 4.8b). However, compound 2 or
compound 3 could perturb one of the α4-α5 salt-bridges (E97-K110) marginally more than
compound 1 (Fig. 4.8a,b).
The data from two simulations of Model 2 (Fig. 4.8c,d) reveal no significant perturba-
tions in these salt-bridging interactions although salt-bridges between the helical pairs α4-α5
(D90-K125/E97-K110) and α4-α7 (K99-D150) are marginally stabilized in comparison to
apo-RGS4. These data suggest that in Model 1 compounds with aromatic functional groups
destabilize interhelical salt-bridging interactions more than the compounds with aliphatic
functional groups. Moreover, the perturbations are allosteric since two salt-bridges signifi-
cantly perturbed by compound 1 (D90-K125 and D130-K155) have residues K125 and D130
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that are located in the α5-α6 interhelical loop, away from the docking site residue (C95). As
highlighted above, this loop directly participates in the protein-protein interaction between
RGS4 and the Gα-subunit (Fig. 4.1b). Overall, the mode of binding of TDZD compounds in
Model 2 resulted in largely insignificant perturbations in the RGS4 structure in comparison
to binding of these compounds in Model 1.
Figure 4.9. The data from RMSF (panel a/d), BSA (panel b/e), and salt-bridging interac-
tions (panel c/f) are shown from two simulations of each non-TDZD compound in Model 1
(compound 4, yellow trace; compound 5, magenta trace). Other details in panels a/d, b/e,
and c/f are similar to Figs. 4.4, 4.7, and 4.8, respectively.
4.4.2 Simulations of non-covalent (non-TDZD) ligands 4 and 5
We further studied compounds 4 and 5 that are analogues of compound 1 with aromatic
functional groups but lacking sulfur atoms (Fig. 4.1a). While compound 1 is a known
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Figure 4.10: Data similar to those presented in Fig. 4.9 are shown from Run3 for compounds
4 and 5 in which diffusion of each compound out of the protein pocket was observed. The
left-panels show data for parts of trajectories when compounds still reside within the protein,
and the right-panels show data for the remaining parts of trajectories when compounds have
diffused out of the pocket.
inhibitor of the wild-type RGS4/Gα protein-protein interaction, compounds 4 and 5 do not
inhibit this interaction [4]. The mechanistic basis of this observation remains unknown. To
test the ability of compounds 4 and 5 to perturb the RSG4 structure, we conducted MD
simulations after docking both compounds in each model of RGS4 (Fig. 4.2 and Fig. 4.3). For
71
Model 1, we conducted three independent 1 µs long MD simulations of each compoundand
observed that in two out of three simulations, these compounds reside within the α4-α7
helical bundle throughout 1 µs, but in one simulation, each compound diffuses out of the
helical bundle into the solvent after transiently residing within the helices. For Model 2
as well, we conducted three independent simulations of each non-TDZD compound. From
these simulations, we observed non-specific interactions of compounds (with residues on the
protein surface in the vicinity of the docking site) that lead to their rapid dissociation into
the solvent. We discontinued these trajectories after the dissociation of each compound. We
therefore present analyses from three trajectories of each non-TDZD compound for Model 1
where compounds can transiently reside within the protein.
The data from RMSF, BSA, and salt-bridge measurements from the first two simulations
of each compound in Model 1 (where compounds remain bound) are presented in Fig. 4.9
and from the third simulations (where compounds dissociate) are shown in Fig. 4.10. The
RMSF data (Fig. 4.9 a,d and Fig. 4.10a) show that both compounds in their transiently
bound states perturb the α5 and α6 helices as well as the α5-α6 interhelical loop, and the
perturbations by compound 5 are marginally higher than compound 4. The peaks of the
BSA histograms (Fig. 4.9 b,e and Fig. 4.10b). for each compound are shifted away from
the values in the crystal structure or in the apo-RGS4 simulation, thereby indicating an
open conformation of these helices. Accordingly, 4 of 5 interhelical salt-bridges (D90-K125,
E97-K110, E126-R134, and D130-K155) are significantly perturbed, while the α4-α7 (K99-
D150) is marginally stabilized (Fig. 4.9 c,f and Fig. 4.10c). This is consistent with the
observation that in two simulations of Model 1, both non-TDZD compounds reside within
the α4-α7 helical bundle. On dissociation of compound 4 in the third simulation, we observed
decreased fluctuations in the α5-α6 interhelical loop and a shift of the BSA-histogram peak
toward the crystallographic or apo-RGS4 values (yellow traces in Fig. 4.10 d,e vs. Fig. 4.10
a,b). After compound 5 moved out of helices, it continued to interact with the protein surface
thereby perturbing the α5-α6 interhelical loop and neighboring helices (magenta traces in
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Fig. 4.10 d,e). The compounds continue to perturb salt-bridging interactions (Fig. 4.10 c,f)
so long as they reside within the helices or near the protein surface on dissociation from the
pockets.
In each model, simulations of the non-TDZD compounds (4 and 5) show spontaneous
dissociation, consistent with the hypothesis that these two compounds do not reside inside
RGS4 for longer time-scales, as they cannot covalently bind to the key cysteine residue
(C95). However, despite the transient residence of non-TDZD compounds within the protein
domain and their subsequent spontaneous dissociation to the solvent, their ability to perturb
the RGS4 structure while bound suggests the potential of non-covalent compounds (possibly
with higher binding affinities) as promising candidates for developing the next generation of
RGS inhibitors.
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Figure 4.11: (a and b) Free energy profiles are plotted against the collective variable (CV)
for structural transitions (between open and closed states) in RGS4 when three TDZD com-
pounds are docked in distinct pockets created in Models 1 and 2. For each model, thermo-
dynamically favorable conformations of RGS4 bound to TDZD compounds are also shown
as cartoons in panels a and b. (c) For compound 2 in Model 2, highlighted as cartoons
are conformations of RGS4 showing spontaneous diffusion of compound 2 (CCG-203769;
Fig. 4.1a) from its initially-docked position on the protein surface to within the α4-α7 helical
bundle. The circle in panel c denotes the combined location of covalently-linked residue C95
and compound 2. For all panels, the protein backbone in snapshots is depicted in white
ribbons except helices α4 through α7 that are uniquely colored as in Fig. 4.1b (This figure
was created by my co-author Hossein Mohammadiarani [14]).
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Figure 4.12: (a) A schematic highlighting the proposed mechanism of binding of TDZD small-
molecules to RGS4 is shown. In this scheme, the exposure of C95 (orange circle labeled C)
in the apo-RGS4 conformation (panels 1 and 2) allows initial covalent recognition (panel 3)
of small-molecules (orange circle labeled L flanked by filled/empty circles indicating R1 and
R2 functional groups) and a subsequent migration of compounds to the core of the α4-α7
helical bundle causing allosteric structural perturbations in helices (panel 4), especially in
residues in the RGS/Gα protein-protein interface. (b) Previously proposed mechanism [15]
for the exposure of C95 in the apo-RGS4 conformation (panels 1 and 2) and subsequent
binding of compounds causing allosteric structural perturbations (panel 3).
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4.4.3 Thermodynamic analyses of apo-RGS4 and RGS4/TDZD complexes
To understand thermodynamics of conformational changes in RGS4 in the apo-form as
well as when bound to TDZD small-molecules (compounds 1, 2, and 3 in Fig. 4.1a), we
carried out seven independent enhanced sampling MD simulations using the metadynamics
method [153] (see methods). Specifically, we resolved free-energy profiles for structural tran-
sitions between the open and closed-states in apo-RGS4 and in Models 1 and 2 of RGS4 when
bound to the three TDZD compounds (Fig. 4.11a and 4.11b). The free-energy profiles were
resolved in a multidimensional projection of atomic Cartesian coordinates on an eigenvector
reaction coordinate (also referred to as a collective variable, CV) such that the CV spans a
range between 0 and 1 for closed and open conformations, respectively. The reference con-
formational states defining the CV were chosen to represent the apo-RGS4 crystal structure
(closed conformation of RGS4) and the conformation reported in our previous work (open
conformation of RGS4) [102].
Figure 4.13: (a) The structures of the single-cysteine RGS4 construct (RGS4 C95) and three
compounds used in the flow cytometry protein-protein interaction assay are shown. (b)
Inhibition of the RGS4 C95/Gα protein-protein interaction by compounds 1, 2 and 3 over
a range of concentrations is shown (This figure is provided by my co-author Vincent Shaw
[14]).
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We observed that the free-energy profile for a structural transition from a closed to open-
state in apo-RGS4 (black trace in Fig. 4.11a,b) has a global minimum (marked by a black
filled circle in Fig. 4.11a,b) very close to the initial value of CV = 0, which indicates that
RGS4 in its apo-state thermodynamically favors a closed-state, as also seen in the crystal
structure. On comparing free-energy profiles of protein bound to compound 1 (cyan traces
in Fig. 4.11a,b), we observed that the global minimum in Model 1 (marked by a cyan filled
circle in Fig. 4.11a) is located at a CV value of ∼0.35, while in Model 2 the global minimum
(marked by a cyan filled circle in Fig. 4.11b) is located very close to zero. This suggests
that open-like RGS4 states are thermodynamically favored when compound 1 is docked in
the binding pocket in Model 1 in comparison to Model 2, where thermodynamically favored
conformations are similar to the closed-state, as in apo-RGS4.
However, from the free-energy profiles for compound 2 in both models (green traces in
Fig. 4.11a,b), we observed that the global minimum (marked by a green filled circle in
Fig. 4.11a,b) is located in the vicinity of a CV value of ∼0.20. This suggests that open-like
RGS4 states likely exist for compound 2 not only in Model 1 but also in Model 2. The
ability of compound 2 to stabilize open-like conformations in Model 2 is explained by the
observation that the compound 2 spontaneously diffuses during the metadynamics simula-
tion from its initially-docked position on the protein surface to its final position within the
α4-α7 helical bundle (snapshots in Fig. 4.11c), thereby acquiring conformations similar to
Model 1. Importantly, the diffusion of compound 2 from the protein surface to within this
helical bundle is driven both by the flexibilities in helices and burial of the side-chain of key
cysteine residue C95.
For compound 3, the location of the global minimum in each free-energy profile (marked
by a magenta filled circle in Fig. 4.11a,b) indicates a conformational stability behavior similar
to compound 1 in that the open-like RGS4 states are thermodynamically favored in Model
1 and a closed state is favored in Model 2. However, the global minimum for compound 3 in
Model 1 is located at a CV value of ∼0.14 smaller than the CV value of ∼0.35 for the global
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minimum for compound 1 (magenta vs. cyan filled circles in Fig. 4.11a). This suggests that
perturbations to the RGS4 structure (relative to the closed state) are smaller for compound
3 (with aliphatic functional groups) than for compound 1 (with aromatic functional groups).
Overall, the shift in the free-energy minimum from the higher to lower CV values on binding
of TDZD compounds in Model 1 (CV = 0.35, 0.20 and 0.14 for compounds 1, 2, and 3,
respectively) is consistent with the perturbation trends observed in classical MD simulations
(Fig. 4.4, 4.7, 4.8).
The possibility of binding of TDZD analogues (1, 2, and 3) to C95 in a closed-state
conformation of RGS4 due to a transient exposure of C95 (Model 2) [13] shows that multiple
binding mechanisms may exist by which these small-molecules can access the otherwise
buried cysteine residue C95. In Model 2, all compounds are docked on the protein surface
located near the "B-site" of RGS4 [65], entirely outside of the α4-α7 helical bundle. Therefore,
the initial binding of TDZD analogues to C95 is not dependent on a significant opening of
the α5-α6 helical pair. This mechanism of small-molecule recognition by C95 is distinct
from our previously suggested mechanism [102] that highlighted the flexibility in the α5-α6
helical pair as a potential route for compound binding. However, our enhanced sampling
metadynamics simulations showed that compounds covalently-bound to the exposed C95
residue in Model 2 (e.g. compound 2) could translocate from the protein surface to the
core of the α4-α7 helical bundle (Fig.4.11c) and stabilize open-like states similar to Model
1 while remaining covalently-bound, thereby suggesting that Model 2 can evolve toward
Model 1 (Fig. 4.12). Therefore, we propose that these mechanisms of binding of compounds
may not be mutually exclusive. This substantiates the importance of coupling between local
conformational flexibilities in protein side-chains (e.g. exposure of C95) with global protein
dynamics (e.g. flexibilities in RGS4 helices) to facilitate small-molecule recognition and allow
allosteric inhibition of the protein-protein interface.
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4.4.4 Functional analysis of the inhibition of the RGS4-C95/Gα protein-protein
interaction by TDZD compounds
To further investigate the effect of binding of TDZD compounds 1, 2 and 3 on the inter-
action of single-cysteine RGS4 (RGS4 C95) and Gα in vitro, we utilized a flow cytometry
protein interaction assay (FCPIA) (see methods) [72]. A single-cysteine (RGS4 C95) mu-
tant was used to limit compound binding to C95, such that the results reflect compound
action at the same cysteine to which compound was covalently docked in simulations. The
concentration-response curves (Fig. 4.13) show that the single-cysteine protein is inhibited
by compound 1 with an IC50 value of ∼4.5 µM, and less inhibited by compounds 2 and
3 (Fig. 4.13b). The magnitude of structural perturbations and deviations from the native
RGS4 conformation (Fig. 4.4, 4.7, 4.8, and 4.11) induced by the compounds in modeling
and simulation studies correlate well with the results of inhibition experiments. The use of
single-cysteine mutants resulted in lower potencies of inhibition by each compound compared
to wild-type proteins [4]. Notably, the difference in potencies between aromatic compound
(1) and aliphatic compounds (2 and 3) is more pronounced in single-cysteine RGS4 C95 than
in WT RGS4. This may be because in WT proteins, differences in dynamics between com-
pounds bound to C95 are masked by the action of compounds at other cysteines. Compound
1 causes the greatest perturbations in the RGS4 structure and also showed the greatest po-
tency to inhibit RGS4/Gα binding. Compounds 2 and 3 caused smaller perturbations in
the RGS4 structure and accordingly showed a reduced ability to inhibit RGS4/Gα binding.
4.5 Conclusion
In this chapter, I have presented modeling and simulation studies predicting structural per-
turbations in the RGS4 protein on binding to various small-molecules. We found that com-
pounds with aromatic functional groups significantly perturb the protein structure in com-
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parison to those with the aliphatic functional groups. Non-covalent compounds only tran-
siently perturb the protein as these compounds spontaneously dissociate to solvent. Ther-
modynamic analyses of RGS4/small-molecule complexes suggest that two distinct modes of
binding can lead to a two-step mechanism in which compounds are initially recognized by
the exposed side-chains of conserved and buried cysteine residues (C95 in RGS4) followed by
their migration to the helical core of RGS4 that leads to significant allosteric perturbations
in those RGS4 residues that are located in the RGS4/Gα protein-protein interface. These
findings will inform future drug development efforts focused on the discovery of non-covalent
compounds capable of inducing similar allosteric perturbations.
4.6 Publications
The work described in this chapter has resulted in the following journal article:
• Mohammadi, M., Mohammadiarani, H., Shaw, V. S., Neubig, R. R., Vashisth, H.
(2019). Interplay of cysteine exposure and global protein dynamics in small-molecule
recognition by a regulator of G-protein signaling protein. Proteins: Structure, Func-
tion, and Bioinformatics, 87(2), 146-156.




STUDIES ON COUPLING OF PROTEIN DYNAMICS AND
SALT-BRIDGING INTERACTIONS IN RGS PROTEINS
5.1 Abstract
RGS proteins modulate receptor signaling by binding to activated G-protein α-subunits,
accelerating GTP hydrolysis. Selective inhibition of RGS proteins increases G-protein ac-
tivity and may provide unique tissue specificity. Thiadiazolidinones (TDZDs) are covalent
inhibitors that act on cysteine residues to inhibit RGS4, RGS8 and RGS19. There is a cor-
relation between protein flexibility and potency of inhibition by the TDZD CCG-50014. In
the context of a single conserved cysteine residue on the α4 helix, RGS19 is the most flexible
and most potently inhibited by CCG-50014, followed by RGS4 and RGS8. We hypothesized
that interhelical salt-bridge forming residues are responsible for differences in both flexibility
and potency of inhibition among RGS isoforms. RGS19 lacks a charged residue on the α4
helix that is present in RGS4 and RGS8. Introducing a negative charge at this position
(L118D) increased the thermal stability of RGS19 and decreased the potency of inhibition
by CCG-50014. Mutations which eliminated salt bridge formation in RGS8 and RGS4 led to
decreased thermal stability in RGS8 and increased potency of inhibition of both RGS4 and
RGS8. Molecular dynamics (MD) simulations with an added salt bridge in RGS19 (L118D)
showed reduced RGS19 flexibility. Hydrogen-deuterium exchange (HDX)∗ studies showed
striking differences in flexibility in the α4 helix of RGS4, 8, and 19 with salt bridge modify-
ing mutations. These results show that an α4 salt bridge-forming residue controls flexibility
in several RGS isoforms and supports a causal relationship between RGS flexibility and the
potency of TDZD inhibitors.
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∗ The experimental works (mutegenesis, HDX, and compound potency studies) performed
by my collaborator Vincent Shaw at Michigan State University.
5.2 Background
Drug specificity is often considered to be like a key fitting into a complementary shaped
lock. It has become clear recently that protein dynamics can play an important role in drug
discovery. RGS proteins bind to activated Gα subunits of G-proteins, thereby accelerating
GTP hydrolysis and attenuating G-protein signaling. In regulating G-Protein Coupled Re-
ceptor (GPCR) signaling, RGS proteins play a role in the physiology of numerous systems.
By inhibiting RGS proteins, signaling via a GPCR may be enhanced. There are twenty
RGS isoforms, each with a different tissue distribution. Combination of GPCR agonists
with inhibitors specific for a single RGS isoform should limit effects on GPCR signaling to
a subset of target tissues that intersects with the distribution of the GPCR. This has the
potential to reduce agonist off-target effects, and makes RGS proteins an attractive target
for modulation of GPCR signaling.
RGS inhibitors discovered to date are covalent modifiers of cysteine residues and are
selective for RGS4 and RGS1 [84, 207]. These have four and three cysteines, respectively,
in the RGS homology domain, which is more than in most other RGS proteins. RGS4 has
been linked to nervous system related disease states in which RGS4 inhibition may be desir-
able, including seizures [208] and Parkinson’s disease [90, 91, 93]. Continued efforts to seek
non-covalent inhibitors are attractive, because the lower risk associated with non-covalent
inhibitors is considered safer and may ease further development [209]. In addition, it would
be valuable to discover RGS inhibitors with other specificities since other RGS proteins less
potently inhibited by covalent modifiers have been implicated as potential targets, includ-
ing RGS17 in cancer [210, 211] and RGS19 in depression [212]. To identify noncovalent
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inhibitors with novel specificities, it will be necessary to understand what factors apart from
the number of cysteines in the RGS domain drive selectivity of RGS inhibitors.
The RGS homology domain contains nine helices. A cysteine residue on α4, which faces
the interior of the α4-α7 helical bundle, is conserved among all 20 RGS isoforms with the
exception of RGS6 and RGS7 [100]. Interestingly, when RGS proteins are mutated to contain
only this single, shared cysteine, there are still dramatic differences in potencies by which
different isoforms are inhibited [13]. RGS19, which contains only the shared α4 cysteine, is
more potently inhibited than single-cysteine versions of RGS4 and RGS8 [13, 202].
Hypothesis: Inhibitor potency can be modulated by salt-bridging interactions.
Previously, we found using MD simulations that RGS19 is more flexible than RGS4 and
RGS8 [13]. In these modeling studies we also found that the extent of perturbations of salt
bridge interactions by inhibitor compounds correlated with structural flexibility in RGS4
[14, 17]. In this work, we sought to identify the cause of flexibility differences among these
isoforms and hypothesize that mutations aimed at salt bridge interactions that enhance RGS
protein flexibility can increase the potency of inhibitors such as CCG-50014.
5.3 Methods
We performed two sets of classical all-atom and explicit-solvent MD simulations (section
2.2) for single-cysteine RGS4/ RGS4 D90L, single-cysteine RGS8/ RGS8 E84L, and RGS19/
RGS19 L118D using the NAMD software [111] and the CHARMM force-field with the CMAP
correction [122, 123]. We used VMD for system creation and post-simulation analysis [110].
The initial coordinates were obtained from the protein data bank files with codes 1AGR
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(RGS4), 2ODE (RGS8), and 1CMZ (RGS19). Except Cys95 in RGS4 and Cys1071 RGS8,
all cysteines were mutated to alanines. Each protein was then solvated in a simulation
box of TIP3P water molecules [205] and charge-neutralized with NaCl. Each solvated and
ionized system was energy minimized for ∼500-1000 cycles via conjugate-gradient optimiza-
tion, then equilibrated via 1µs MD simulations conducted with a time-step (∆t) of 2 fs. The
NPT ensemble with a Langevin thermostat and a damping coefficient of 5 ps−1 was used
for temperature control and the Nosé-Hoover barostat was used for pressure control. Peri-
odic boundary conditions were used throughout; non-bonded interactions were accounted for
with a cut-off of 10 Å where smooth switching was initiated at 8 Å. Long-range electrostatic
interactions were handled using the Particle Mesh Ewald (PME) method. The dynamic
cross-correlation (DCC) maps were created, and salt-bridge interaction analysis were per-
formed as described in section 2.3.2.
5.4 Results and Discussion
Comparison of the structures for RGS19 (PDB 1CMZ[213]), RGS4 (PDB 1AGR[101]), and
RGS8 (PDB 2ODE [214]) shows that there are differing numbers of interhelical salt bridges
among their α4-α7 helix bundles. Some of these may contribute to differences in stability
and dynamics among the RGS isoforms.
RGS19 has only one interhelical salt bridge in this bundle, between E125 (α4) and K138
(α5) (Fig. 5.1E). This salt bridge is well conserved among all three proteins, however, so it
is unlikely to contribute to observed differences in flexibility [13].RGS4 has this salt bridge
(E97-K110, Fig. 5.1B) as well as two additional interhelical salt bridge locations, between
D130 (α6) and K155 (α7) (Fig. 5.1D); and a salt bridge network that connects D90 (α4),
K125 on the α5-α6 interhelical loop, and E117 on α5 (Fig. 5.1B). RGS8 has four interhelical
1Note, amino acid numbering follows that for RGS8, Isoform 1, NCBIRefSeqNP203131.1
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Figure 5.1. (a) Alignment of RGS19, RGS4, and RGS8 sequences in α4-α7 helix bundle.
Charged residues that make interhelical contacts are indicated in red and blue. Structural
alignments of α4-α5 (b and e), α5-α6 (c and f), and α6-α7 (d and g) helix pairs are shown,
with highlighted residues in panel a rendered as sticks. RGS19 (PDB 1CMZ) is in green,
RGS4 (PDB 1AGR) is in yellow, and RGS8 (PDB 2ODE) is in cyan (This figure was created
by my co-author Vincent Shaw [16]).
salt bridges in the α4-α7 bundle. One salt bridge (E91-K104, Fig. 5.1B) is shared by both
RGS19 and RGS4. Two salt bridges (D124-K149, Fig. 5.1D, and E84-R119-E111, Fig.
5.1B) are shared with RGS4. Finally, a salt bridge between D114 (α5) and R132 (α6) is
unique to RGS8 (Fig. 5.1C).
To estimate the relevance of each of these salt bridges in maintenance of helix bundle
rigidity, the time each amino acid in a charged pair spent within a Å of one another over the
course of a long timescale MD simulation was measured [13]. The α6-α7 salt bridge, which
is present in RGS4 and RGS8 but absent in RGS19, was stably maintained. It occupied a
salt bridge-forming distance for 31.5% of the simulation in RGS4 and 36.1% in RGS8. The
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Figure 5.2. Thermal stability was determined by differential scanning fluorimetry. A) The
L118D mutation in RGS19 increased melting temperature by 7 ◦C compared to WT. B)
The E84L mutation in RGS8 decreased melting temperature by 8 ◦C. C) The RGS4 D90L
mutation introduced a biphasic melt curve and increased melting temperature by 5 ◦C. For
each pair, derivative melt curves are shown on the left and melt temperatures are shown on
the right. Error bars represent SD. n=3. Analyzed by 1-way ANOVA with Sidak’s Multiple
Comparisons test (This figure is provided by my co-author Vincent Shaw [16]). ****p <
0.0001
salt bridge interaction between residues of α4 and α5-α6 interhelical loop, also not present
in RGS19, was maintained for 58.7% of time in RGS4 and 44.2% in RGS8. The charged
pair that is unique to RGS8 between α5 and α6 helices remained in contact for 47.5% of the
simulation.
Based on these MD results, we elected to make mutations that altered interhelical (α4-α5
and α6-α7) salt bridges to test their functional roles. In helix α4, L118 in RGS19 (Fig. 5.1E)
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Figure 5.3. Change in RMSF per residue (∆RMSF) between wild-type RGS proteins and
RGS proteins with mutation in the α4-α5 salt bridge forming residue. (a) L118D in RGS19
(b) E84L in RGS8 and (c) D90L in RGS4. Data represent differences in RMSF from two
independent MD simulations of the mutated and unmutated forms of RGS proteins.
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was mutated to an aspartate to introduce the salt bridge found in RGS4 and RGS8 (Fig.
5.1B). In helix α7, Q183 in RGS19 (Fig. 5.1G) was mutated to a lysine, to introduce the
α6-α7 salt bridge found in RGS4 and RGS8 (Fig. 5.1D). In order to eliminate confounding
effects due to multiple cysteines in inhibitor potency experiments, all proteins, with and
without salt-bridge mutations, used a single-cysteine protein background. Each construct
has only the conserved cysteine in helix α4 of the RGS domain.
To determine how disruption of the salt bridges D90-K125 in RGS4 and E84-R131 in
RGS8 and addition of a salt bridge by L118D mutation in RGS19 may alter protein struc-
ture or dynamics, thermal stability was measured by differential scanning fluorimetry. As
expected, addition of a salt bridge in RGS19 by the L118D mutation caused a 7 ◦C increase
in thermal stability compared to WT (Fig 5.2A). Removal of a salt bridge by the E84L
mutation in RGS8 caused an 8 ◦C decrease in thermal stability (Fig 5.2B). Unexpectedly,
RGS4 showed a more complex pattern, in which D90L mutation resulted in a biphasic melt
curve and a 5 ◦C increase in melting temperature rather than a decrease (Fig 5.2C).
To probe the molecular details of changes in structural flexibility in the mutated RGS4,
RGS8, and RGS19, we conducted microsecond timescale classical MD simulations in explicit-
solvent for RGS4 D90L, RGS8 E84L, and RGS19 L118D. To understand the effect of the
mutations on the protein structures, particularly in helices in the vicinity of the mutated
site, we computed the root-mean-squared-fluctuation (RMSF) per residue from two indepen-
dent MD simulations of mutated and WT RGS4, RGS8, and RGS19. There were minimal
changes in RMSF in RGS4 in comparison to RGS8 and RGS19 (Fig. 5.3). We find a mod-
est increase in fluctuation of residues in mutant (E84L) RGS8 vs. the wild-type structure.
These changes are in the loop region connecting helices α5 and α6, the α6 helix, and the loop
connecting helices α6 and α7. Similar changes in lesser extend were found in the mutant
(D90L) RGS4. The calculated change in RMSF per residue of the mutant (L118D) RGS19
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from wild-type RGS19 reveals a strong stabilization and decrease in fluctuations of residues
located in helices α4-α7 and the interhelical loops between these helices. There is a particu-
larly pronounced decrease in motion in the α5-α6 interhelical loop (Fig. 5.3). Additionally,
the RMSF values of residues in helices α3 and α8 of the mutated RGS19 are more stable in
compared to wild-type than in mutated RGS4 and RGS8 (Fig. 5.3).
To further investigate whether the mutations D90L in RGS4, E84L in RGS8, and D118L
in RGS19 affect residue-residue interactions, we calculated the dynamic cross-correlation ma-
trix for the Cα atoms in all MD trajectories. For wild-type RGS8, we find that the motions
of residues in the α4 helix (highlighted by the dashed lines in Fig. 5.4) and the α5 helix
(highlighted by the solid-lines in Fig. 5.4) are marginally positively correlated. This positive
correlation between the α4 and α5 helices remains in the RGS8 E84L mutant, but shows
a modest shift in areas of correlation away from the loop connecting α4-α5 to mid-regions
of the α4 and α5 helices (see arrows). For WT RGS4 and RGS19 the correlation matrices
show slight positive correlation between the residues of the α4 helix and the residues of the
α5 helix. For the RGS19 L118D mutant, we find higher residue-residue correlations between
residues in helices α4 and α5 in comparison to unmutated RGS19 (see arrows).
In order to experimentally determine which regions in WT and mutant proteins were
affected by the salt bridge mutations, hydrogen-deuterium exchange was performed. After
exposure to solvent containing 90% D2O, proteins were digested with pepsin and deuterium
incorporation (DI) was measured by mass spectrometry as previously reported [13]. In RGS4,
the fragment surrounding the salt-bridge mutation site (aa 88-91) took up deuterium very
slowly in both the WT and D90L mutant constructs, reaching 8.1% and 6.7% DI, respec-
tively. However, the D90L mutation led to a substantial increase in deuterium exchange in
the 92-97 fragment surrounding Cys95, from 17.5% to 37.0% DI. The RGS4 D90L mutant
also trended toward increased DI across all protein fragments compared to WT RGS4, espe-
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Figure 5.4. (a) Dynamic cross-correlation matrix calculated for the Cα atoms of (a)
RGS19/RGS19 L118D, (b) RGS8/RGS8 E84L, (c) RGS4/RGS4 D90L. Horizontal dotted
lines indicate the regions of the α4 helix, while vertical solid lines indicate the regions of
the α5 helix for each protein. The color scheme ranges from anticorrelation (-1.0, blue), no
correlation (0, green), and positive correlation (+1.0, red). Values are the average for the
two independent simulation runs of each protein.
90
Figure 5.5. Difference in % deuterium incorporation (∆%DI) between mutated and un-
mutated proteins in RGS19 L118D (A), RGS8 E84L (B), and RGS4 D90L (C) fragments,
as measured by HDX. Red arrows indicate fragments containing mutated residue, and black
arrows indicate fragments containing conserved α4 cysteine. Kinetics of deuterium incor-
poration in these fragments for individual constructs are shown below. n=3. Error bars
represent SD. Analyzed by 2-way ANOVA with Sidak’s multiple comparisons test (This
figure is provided by my co-author Vincent Shaw [16]). *p < 0.05, **p < 0.01, ****p <
0.0001
cially at higher timepoints (Fig. 5.5A). In RGS8, removal of the salt-bridge forming residue
by the E84L mutation did not cause a significant change in DI in either of the fragments
of the α4 helix but trended toward a global increase in DI throughout the protein (Fig.
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Figure 5.6. Potency of inhibition of CCG-50014 against α4 is altered in salt bridge mutants
of RGS proteins. (A) RGS4 IC50: 8.8 µM, RGS4 D90L IC50: 2.2 µM. (B) RGS8 IC50: 29
µM, RGS8 E84L IC50: 4.6 µM (C) RGS19 IC50: 7.0 µM, RGS19 L118D IC50: 1.1 µM. n=3
(This figure is provided by my co-author Vincent Shaw [16]).
5.5B). In RGS19, mutation of L118 to a salt bridge-forming residue, aspartic acid, caused
significant decreases in DI in both α4 helical fragments, aa 116-119 and aa 120-125. In the
116-119 fragment, WT RGS19 had reached 43.1% DI by 10 minutes, while the RGS19 L118D
mutant showed less than half as much DI (18.7%). In fragment 120-125, WT RGS19 reached
18.5% DI at 10 minutes, while the RGS19 L118D mutant reached only 6.2%. Unlike RGS4
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and RGS8, the RGS19 L118D mutant’s changes in DI were more restricted to fragments
from helices neighboring the mutation site, and were most pronounced in the early (1 to 10
minute) timescale (Fig. 5.5C).
Finally, to see whether differences in the α4 salt-bridge forming residue altered com-
pound potency, we used a flow-cytometry based protein-protein interaction assay (FCPIA)
[215, 216] to measure the binding of RGS proteins to Gαo and inhibition by CCG-50014.
The L118D mutation in RGS19 induced an increase in IC50 from 1.1 µM (WT) to 7.0 µM
(L118D). Conversely, removal of this charged α4 residue in RGS4 and RGS8 induced a de-
crease in IC50. CCG-50014 inhibited the RGS-Gα interaction with an IC50 of 8.8 µM for
WT RGS4 and 2.2 µM for the RGS4 D90L mutant. It showed a potency of 29 µM for WT
RGS8 and 4.6 µM for the RGS8 E84L mutant. None of the mutations to salt bridge-forming
residues on the α4 helix caused notable changes in affinity between Gαo and RGS proteins.
The L118D mutation in RGS19 shifted the Kd of the Gαo interaction from 16.6 nM to 20.2
nM, the E84L mutation in RGS8 shifted the Kd from 5.9 nM to 4.8 nM, and the D90L
mutation in RGS4 shifted the Kd from 5.2 nM to 3.9 nM (Fig. 5.6).
5.4.1 The analysis of mutated RGS proteins flexibility
A comparison of the crystal structures of the three RGS proteins studied here revealed
several differences in charged residue contacts among the proteins. We first observed that
RGS19 has fewer interhelical salt bridges between helices in its α4-α7 helical bundle than
RGS4 or RGS8, which may be responsible for the high flexibility and low melting tempera-
ture previously observed in WT RGS19 [13]. RGS8 has four distinct interhelical salt bridge
locations within the helical bundle, while RGS4 has three and RGS19 has one (Fig 5.1A),
correlating with previously observed flexibility differences. RGS19 is most flexible, followed
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by RGS4 and RGS8 [13]. This further suggests a role of salt bridges in RGS protein flexibility.
To determine which of these salt bridge locations was most relevant to the overall sta-
bility of the RGS proteins, we analyzed the stability of salt bridges via µs-timescale MD
simulations. A salt bridge between a glutamate on α4 and lysine on α5 is well conserved
among RGS proteins (Fig. 5.1A, 5.1B, and 5.1E). Therefore, it is unlikely to contribute to
differences in flexibility among RGS isoforms. This leaves two positions at which interhelical
salt bridges are shared by RGS4 and RGS8 but lack necessary residues in RGS19: L118
(α4) and Q183 (α7). Because these positions were most likely to contribute to differences in
RGS19 protein flexibility, we chose to mutate each of these positions in RGS19 (L118D and
Q183K) in order to replicate the residues in RGS4 and RGS8. The RGS19 L118D mutation
significantly increased the melting temperature compared to WT (Fig 5.2A). This increased
stability suggests that addition of a D118-K125 salt bridge interaction in RGS19 was suc-
cessful. Attempts to add a salt bridge at the α6-α7 position in RGS19 by Q183K mutation,
however, produced no significant change in either thermal stability or potency of inhibition.
This correlates with the observation that the α6-α7 salt bridge (D130-K155 in RGS4 and
D124-K149 in RGS8) was less stably maintained in simulations than was the α4-α5 salt
bridge (D90-K124 in RGS4 and E84-R119 in RGS8). It is possible that hydrogen bonding
contacts between Gln183 on α7 and Asp158 on α6 in RGS19 are sufficient to compensate for
the lack of a salt bridge at this position. In light of these results, we found it unlikely that
the difference between Gln183 in α6 of RGS19 and the lysines found in RGS4 and RGS8
(K155 and K149 respectively) play a major role in the flexibility differences between these
proteins. Rather, the salt bridge-forming residue on α4 is a stronger driver of differences in
protein flexibility.
To verify the importance of differences in the α4-α5 salt bridge in protein structure and
function, we also tested whether the elimination of this salt bridge in RGS4 and RGS8
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could reduce the thermal stability of the proteins. The acidic residues D90 (RGS4) and E84
(RGS8) were each mutated to a leucine, which is the corresponding residue in RGS19. As
expected, this significantly reduced thermal stability in RGS8, suggesting a successful re-
moval of this salt bridge (Fig 5.2B). However, while the thermal stability of the RGS4 D90L
mutant was significantly altered compared to WT RGS4, the mutation resulted in a biphasic
melt curve shape with increased overall thermal stability (Fig 5.2C). This may indicate that
the mutation had a more complex effect on the protein structure and its dynamics than a
simple disruption of the salt bridge.
To determine the effects of mutations in salt bridge-forming residues on protein dynam-
ics, both an in silico approach (all-atom MD simulations) and an experimental approach
(hydrogen-deuterium exchange) were employed. MD simulations demonstrated that the ad-
dition of a salt bridge by the L118D mutation in RGS19 drastically reduces fluctuations
throughout the α3-α8 helical bundle. This stabilization was particularly dramatic in the α6
helix and the α5-α6 interhelical loop (Fig 5.3C). Likewise, in HDX analysis, decreases in
DI were observed in the RGS19 L118D mutant compared to WT. As expected, the highest
magnitude of decrease was observed in the fragment containing the mutation site, suggest-
ing a strong reduction in solvent exposure at the α4 helix. Other decreases in DI were most
prominent at 1 to 3 minutes in fragments from the α4 and α5 helices and the α5-α6 inter-
helical loop (Fig. 5.5C). The α4 helix changes are of particular interest given the location of
the Cys123 as a target of the TDZD compounds. Conversely, mutations that eliminated salt
bridges in RGS4 and RGS8 increased deuterium incorporation. Both mutants had increased
DI in some fragments from the α4 helix (Fig. 5.5A and 5.5B), but the RGS4 D90L mutant
did not have increased DI in the fragment spanning the mutation site (Fig. 5.5A). This fits
with the thermal stability data that suggest that the effect of the D90L mutation in RGS4
is more complex than disruption of a single interacting pair.
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5.4.2 MD simulations to probe mutated RGS proteins conformations
In MD simulations, the RGS4 D90L and RGS8 E84L mutations did not have as large an
effect on the magnitude of residue fluctuations as did mutation of L118D in RGS19 (Fig 5.3A
and B). This may be because differences become apparent on shorter timescales in RGS19
than in RGS4 and RGS8, so simulations on µs timescales may not have captured all of the
differences in dynamics caused by mutations in RGS4 (D90L) and RGS8 (E84L). Indeed, in
HDX studies, stronger differences in DI were observed between RGS19 and RGS19 L118D
at shorter timepoints (1 and 3 minutes) than in RGS4 D90L and RGS8 E84L (Fig 5.5A-C).
The µs-timescale MD simulations of mutated (D90L) RGS4 and WT RGS4 captured
positive residue-residue (Cα-Cα) correlations between the α4 and α5 helices. This indicates
a complex effect of the D90L mutation on the protein structure and dynamics, especially
alongside data indicating increased thermal stability in mutant (D90L) RGS4. We also ob-
served a change in the pattern of positive correlations between the α4 and α5 helices in the
RGS8 E84L mutant from those of WT RGS8, possibly resulting from the removal of the
interhelical salt-bridge. The marked increase in positive correlation between residues in the
α4 and α5 helices in the RGS19 L118D mutant likely results from the introduced interhelical
salt-bridge.
Finally, to determine how changes in protein flexibility affected the potency of inhibi-
tion by an RGS inhibitor, we used a flow-cytometry based protein-protein interaction assay
(FCPIA) to evaluate the inhibition of Gα binding by CCG-50014. Importantly, manipula-
tion of RGS protein flexibility induced the expected changes in the potency of inhibition by
TDZD covalent modifiers. The inhibition curve of the RGS19 L118D mutant was shifted
rightward in comparison to RGS19, indicating that the more flexible mutant is less potently
inhibited. Conversely, the inhibition curves for the RGS4 D90L mutant and the RGS8 E84L
mutant were shifted leftward in comparison to those for RGS4 and RGS8, respectively. Thus,
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enhancing flexibility by removal of salt bridge-forming residues increased the potency of in-
hibition by CCG-50014. These results support a causal relationship between the protein
flexibility and the potency of inhibition.
5.5 Conclusion
In conclusion, differences in flexibility among RGS isoforms are capable of driving differences
in potency of inhibition of a covalent inhibitor, CCG-50014. The differences in isoform flexi-
bility in turn are strongly influenced by the presence or absence of an α4-α5 salt bridge and
manipulation of this salt bridge is sufficient to induce changes in inhibitor potency among
single-cysteine RGS proteins. Developing a deeper understanding of these differences in
flexibility may enable the development of a new generation of RGS inhibitors with novel
specificities.
5.6 Publications
The work described in this chapter has submitted in the following journal article:
• Shaw, V.S., Mohammadi, M., Quinn, J.A., Vashisth, H., and Neubig, R.R. (20XX). An
Interhelical Salt Bridge Controls Flexibility and Inhibitor Potency For Regulators of G-
protein Signaling (RGS) Proteins 4, 8, and 19. Molecular Pharmacology, (Submitted).
97
CHAPTER 6
OTHER SYSTEMS STUDIED: PHOSPHODIESTERASE 4
(PDE4) ENZYME
6.1 Abstract
Novel chemical controls are needed that selectively target human, animal, and plant parasitic
nematodes with reduced adverse effects on the host or the environment. We hypothesize that
the phosphodiesterase (PDE) enzyme family represents a potential target for development
of novel nematicides and anthelmintics. MD simulations were used to evaluate differences in
binding interactions of these inhibitors within the PDE4 catalytic domain. Of 32 residues
within 5 Å of the ligand binding site, five revealed significant differences in non-bonded in-
teraction energies that could account for the differential binding affinities of roflumilast and
zardaverine. One site (Phe506 in human PDE4, Tyr253 in the C. elegans PDE4 catalytic
domain) is predicted to alter the binding conformation of roflumilast and zardaverine (but
not IBMX) into a less energetically favorable state. These results support the feasibility
of designing the next generation of anthelmintics/nematicides that could selectively bind to
nematode PDEs.
6.2 Background
Cyclic nucleotide metabolism is of central importance for a wide range of physiological pro-
cesses in nematodes, as attested by the presence in C. elegans of 38 genes that synthesize
cAMP or cGMP [217], as well as six PDE genes [218, 219, 220]. The cAMP second messenger
has been linked to various behaviors including feeding and locomotion [221, 222]. Neural
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pathways responsible for sensory signaling (chemoreceptors, thermotaxis, phototaxis) ap-
pear to be regulated through cGMP signaling pathways [218, 223, 224, 225]. Furthermore,
RNAi, gene deletion, and pharmacological studies have shown that altered PDE activity
can cause lethality, sterility, aberrant locomotion, lethargy, and altered development in C.
elegans [226, 227, 228, 229, 230]. Some of the observed phenotypes (e.g., lethality, sterility)
are clearly relevant to developing effective anthelmintics nematicides that specifically tar-
get parasitic nematodes-but not other animal phyla. Indeed, PDEs and their inhibitors are
being investigated for their therapeutic potential in combatting various protozoal diseases
[231]. Another advantage to targeting phytoparasitic nematode PDEs for the development of
nematicides is the greatly reduced likelihood that a PDE inhibitor-based nematicide would
have adverse effects on plants, since Class I PDEs have not been identified to date in plants
[232].
The Class I PDE superfamily in vertebrates consists of eleven PDE families that have
been identified throughout the animal kingdom [233]. The eleven families are distinguished
by differences in their substrate specificity, modes of regulation, pharmacological properties,
and tissue distribution [234]. However, all Class I PDE enzyme families share a conserved
Prosite domain signature (Prosite PS001261) in the catalytic domain consisting of the amino
acid sequence pattern HD[LIVMFY]xHx[AG]xx[NQ]x[LIVMFY]. The crystal structures of
the catalytic domains of almost all the PDE families have been solved, providing atomic-level
details on the enzymatic and pharmacological properties of this enzyme superfamily [108].
The catalytic domains of the Class I PDE superfamily are made up of 330 amino acids
whose secondary structure consists of 16 α-helices. These α-helices create three subdomains
[109], which form a deep catalytic pocket at their center. The active site is composed of two
sub-pockets, which bind two divalent metal ions and the substrate, respectively [108]. Zinc
1https://prosite.expasy.org/PDOC00116
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Figure 6.1. Interactions of five key Cα-atoms of the 32 residues that interact with ligands
in (a) human PDE4D and (b) C. elegans PDE4 binding pocket. The Zn and Mg ions are
shown as gray and green spheres, respectively. The three Asp residues coordinating with Zn
and Mg ions are highlighted by purple spheres. The Gln and Phe/Tyr residues are shown
as red and blue spheres, respectively. The protein backbone is represented as ribbons, the
Cα-atoms of residues of the binding pocket and ions are shown as space-filling. (c) Changes
in total non-bonded interaction energy and its components for C. elegans PDE4 relative to
human PDE4D are shown for selected residues in the binding pocket (labeled 1-5 in panel a
and b).
and magnesium ions are stabilized by conserved His and Asp residues in the metal binding
pocket [108]. The crystal structure of human PDE4 catalytic domain in a complex with
5′-AMP [235] has revealed that cyclic nucleotides are stabilized by ionic interactions with
the bound divalent cations and with Asp and His residues in the metal binding pocket, as
well by hydrophobic interactions with conserved Gln and Phe residues in the hydrophobic
pocket. The invariant Gln residue of PDEs have been shown to be critical for substrate and
inhibitor binding [108].
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Figure 6.2. The traces of root-mean-squared-deviation (RMSD) vs. simulation time (ns)
for PDE4D and C. elegans PDE4. (a and b) Two independent simulation runs for complexes
of human PDE4D and C. elegans PDE4 with IBMX, zardaverine, or roflumilast. (c) RMSD
traces of three independent simulation runs of apo-PDE4D and apo-C. elegans PDE4.
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Figure 6.3. Probability (P) distributions of interatomic distances between ligand (O4
atom in roflumilast or zardaverine, or O6 atom in IBMX) and binding pocket residues. a)
shows measurements of d1 [between the oxygen atom on the ligand and the Nδ atom on
Gln535(human)/Gln282(C. elegans)] and of d2 [between the oxygen atom of the ligand and
the C4 atom of Phe506 (human)/O atom on the side chain of Tyr253(C. elegans)]. b)
illustrates the distributions for distance d1 for C. elegans PDE4 (red) and human PDE4D
(yellow). c) shows the distributions for the distance d2 for C. elegans PDE4 (blue) and
human PDE4D (cyan). Vertical dotted lines in panels b and c indicate the distances in the
crystal structures of inhibitors bound to human PDE4D.
Hypothesis: PDEs in parasitic nematodes represent a viable target for anthelmintic or
nematicidal compounds.
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The extensive literature on human PDE inhibitor pharmacology [236] and the commercial
availability of many types of family-specific PDE inhibitor compounds enabled us to experi-
mentally evaluate the potential of PDE inhibitors to serve as chemical nematicides targeting
parasitic nematodes. In this chapter, I have used atomistic MD simulations (an approach
used previously to compare the binding of inhibitors to different molecular human PDE4
isoforms [237, 238]) to investigate the role of structural differences in inhibitor interactions
in human and nematode PDE4 that underlie the different pharmacological properties of ne-
matode and human PDE4. These results support the idea that differences in the inhibitor
binding site of nematode PDEs can be exploited to rationally design nematode-selective PDE
inhibitors that act as an anthelmintic or nematicide without adverse effects on vertebrate
animals or crops.
6.3 Methods
The initial coordinates for protein structures were obtained from the crystallographic struc-
tures of PDE4D bound to ligands with PDB codes: 1ZKN [239], 3G4L [240] [241], and
1MKD; in each instance, only one polypeptide chain of the overall structure was modeled,
since the crystal structures of PDE4D consisted of identical PDE catalytic domains that
co-crystallized into an oligomeric crystal. Numbering of amino acid residues for human
PDE4D sequences used for MD simulations reflect the PDE4D 3 amino acid sequence. For
simulation studies of C. elegans PDE4 with bound inhibitors, we created structural models
using SwissModel2 [242] with each of the previously mentioned PDE4D crystal structures as
templates.
Upon comparing the C. elegans homology models with their templates, we observed that
each model had initial mean-squared deviations (relative to their templates) of 0.12 Å,
2https://swissmodel.expasy.org/
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Figure 6.4. Root-mean-squared-fluctuation (RMSF) per residue (top panel) and the change
in RMSF (∆RMSF) per residue (bottom panel) are shown for (a) human PDE4D and (b) C.
elegans PDE4 complexes with IBMX, zardaverine, and roflumilast. The superimposed struc-
tures for human PDE4D/C. elegans PDE4 along with superposition of IBMX, zardaverine,
and roflumilast ligands (sticks) are shown at the top. The colored helices and vertical bars
labeled α1 through α16 highlight the location of residues in the 16 helices in the catalytic
domain. The Val334/81 and Met439/186 residues for human/C. elegans PDE4 are shown
by red and blue spheres, respectively.
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indicative of the homology models having a high structural similarity to the human PDE4
crystal structures. The stability of homology models was further tested using all-atom and
explicit-solvent MD simulations. The stability of the C. elegans structural homology models
in our MD simulations [in conjunction with the highly conserved nature of the PDE cat-
alytic domain structure (PDEase_I; Pfam PF00233)] support their usefulness in the absence
of experimentally determined structures.
We prepared six systems for MD simulations: three each for human PDE4D and C. ele-
gans PDE4 such that each of the starting structures had a PDE inhibitor bound to it. Each
system was then solvated with explicit TIP3P [205] water molecules, and charge-neutralized
with counter-ions resulting in various system sizes. We used the software NAMD [111] for all
MD simulations, and VMD [110] for system setup and post-processing analysis. CHARMM36
[238] force field was used including the CMAP correction [122, 123] for protein structures,
and developed force-fields for all inhibitors using MATCH [125].
We used periodic boundary conditions [243] and computed long range-electrostatics using
the particle-mesh Ewald summation [244] with a grid spacing of 1 Å, an integration time-
step of 2 fs, and a cutoff-distance of 10 Å for van der Waals interactions; these settings are
typically used for conducting MD simulations of solvated systems of proteins using NAMD
[111]. We first energy minimized each system, and continued production runs of each system
in the NPT-ensemble for 120 ns using a Langevin thermostat and Nosé-Hoover barostat
[133, 134, 135]. We also carried out an independent run with the same length of simulation
for each system, giving two production runs for each prepared system. Additionally, we
carried out simulations of the same length for the apo states of human PDE4D and C.
elegans PDE4.
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6.3.1 Nonbonding interaction energy calculations
To investigate the role of individual amino acids in the binding pocket of each protein/li-
gand complex, we computed non-bonded interaction energies between all atoms of ligands
and those of residues forming the binding pocket (i.e., within 5 Å from each ligand). Inter-
action energy values were estimated by splitting them into electrostatic and van der Waals
interactions, as follows:
∆Enon−bonded = ∆Eelec + ∆EvdW (6.1)
We carried out these calculations by including all frames in each MD trajectory.
6.3.2 Analysis of salt-bridging interactions
The salt-bridging interaction analysis was carried out using VMD based on a distance
criterion uniformly applied to determine the existence of salt-bridges for each frame in all
trajectories [14]. Specifically, the formation of a salt-bridging interaction was considered if
the distance between any of the oxygen atoms of acidic residues and the nitrogen atoms of
basic residues were within a cut-off distance of 3.2 Å.
6.4 Results and Discussion
6.4.1 MD simulations to predict inhibitor binding conformations
To investigate the mechanistic details of differences in binding of each inhibitor, we per-
formed two independent sets of MD simulations (120 ns each) of human and C. elegans
PDE4 with each inhibitor (IBMX, zardaverine and roflumilast) (Fig. 6.1), and also car-
ried out simulations of each enzyme without inhibitors. The root-mean-squared-deviation
(RMSD) measured relative to initial structures revealed deviations below 2 Å indicating
stable structures for both enzymes (Fig 6.2). Through visual analyses of these simulations,
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we identified 32 residues in the immediate vicinity of bound ligands (defined as within 5
Å of any of the inhibitors; Figs 6.1a-b) as forming a binding pocket and then computed
interaction energies of inhibitors with each of these 32 residues. In Figs H.1 and H.2, we
present non-bonded interaction energies (van der Waals and electrostatic) for each of the
32 residues where energies were computed based upon all atoms of each residue and of the
inhibitor molecule. These analyses for human PDE4D and C. elegans PDE4 resulted from
two independent sets of simulations. From our interaction energy analyses, we identified five
key residues showing differences between the human and C. elegans PDE4 (Fig 6.1a-b):
(a) three conserved Asp residues (residues 367, 438, and 484 in human PDE4D correspond-
ing to residues 114, 185, and 231 in C. elegans PDE4; purple spheres) that are critical for
the coordination of the zinc and magnesium ions; (b) a conserved Gln residue (Gln535 in
human PDE4D and Gln282 in C. elegans PDE4; red spheres) that stabilizes ligand bind-
ing via non-covalent interactions; and (c) a Phe residue in human PDE4D (Phe506; blue
sphere) and a Tyr residue at the same position in C. elegans (Tyr253; blue sphere) that
show differences in non-bonded interactions. Fig 6.1c presents the differences in the total
non-bonded interaction energy and its components (∆E) for C. elegans PDE4 relative to
the human PDE4D at these five sites. A positive value of ∆E indicates a higher non-bonded
interaction energy of a given residue with the inhibitor in C. elegans in comparison to human
PDE4D, and a negative value of ∆E indicates a lower, non-bonded interaction energy. We
observed positive ∆E values for the three conserved Asp residues for roflumilast and, to a
lesser extent, zardaverine, indicating stronger interactions in C. elegans relative to human
PDE4D. In contrast, for IBMX the ∆E values between C. elegans PDE4 and human PDE4D
are comparable. For all three inhibitor complexes with C. elegans PDE4, Tyr253 showed
higher nonbonded interaction energy with the inhibitors in comparison to the corresponding
Phe506 residue in human PDE4D. Based on the interaction energy analysis, we observed a
correlation between the change in the interaction energy at the non-conserved and conserved
residue sites. Primarily for roflumilast and to a lesser extent for zardaverine and IBMX, we
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observed that an increase in the total non-bonded interaction energy at the non-conserved
site (F506 in human vs. Y253 in C. elegans; labeled as the residue 4 in Fig 6.1) is correlated
with a decrease in the total non-bonded interaction energy at the conserved site (Q535 in
human vs. Q282 in C. elegans; labeled as the residue 5 in Fig 6.1). Similar correlation was
observed between an increase in the total non-bonded interaction energy at the conserved
site (D484 in human vs. D231 in C. elegans; labeled at the residue 3 in Fig 6.1) and a
decrease at the conserved site (Q535 in human vs. Q282 in C. elegans; labeled as the residue
5 in Fig 6.1).
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Figure 6.5. Dynamic cross correlation matrices calculated for the Cα atoms of human
PDE4D and C. elegans PDE4 complexed with IBMX (a), zardaverine (b), and roflumilast
(c). Residues in the α14 and α15 helices are shown by areas between dashed-lines and solid-
lines, respectively. Red tick-marks on the axes represent the 32 residues in the binding site
(as depicted in Fig. 6.1a-b). The color scheme ranges from anticorrelation (-1.0, blue), no
correlation (0, green), and positive correlation (+1.0, red). Values are the average for the
two independent simulation runs.
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Figure 6.6. Dynamic cross correlation matrices calculated for the Cα atoms of human
PDE4D and C. elegans PDE4 in their apo state. Color scheme is the same as for Fig. 6.5.
Panels a-c represent three independent simulations.
To investigate the variation in the docked positions of ligands in the binding pockets of
human and C. elegans PDE4, I computed the interatomic distances between specific atoms
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Figure 6.7. Key salt-bridging interactions are shown based upon the first set of MD
simulations of human PDE4D and C. elegans PDE4 with IBMX (a), zardaverine (b), and
roflumilast (c). Three conserved salt-bridges are labeled in blue.
in the ligands and the nearby Gln535(human)/Gln282(C. elegans) residues (d1 in Fig 6.3).
For C. elegans PDE4, the distributions of d1 are bimodal (red traces in Fig 6.3b) for all
three inhibitors, with roflumilast and zardaverine having a higher probability of being in
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Figure 6.8. Data similar to Fig. 6.7 are shown for a second set of MD simulations with
the three inhibitors.
states with d1∼ 3Å, while for IBMX both states at d1∼ 3Å and ∼ 6Å are equally probable.
For human PDE4D, all inhibitors show an increased probability of being in states at shorter
distances (∼ 3Å) but bimodal distributions with lower probabilities of states at larger dis-
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Figure 6.9. Data similar to Fig. 6.7 are shown for three independent sets of MD simulations
of apo human PDE4D and apo C. elegans PDE4.
tances are observed for zardaverine and IBMX. These observations suggest that zardaverine
and IBMX are more likely to transition between two distinct states within the binding pocket
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Figure 6.10. C. elegans PDE4 catalytic domain illustrating three conserved salt-bridges.
Residues participating in each salt-bridge are colored and labeled. The three inhibitors are
shown as sticks.
in comparison to roflumilast, which appears to be stably bound, largely in a single state.
In addition, we measured the interatomic distance (d2 in Fig 6.3) between the oxygen
atom of the inhibitors to the side-chains of Tyr253 (C. elegans) or Phe506 (human PDE4D).
In C. elegans PDE4, the distance distributions are bimodal and span a larger distance range
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418 (∼3-9 Å) for zardaverine and IBMX in comparison to a unimodal and narrower (∼4-6
Å) distribution for roflumilast. In human PDE4D, the distributions are unimodal for roflu-
milast and zardaverine and bimodal for IBMX, with mean values distinct from those in C.
elegans PDE4. Overall, the measurements on these distances suggest distinct positioning of
inhibitors in the proximity of Phe506 and Gln535 residues in human PDE4D and the corre-
sponding residues Tyr253 and Gln282 in C. elegans. Specifically, roflumilast is significantly
more stable than other inhibitors in the binding pocket of the human PDE4D and showed a
higher non-bonded interaction energy with the Gln535 residue in human PDE4D (Fig 6.1c).
To further probe per-residue perturbations on binding of each inhibitor in both enzymes,
we have computed the per-residue root-mean-squared fluctuation (RMSF) of the liganded
enzyme structures (top panels in Figs 6.4a-b) and the change in per-residue RMSF relative
to their unliganded apo-forms (∆RMSF) (bottom panels in Figs 6.4a-b). Among binding
pocket residues, we observed that ligand binding increased fluctuations in Val334 and Met439
in human PDE4D (corresponding to Val81 and Met186 in C. elegans PDE4). However, the
residues located in loops connecting α5-α6, and α11-α12 helices are more stabilized by the
ligands in human PDE4D in comparison to C. elegans PDE4. The residues located in the M
loop between α8 and α9 helices are more stabilized in C. elegans PDE4 by zardaverine and
roflumilast and to a lesser extent by IBMX in comparison to human PDE4D. Residue Phe506
(human)/Tyr253 (C. elegans) is located in α14-helix which appear more stabilized by ligands
in C. elegans PDE4 in comparison to human PDE4D. Residue Gln535 (human)/Gln282 (C.
elegans) is located in the α15-helix which is perturbed to a greater extent in human PDE4
than C. elegans PDE4 (Fig 6.4). The fluctuations in residues of the binding pocket as
observed in the RMSF analyses are correlated with the analyses of non-bonded interaction
energies.
115
To further investigate whether the higher flexibility of the α14-helix in human PDE4D
complexes with bound ligands affects the motion of the residues belonging to the α15-helix,
we calculated the dynamic cross-correlation matrix for the Cα atoms in all MD trajectories.
For human PDE4D, the correlation matrices showed neither significant positive correlation
nor significant anti-correlation between the residues of the α14-helix (highlighted by the
dashed-lines in Figs 6.5-6.6) and the residues of the α15-helix (highlighted by the solid-lines
in Figs 6.5-6.6). However, we find that the motion of residues in the α14 and α15 helices
are marginally more correlated in C. elegans PDE4 in comparison to human PDE4D. The
correlation between the α14 and α15 helices is mostly found between neighboring residues of
Tyr253 (C. elegans) and Gln282 (C. elegans). We also observed (Fig 6.5) significantly higher
positive residue-residue (Cα-Cα) correlation within human PDE4D complexes with IBMX
and zardaverine in comparison to C. elegans PDE4, whereas the complexes with roflumilast
showed significantly lower positive correlation in human PDE4D in comparison to C. elegans
PDE4. This indicates that roflumilast induces a different pattern of correlated motions in
the protein backbone in comparison to IBMX and zardaverine, and comparable to those of
the apo states (Fig 6.6).
To better understand the effect of ligands on the protein structure outside the binding
site, we identified all possible salt-bridging interactions within human PDE4D and C. el-
egans PDE4 (Figs 6.7-6.10). Qualitatively, the salt-bridging interactions are observed to
occur with a lower frequency in human PDE4D in comparison to C. elegans PDE4. We
also found a smaller number of salt-bridging interactions in human PDE4D complexed with
roflumilast, but these salt-bridging interactions were comparatively stable for longer times
during simulations. Furthermore, we identified three salt-bridge pairs conserved between
human PDE4D and C. elegans PDE4 with higher occupancy number: D179-K175 (C. el-
egans), D204-K214 (C. elegans), and D80-K237 (C. elegans) (Fig 6.7, and labeled in Figs
6.8 and 6.9). D179-K175 (C. elegans) is an intra-helical salt-bridge in the α11-helix, and
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D204-K214 (C. elegans) is in the loop connecting the α12 and α13 helices. The D179-K175
(C. elegans) interaction pair in the human PDE4D complexes with ligands showed a lower
occupancy in comparison to apo human PDE4D. The occupancy of the D204-K214 (C. el-
egans) is higher in the apo-human PDE4D in comparison to C. elegans PDE4, whereas it
has a higher occupancy in C. elegans PDE4 complexes with ligands in comparison to human
PDE4D complexes with ligands (Figs 6.7-6.10). The D80-K237 (C. elegans) salt-bridge is
located near the binding pocket, the D80 residue is in the α6-helix and the K237 residue is
in the loop connecting α13 and α14. I observed that the occupancy of the D80-K237 (C.
elegans) salt-bridge was significantly suppressed by roflumilast in human PDE4D in com-
parison to zardaverine and IBMX, while the occupancy of this salt-bridge is not affected by
the presence of IBMX and zardaverine (Figs 6.7-6.10).
Both dynamic cross-correlation analysis and salt-bridging interactions revealed allosteric
effects of each ligand on the protein structure. Unlike IBMX and zardaverine, roflumilast in-
duced distinct patterns of structural perturbations outside of the binding pocket for human
PDE4D compared with C. elegans PDE4. Specifically, we observed lower residue-residue
correlations for roflumilast in comparison to zardaverine and IBMX in human PDE4D in
comparison to C. elegans PDE4. While we observed overall a smaller number of salt-bridging
interactions in human PDE4D in comparison to C. elegans PDE4, the salt-bridging interac-
tions in human PDE4D were significantly more stable for roflumilast. In contrast, roflumilast
significantly perturbed some salt-bridging interactions (D88-K237) more than zardaverine
and IBMX in C. elegans PDE4. Therefore, we suggest that modulation of salt-bridging
interactions could be one of the factors that contribute to an altered binding affinity of an
inhibitor among different protein isoforms. Taken together, these structural analyses provide
a molecular basis for better understanding differential binding of inhibitory compounds in
the human PDE4 versus C. elegans PDE4 catalytic domain.
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6.4.2 Atomistic simulations provide insight into altered pharmacological prop-
erties
The substantial differences in the primary sequence of nematode and vertebrate PDEs
and pharmacological results revealed significant changes in binding affinities of compounds
that were designed for human PDE4D. To gain further insights into differences in the ligand
binding sites of C. elegans PDE4 and human PDE4D that could explain the reduced affinity
of C. elegans PDE4 for compounds optimized as human PDE inhibitors, I used homology
models and all-atom explicit-solvent MD simulations. The use of homology models has been
successfully used in previous studies to identify amino acid residues that are responsible
for differences in binding of inhibitors to PDE5 and PDE6 [238]. From the 32 amino acid
residues that we defined as constituting the inhibitor-binding site, only five sites differed be-
tween the two enzymes and four of those were conservative substitutions that preserved the
polar or hydrophobic nature at its position and thus are unlikely to drastically change the
binding conformation or energy. However, I observed differences in nonbonded interaction
energies due to the movement of inhibitors in the vicinity of residue Phe506 in H. sapiens
(corresponding to Tyr253 in C. elegans). Overall, this Tyr residue contributes significantly
more total non-bonded interaction energy than the Phe in the same position for all three
inhibitors (Figs H.1 and H.2), likely due to the hydrogen bonding that results from the ad-
dition of a hydroxyl group at the 4-C of the aromatic ring.
For IBMX, the Phe to Tyr substitution appears to have little impact on the overall bind-
ing of IBMX to either human PDE4D or C. elegans PDE4. This is likely a result of IBMX
interacting solely with the hydrophobic pocket of PDE4, as suggested by IBIS [245, 246].
Despite the polar Tyr residue coordinating to the ketone at position 6 in the purine ring
of IBMX in C. elegans, our MD results indicate that the interactions and conformation of
IBMX are very similar in the two PDE4 catalytic domains. This is consistent with the ob-
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Figure 6.11. Enzyme activity was tested over a range of inhibitor concentrations with 1 µM
cAMP substrate 323 concentration. The dose-response relationship was fit to a 3-parameter
logistic equation to obtain the 324 IC50 and the standard error of the mean for the indicated
number of experiments (This figure was created by my co-author Kevin Schuster).
served similarity in IC50 values for IBMX with the two enzymes (Fig 6.11).
In contrast, the MD simulations suggest that the binding conformation of zardaverine or
roflumilast are altered as a result of the substitution of Tyr253 for Phe506 at this site in the
binding pocket of the two enzymes, consequently inducing a different pattern of correlated
motions in the protein backbone. In C. elegans, the hydroxyl group of the Tyr residue co-
ordinates strongly with the methoxyphenyl and cyclopropylmethoxyl group of zardaverine
and roflumilast, respectively. This increase in energy contribution appears to result in a
displacement of both ligands away from the hydrophobic sub-pocket that further disrupts
stabilization by the conserved glutamine residues (Gln535 in human PDE4; Fig 6.1c).
It has been previously reported that Tyr495, Phe506, Gln535 are critical for stabilizing
PDE4 inhibitors [237]. This disruption of the desired binding conformation in C. elegans
could partially explain the reduced IC50 values for these two compounds (Fig 6.11). While
per-residue fluctuations are also found to be correlated with non-bonded interaction energy
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analyses, other analyses (e.g. interatomic distances and residue-residue correlations) suggest
that, among the three inhibitors, roflumilast is more stable in the binding pockets and in-
duces a distinct pattern of correlated motions in comparison to zardaverine and IBMX. In
summary, these MD analyses highlight the importance of considering not only differences in
residue substitutions (e.g. Tyr253 in C. elegans vs. Phe506 in H. sapiens) but also allosteric
perturbations and overall inhibitor stabilization of catalytic domain conformation in future
efforts to design and optimize nematode-specific PDE inhibitor compounds using in silico
approaches such as virtual screening and fragment-based drug design [247, 248].
6.5 Conclusion
MD simulations were used to support the hypothesis that the nematode PDE enzyme family
differs sufficiently from the vertebrate PDE orthologs to validate the feasibility of devel-
oping PDE inhibitor compounds as potent and selective anthelmintics/nematicides. While
analysis of the differences in the amino acid sequence or structure-activity relationships for
selected PDE inhibitor compounds did not immediately identify which sites of interaction
may have been disrupted in C. elegans PDE4 for inhibitors designed for human PDE4D, MD
simulations revealed the importance of Phe506 (human)/Tyr253 (C. elegans) substitution
and demonstrated that changes in the conformation of the catalytic domain may collectively
lead to inhibitor discrimination in the binding pocket, based on the following analyses: (1)
non-bonded interaction energy analysis; (2) changes in the ligand orientation in the binding
pocket; (3) RMSF analysis; (4) cross correlation analysis; and (5) salt-bridge interaction
analysis.
Collectively, the results indicate that future efforts to discover inhibitor compounds specif-
ically targeting nematode PDE4 must take into consideration not only the molecular archi-
tecture of the inhibitor binding site, but also the conformational dynamics of the entire
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catalytic domain of the enzyme. Insights gained from this study will advance efforts to ra-
tionally design inhibitor compounds that selectively and potently inhibit plant and animal
parasitic nematode, PDEs to disrupt their lifecycle, thereby enhancing public health and
agricultural productivity.
6.6 Publications
The work described in this chapter has resulted in the following journal article:
• Schuster, K.D., Mohammadi, M., Cahill, K.B., Matte, S.L., Maillet, A.D., Vashisth,
H., and Cote, R.H. (2019). Pharmacological and molecular dynamics analyses of differ-
ences in inhibitor binding to human and nematode PDE4: implications for management
of parasitic nematodes. PLoS ONE 14(3): e0214554.
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CHAPTER 7
CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS
In this thesis, I used MD simulations described in section 2.2 and enhanced sampling tech-
niques such as TAMD described in section 2.4.1, and single-sweep method [141] described
in sections 2.4.1, 2.4.1.1, and 2.4.1.2. Additionally, I used various conformational metrics
calculations based on MD simulations (e.g. RMSD, RMSF, DCC, and non-bonded inter-
action energy). The overall understanding gained from work presented in this thesis could
further guide mutagenesis studies in [FeFe]-hydrogenase or drug discovery efforts aimed at
RGS proteins and nematode PDEs.
The primary outcome of this thesis work has been an enhanced understanding of the
protein-inhibitor interactions in the studied cases. Specifically, the studies of protein confor-
mational changes show transient states (beyond static protein states) that play a key role
in inhibitor recognition and migration within protein-cavities. By characterizing the inter-
connected pathways of inhibitory gases within [FeFe]-hydrogenase, more effective mutations
in residues could be performed for increasing the enzyme tolerance to inhibitory gases. The
studies of inhibitory compounds of RGS4 protein provide enhanced view of the mechanism
of action of TDZD inhibitors among isoforms of RGS proteins, and further elucidate the
alternative binding mechanisms for these allosteric inhibitors and correlations between their
potencies and the protein dynamics. The studies of human PDE4D inhibitors and C. ele-
gans PDE4 provide enhanced insight into effects of inhibitors on the catalytic domain of the
enzyme.
122
In chapter 3, I studied the interconnected network of pathways of inhibitory gases (O2 and
CO) within [FeFe]-hydrogenase. The differences in the free-energy levels of pathways between
O2 and CO show that any residue mutation directed toward one gas might affect the enzyme
structure that may affect the interconnected network of the other gases (e.g. hydrogen).
In addition to the challenge of increasing tolerance of the enzyme to inhibitory gases, one
should consider that the successful mutagenesis studies would require characterization of
pathways of other molecules that compete with O2 and CO such as H2 and H2O within
the enzyme. Therefore, one future work may be the studies of interconnected network of
pathways of H2 and H2O within [FeFe]-hydrogenase. The final step in understanding the
network of pathways of all of these molecules in the enzyme would be the computation
of kinetic rates across each migration pathway for each gas/solvent molecule. One can
conduct the calculation for finding the kinetic rates, and further enhance the experimental
mutagenesis studies aimed at H2 production from [FeFe]-hydrogenase.
In chapters 4 and 5, I studied the covalent inhibitors of RGS proteins that inhibit the
RGS/Gα protein-protein interaction. Here, the computational studies were solely directed
toward the RGS proteins and not when they are bound to Gα proteins. The differences in
potency of the inhibitor molecules across isoforms of RGS proteins suggest similar differences
may exist in the interaction of the RGS-inhibitor complex with Gα subunits. The final goal
of these inhibitors is to prevent the formation of the RGS-Gα complex. Therefore, one
future work may be the MD simulation of the RGS-Gα complex with and without inhibitor
molecules. Another future work may be the studies to enhance our view of binding and
unbinding rate [249] of the inhibitory compounds to RGS proteins.
In chapter 6, I studied the PDE inhibitor compounds designed for human PDE4D on
C. elegans PDE4. In this study, I found key sites in the catalytic domain of the enzyme
for interaction with the selected PDE inhibitory compounds. The knowledge of differences
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in the conformation of the catalytic domain may be supplemented with the calculation of
free-energy of binding of inhibitory molecules. The free-energy of binding of compounds can
be computed using MM/PBSA and MM/GBSA methods [250]. Another future work may
be the computation of network of pathways of inhibitory compounds within the catalytic
domain. This study can be performed using the single-sweep method [141] described in
sections 2.4.1, 2.4.1.1, and 2.4.1.2.
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[133] Shūichi Nosé. A molecular dynamics method for simulations in the canonical ensemble.
Mol. Phys., 52(2):255–268, 1984.
[134] William G Hoover, Anthony JC Ladd, and Bill Moran. High-strain-rate plastic flow
studied via nonequilibrium molecular dynamics. Phys. Rev. Lett., 48(26):1818, 1982.
[135] William G Hoover. Canonical dynamics: Equilibrium phase-space distributions. Phys.
Rev. A, 31(3):1695, 1985.
[136] Juan R Perilla and Klaus Schulten. Physical properties of the HIV-1 capsid from
all-atom molecular dynamics simulations. Nat. Commun., 8:15959, 2017.
[137] Cameron F. Abrams and Giovanni Bussi. Enhanced sampling in molecular dynam-
ics using metadynamics, replica-exchange, and temperature-acceleration. Entropy,
16(1):163–199, 2014.
[138] Daniele Granata, Carlo Camilloni, Michele Vendruscolo, and Alessandro Laio. Char-
acterization of the free-energy landscapes of proteins by NMR-guided metadynamics.
Proc. Natl. Acad. Sci. U.S.A., 110(17):6817–6822, 2013.
[139] Yanier Crespo, Fabrizio Marinelli, Fabio Pietrucci, and Alessandro Laio. Metadynam-
ics convergence law in a multidimensional system. Phys. Rev. E., 81(5), 2010.
[140] Luca Maragliano and Eric Vanden-Eijnden. A temperature accelerated method for
sampling free energy and determining reaction pathways in rare events simulations.
Chem. Phys. Lett., 426(1):168–175, 2006.
142
[141] Luca Maragliano and Eric Vanden-Eijnden. Single-sweep methods for free energy
calculations. J. Chem. Phys., 128(18):184110–184120, 2008.
[142] Harish Vashisth, Luca Maragliano, and Cameron F. Abrams. “DFG-flip” in the insulin
receptor kinase is facilitated by a helical intermediate state of the activation loop.
Biophys. J., 102:1979–1987, 2012.
[143] Harish Vashisth, Georgios Skiniotis, and Charles L. Brooks III. Using enhanced sam-
pling and structural restraints to refine atomic structures into low-resolution electron
microscopy maps. Structure, 20:1453–1462, 2012.
[144] Harish Vashisth and Charles L. Brooks III. Conformational sampling of maltose-
transporter components in cartesian collective variables is governed by the low-
frequency normal modes. J. Phys. Chem. Lett., 3 :3379–3384, 2012.
[145] Cameron F Abrams and Eric Vanden-Eijnden. Large scale conformational sampling
of proteins using temperature accelerated molecular dynamics. Proc. Natl. Acad. Sci.
U. S. A., 107(11):4961–4966, 2010.
[146] Giovanni Ciccotti, Raymond Kapral, and Eric Vanden-Eijnden. Blue moon sampling,
vectorial reaction coordinates, and unbiased constrained dynamics. ChemPhysChem,
6(9):1809–1814, 2005.
[147] Michele Monteferrante, Sara Bonella, Simone Meloni, Eric Vanden-Eijnden, and Gio-
vanni Ciccotti. Calculations of free energy barriers for local mechanisms of hydrogen
diffusion in alanates. Sci. Model Simul., pages 187–206, 2008.
[148] Michele Monteferrante, Sara Bonella, Simone Meloni, and Giovanni Ciccotti. Modified
single-sweep method for reconstructing free energy landscapes. Mol. Simul., 35(12-
13):1116–1129, 2009.
143
[149] Weinan E, Weiqing Ren, and Eric Vanden-Eijnden. String method for the study of
rare events. Phys. Rev. B, 66(5):052301, 2002.
[150] Luca Maragliano, Alexander Fischer, Eric Vanden-Eijnden, and Giovanni Ciccotti.
String method in collective variables: Minimum free energy paths and isocommittor
surfaces. J. Chem. Phys., 125(2):024106, 2006.
[151] E Weinan, Weiqing Ren, and Eric Vanden-Eijnden. Simplified and improved string
method for computing the minimum energy paths in barrier-crossing events. J. Chem.
Phys., 126(16):164103, 2007.
[152] Luca Maragliano and Eric Vanden-Eijnden. On the fly string method for minimum
free energy paths calculation. Chem. Phys. Lett., 446(1):182–190, 2007.
[153] Alessandro Laio and Michele Parrinello. Escaping free-energy minima. Proc. Natl.
Acad. Sci. U.S.A., 99(20):12562–12566, 2002.
[154] Alessandro Laio and Francesco L Gervasio. Metadynamics: a method to simulate rare
events and reconstruct the free energy in biophysics, chemistry and material science.
Rep. Prog. Phys., 71(12):126601, 2008.
[155] Vittorio Limongelli, Luciana Marinelli, Sandro Cosconati, Concettina La Motta, Ste-
fania Sartini, Laura Mugnaini, Federico Da Settimo, Ettore Novellino, and Michele
Parrinello. Sampling protein motion and solvent effect during ligand binding. Proc.
Natl. Acad. Sci. U.S.A., 109(5):1467–1472, 2012.
[156] Alessandro Barducci, Massimiliano Bonomi, Meher K Prakash, and Michele Parrinello.
Free-energy landscape of protein oligomerization from atomistic simulations. Proc.
Natl. Acad. Sci. U.S.A., 110(49):E4708–E4713, 2013.
144
[157] Hossein Mohammadiarani and Harish Vashisth. All-atom structural models of the
transmembrane domains of insulin and type 1 insulin-like growth factor receptors.
Front. Endocrinol., 7, 2016.
[158] Hossein Mohammadiarani and Harish Vashisth. Insulin mimetic peptide S371 folds
into a helical structure. J. Comput. Chem., 38(15):1158–1166, 2017.
[159] Xevi Biarnés, Salvatore Bongarzone, Attilio Vittorio Vargiu, Paolo Carloni, and Paolo
Ruggerone. Molecular motions in drug design: the coming age of the metadynamics
method. J. Comput. Aided Mol. Des., 25(5):395–402, 2011.
[160] Matteo Incerti, Simonetta Russo, Donatella Callegari, Daniele Pala, Carmine Gior-
gio, Ilaria Zanotti, Elisabetta Barocelli, Paola Vicini, Federica Vacondio, Silvia Ri-
vara, Riccardo Castelli, Massimiliano Tognolini, and Alessio Lodola. Metadynamics
for perspective drug design: computationally driven synthesis of new protein–protein
interaction inhibitors targeting the epha2 receptor. J. Med. Chem., 60(2):787–796,
2017.
[161] Riccardo Baron, Conor Riley, Pirom Chenprakhon, Kittisak Thotsaporn, Remko T
Winter, Andrea Alfieri, Federico Forneris, Willem JH van Berkel, Pimchai Chaiyen,
Marco W Fraaije, et al. Multiple pathways guide oxygen diffusion into flavoenzyme
active sites. Proc. Natl. Acad. Sci. U. S. A., 106(26):10603–10608, 2009.
[162] Robert Y Igarashi and Lance C Seefeldt. Nitrogen fixation: the mechanism of the
mo-dependent nitrogenase. Crit. Rev. Biochem. Mol. Biol., 38(4):351–384, 2003.
[163] W Lubitz and W Tumas. Hydrogen: an overview. Chem. Rev., 107(10):3900–3903,
2007.
[164] Gregory J Kubas. Fundamentals of H2 binding and reactivity on transition met-
als underlying hydrogenase function and H2 production and storage. Chem. Rev.,
107(10):4152–4205, 2007.
145
[165] Cédric Tard, Xiaoming Liu, Saad K Ibrahim, Maurizio Bruschi, Luca De Gioia, Siân C
Davies, Xin Yang, Lai-Sheng Wang, Gary Sawers, and Christopher J Pickett. Synthesis
of the H-cluster framework of iron-only hydrogenase. Nature, 433(7026):610, 2005.
[166] Gustav Berggren, A Adamska, C Lambertz, TR Simmons, J Esselborn, M Atta,
S Gambarelli, J-M Mouesca, E Reijerse, W Lubitz, T. Happe, V. Artero, and
M. Fontecave. Biomimetic assembly and activation of [FeFe]-hydrogenases. Nature,
499(7456):66, 2013.
[167] Juan C Fontecilla-Camps, Anne Volbeda, Christine Cavazza, and Yvain Nicolet.
Structure/function relationships of [NiFe]-and [FeFe]-hydrogenases. Chem. Rev.,
107(10):4273–4303, 2007.
[168] Paulette M Vignais and Bernard Billoud. Occurrence, classification, and biological
function of hydrogenases: an overview. Chem. Rev., 107(10):4206–4272, 2007.
[169] Zhi-Pan Liu and P Hu. Mechanism of H2 metabolism on Fe-only hydrogenases. J.
Chem. Phys., 117(18):8177, 2002.
[170] John W Peters, William N Lanzilotta, Brian J Lemon, and Lance C Seefeldt. X-ray
crystal structure of the fe-only hydrogenase (CpI) from clostridium pasteurianum to
1.8 angstrom resolution. Science, 282(5395):1853–1858, 1998.
[171] Arti S Pandey, Travis V Harris, Logan J Giles, John W Peters, and Robert K Szi-
lagyi. Dithiomethylether as a ligand in the hydrogenase h-cluster. J. Am. Chem. Soc.,
130(13):4533–4540, 2008.
[172] MW Adams. The mechanisms of H2 activation and CO binding by hydrogenase i
and hydrogenase ii of clostridium pasteurianum. J. Biol. Chem., 262(31):15054–15061,
1987.
146
[173] Gabrielle Goldet, Caterina Brandmayr, Sven T Stripp, Thomas Happe, Christine
Cavazza, Juan C Fontecilla-Camps, and Fraser A Armstrong. Electrochemical kinetic
investigations of the reactions of [FeFe]-hydrogenases with carbon monoxide and oxy-
gen: comparing the importance of gas tunnels and active-site electronic/redox effects.
J. Am. Chem. Soc., 131(41):14979–14989, 2009.
[174] Carole Baffert, Luca Bertini, Thomas Lautier, Claudio Greco, Kateryna Sybirna,
Pierre Ezanno, Emilien Etienne, Philippe Soucaille, Patrick Bertrand, Hervé Bottin,
Isabelle Meynial-Salles, Luca De Giois, and Christophe Léger. CO disrupts the reduced
H-cluster of FeFe hydrogenase. a combined DFT and protein film voltammetry study.
J. Am. Chem. Soc., 133(7):2096–2099, 2011.
[175] Pierre-Pol Liebgott, Fanny Leroux, Bénédicte Burlat, Sébastien Dementin, Carole Baf-
fert, Thomas Lautier, Vincent Fourmond, Pierre Ceccaldi, Christine Cavazza, Isabelle
Meynial-Salles, Philippe Soucaille, Juan Carlos Fontecilla-Camps, Bruno Guigliarelli,
Patrick Bertrand, Marc Rousset, and Léger. Relating diffusion along the substrate
tunnel and oxygen sensitivity in hydrogenase. Nat. Chem. Biol., 6(1):63, 2010.
[176] Thomas Lautier, Pierre Ezanno, Carole Baffert, Vincent Fourmond, Laurent Cournac,
Juan C Fontecilla-Camps, Philippe Soucaille, Patrick Bertrand, Isabelle Meynial-
Salles, and Christophe Léger. The quest for a functional substrate access tunnel in fefe
hydrogenase. Faraday Discuss., 148:385–407, 2011.
[177] Mohammad Mirmohades, Agnieszka Adamska-Venkatesh, Constanze Sommer, Ed-
ward Reijerse, Reiner Lomoth, Wolfgang Lubitz, and Leif Hammarstrom. Following
[FeFe] hydrogenase active site intermediates by time-resolved mid-ir spectroscopy. J.
Phys. Chem. Lett., 7(16):3290–3293, 2016.
[178] Fanny Leroux, Sébastien Dementin, Bénédicte Burlat, Laurent Cournac, Anne
Volbeda, Stéphanie Champ, Lydie Martin, Bruno Guigliarelli, Patrick Bertrand, Juan
147
Fontecilla-Camps, Marc Rousset, and Christophe Léger. Experimental approaches to
kinetics of gas diffusion in hydrogenase. Proc. Natl. Acad. Sci. U.S.A, 105(32):11188–
11193, 2008.
[179] Po-hung Wang and Jochen Blumberger. Mechanistic insight into the blocking of CO
diffusion in [NiFe]-hydrogenase mutants through multiscale simulation. Proc. Natl.
Acad. Sci. USA, 109:6399, 2012.
[180] Thierry Prange, Marc Schiltz, Lucile Pernot, Nathalie Colloc’h, Sonia Longhi, William
Bourguet, and Roger Fourme. Exploring hydrophobic sites in proteins with xenon or
krypton. Proteins, 30(1):61–73, 1998.
[181] Christopher H Chang and Kwiseon Kim. Density functional theory calculation of
bonding and charge parameters for molecular dynamics studies on [FeFe]-hydrogenases.
J. Chem. Theory Comput., 5(4):1137–1145, 2009.
[182] Martin McCullagh and Gregory A Voth. Unraveling the role of the protein environment
for [FeFe]-hydrogenase: A new application of coarse-graining. J. Phys. Chem. B,
117(15):4062–4071, 2013.
[183] E Weinan, Weiqing Ren, and Eric Vanden-Eijnden. String method for the study of
rare events. Phys. Rev. B, 66(5):052301, 2002.
[184] E Weinan, Weiqing Ren, and Eric Vanden-Eijnden. Simplified and improved string
method for computing the minimum energy paths in barrier-crossing events. J. Chem.
Phys., 126(16):164103, 2007.
[185] Luca Maragliano, Alexander Fischer, Eric Vanden-Eijnden, and Giovanni Ciccotti.
String method in collective variables: Minimum free energy paths and isocommittor
surfaces. J. Chem. Phys., 125(2):024106, 2006.
148
[186] Luca Maragliano and Eric Vanden-Eijnden. On-the-fly string method for minimum
free energy paths calculation. Chem. Phys. Lett., 446(1-3):182–190, 2007.
[187] Juan C Fontecilla-Camps, Anne Volbeda, Christine Cavazza, and Yvain Nicolet.
Structure/function relationships of [NiFe]-and [FeFe]-hydrogenases. Chem. Rev.,
107(10):4273–4303, 2007.
[188] Hai Long, Paul W King, and Christopher H Chang. Proton transport in clostrid-
ium pasteurianum [FeFe]-hydrogenase I: A computational study. J. Phys. Chem. B,
118(4):890–900, 2014.
[189] Mariano Andrea Scorciapino, Arturo Robertazzi, Mariano Casu, Paolo Ruggerone, and
Matteo Ceccarelli. Heme proteins: the role of solvent in the dynamics of gates and
portals. J. Am. Chem. Soc., 132(14):5156–5163, 2010.
[190] Bryan J Johnson, Jordi Cohen, Richard W Welford, Arwen R Pearson, Klaus Schul-
ten, Judith P Klinman, and Carrie M Wilmot. Exploring molecular oxygen path-
ways in hansenula polymorpha copper-containing amine oxidase. J. Biol. Chem.,
282(24):17767–17776, 2007.
[191] Patricia Amara, Pierre Andreoletti, HéLène Marie Jouve, and Martin J Field. Ligand
diffusion in the catalase from proteus mirabilis: A molecular dynamics study. Protein
Sci., 10(10):1927–1935, 2001.
[192] Olaseni Sode and Gregory A Voth. Electron transfer activation of a second water chan-
nel for proton transport in [FeFe]-hydrogenase. J. Chem. Phys., 141(22):12B630_1,
2014.
[193] Isaiah Sumner and Gregory A Voth. Proton transport pathways in [NiFe]-hydrogenase.
J. Phys. Chem. B, 116(9):2917–2926, 2012.
149
[194] Jason C Crack, Jeffrey Green, Myles R Cheesman, Nick E Le Brun, and Andrew J
Thomson. Superoxide mediated amplification of the oxygen induced switch from [4Fe-
4S] to [2Fe-2S] clusters in the transcriptional regulator FNR. Proc. Natl. Acad. Sci.
U. S. A., 104(7):2092–2097, 2007.
[195] Matthew C Posewitz, Paul W King, Sharon L Smolinski, Liping Zhang, Michael
Seibert, and Maria L Ghirardi. Discovery of two novel radical s-adenosylmethionine
proteins required for the assembly of an active [Fe]-hydrogenase. J. Biol. Chem.,
279(24):25711–25720, 2004.
[196] Carole Baffert, Marie Demuez, Laurent Cournac, Benedicte Burlat, Bruno Guigliarelli,
Patrick Bertrand, Laurence Girbal, and Christophe Léger. Hydrogen-activating
enzymes: Activity does not correlate with oxygen sensitivity. Angew. Chem.,
47(11):2052–2054, 2008.
[197] A. Bondi. Van der waals volumes and radii. J. Phys. Chem., 68(3):441–451, 1964.
[198] Jordi Cohen, Kwiseon Kim, Paul King, Michael Seibert, and Klaus Schulten. Finding
gas diffusion pathways in proteins: application to O2 and H2 transport in CpI [FeFe]-
hydrogenase and the role of packing defects. Structure, 13(9):1321–1329, 2005.
[199] Udo Radius, F Matthias Bickelhaupt, Andreas W Ehlers, Norman Goldberg, and Roald
Hoffmann. Is CO a special ligand in organometallic chemistry? theoretical investiga-
tion of AB, Fe (CO) 4AB, and Fe (AB) 5 (AB= N2, CO, BF, SiO). Inorg. Chem.,
37(5):1080–1090, 1998.
[200] Sven T Stripp, Gabrielle Goldet, Caterina Brandmayr, Oliver Sanganas, Kylie A Vin-
cent, Michael Haumann, Fraser A Armstrong, and Thomas Happe. How oxygen attacks
[FeFe] hydrogenases from photosynthetic organisms. Proc. Natl. Acad. Sci. U. S. A.,
106(41):17331–17336, 2009.
150
[201] Jamin Koo and James R Swartz. System analysis and improved [FeFe] hydrogenase O2
tolerance suggest feasibility for photosynthetic H2 production. Metab. Eng., 49:21–27,
2018.
[202] Hossein Mohammadiarani, Vincent S Shaw, Richard R Neubig, and Harish Vashisth.
Interpreting hydrogen–deuterium exchange events in proteins using atomistic simula-
tions: Case studies on regulators of G-protein signaling proteins. J. Phys. Chem. B,
122(40):9314–9323, 2018.
[203] James C Phillips, Rosemary Braun, Wei Wang, James Gumbart, Emad Tajkhorshid,
Elizabeth Villa, Christophe Chipot, Robert D Skeel, Laxmikant Kale, and Klaus Schul-
ten. Scalable molecular dynamics with NAMD. J. Comput. Chem., 26(16):1781–1802,
2005.
[204] William Humphrey, Andrew Dalke, and Klaus Schulten. VMD: Visual molecular dy-
namics. J. Mol. Graph., 14(1):33–38, 1996.
[205] William L Jorgensen, Jayaraman Chandrasekhar, Jeffry D Madura, Roger W Impey,
and Michael L Klein. Comparison of simple potential functions for simulating liquid
water. J. Chem. Phys., 79(2):926–935, 1983.
[206] Giacomo Fiorin, Michael L Klein, and Jérôme Hénin. Using collective variables to
drive molecular dynamics simulations. Mol. Phys., 111(22-23):3345–3362, 2013.
[207] Michael P Hayes, Christopher R Bodle, and David L Roman. Evaluation of the selec-
tivity and cysteine dependence of inhibitors across the regulator of G-protein–signaling
family. Mol. Pharmacol., 93(1):25–35, 2018.
[208] Derek W Morris, Alana Rodgers, Kevin A McGhee, Siobhan Schwaiger, Paul Scully,
John Quinn, David Meagher, John L Waddington, Michael Gill, and Aiden P Corvin.
Confirming RGS4 as a susceptibility gene for schizophrenia. Am. J. Med. Genet.,
125(1):50–53, 2004.
151
[209] Michele H Potashman and Mark E Duggan. Covalent modifiers: an orthogonal ap-
proach to drug design. J. Med. Chem., 52(5):1231–1246, 2009.
[210] Michael A James, Yan Lu, Yan Liu, Haris G Vikis, and Ming You. RGS17, an over-
expressed gene in human lung and prostate cancer, induces tumor cell proliferation
through the cyclic AMP-PKA-CREB pathway. Cancer Res., 69(5):2108–2116, 2009.
[211] Christopher R Bodle, Duncan I Mackie, and David L Roman. RGS17: an emerging
therapeutic target for lung and prostate cancers. Future Med. Chem., 5(9):995–1007,
2013.
[212] Qin Wang, Akiko Terauchi, Christopher H Yee, Hisashi Umemori, and John R Traynor.
5-HT1A receptor-mediated phosphorylation of extracellular signal-regulated kinases
(ERK1/2) is modulated by regulator of G-protein signaling protein 19. Cell. Signal.,
26(9):1846–1852, 2014.
[213] Eva de Alba, Luc De Vries, Marilyn Gist Farquhar, and Nico Tjandra. Solution struc-
ture of human GAIP (Gα interacting protein): a regulator of G-protein signaling. J.
Mol. Biol., 291(4):927–939, 1999.
[214] Veronica G Taylor, Paige A Bommarito, and John JG Tesmer. Structure of the regu-
lator of G-protein signaling 8 (RGS8)-Gαq complex molecular basis for Gα selectivity.
J. Biol. Chem., 291(10):5138–5145, 2016.
[215] Levi L Blazer, David L Roman, Molly R Muxlow, and Richard R Neubig. Use of flow
cytometric methods to quantify protein-protein interactions. Curr. Protoc. Cytom.,
pages 13–11, 2010.
[216] David L Roman, Jeffery N Talbot, Rebecca A Roof, Roger K Sunahara, John R
Traynor, and Richard R Neubig. Identification of small-molecule inhibitors of RGS4
using a high-throughput flow cytometry protein interaction assay. Mol. Pharmacol.,
71(1):169–175, 2007.
152
[217] Christopher O. Ortiz, John F. Etchberger, Shoshana L. Posy, Christian Frøkjær-
Jensen, Shawn Lockery, Barry Honig, and Oliver Hobert. Searching for neuronal left-
/right asymmetry: Genomewide analysis of nematode receptor-type guanylyl cyclases.
Genetics, 173(1):131–149, 2006.
[218] Jie Liu, Alex Ward, Jingwei Gao, Yongming Dong, Nana Nishio, Hitoshi Inada, Li-
jun Kang, Yong Yu, Di Ma, Tao Xu, et al. C. elegans phototransduction requires a
G-protein–dependent cgmp pathway and a taste receptor homolog. Nat. Neurosci.,
13(6):715, 2010.
[219] Mamoru Usuyama, Chisato Ushida, and Ryuzo Shingai. A model of the intracellular
response of an olfactory neuron in Caenorhabditis elegans to odor stimulation. PloS
ONE, 7(8):e42907, 2012.
[220] Lindy Holden-Dye and R Walker. Anthelmintic drugs and nematocides: Studies in
caenorhabditis elegans. WormBook: the online review of C. elegans biology, pages
1–29, 2014.
[221] Sylvana Papaioannou, Lindy Holden-Dye, and Robert J Walker. Evidence for a role
for cyclic AMP in modulating the action of 5-HT and an excitatory neuropeptide,
FLP17A, in the pharyngeal muscle of caenorhabditis elegans. Invertebr. Neurosci.,
8(2):91, 2008.
[222] Michael A Schade, Nicole K Reynolds, Claudia M Dollins, and Kenneth G Miller. Mu-
tations that rescue the paralysis of Caenorhabditis elegans ric-8 (Synembryn) mutants
activate the Gαs pathway and define a third major branch of the synaptic signaling
network. Genetics, 169(2):631–649, 2005.
[223] DL Noelle and Cornelia I Bargmann. Olfaction and odor discrimination are mediated
by the C. elegans guanylyl cyclase ODR-1. Neuron, 25(3):575–586, 2000.
153
[224] Suk-Woo Cho, Kyu Yeong Choi, and Chul-Seung Park. A new putative cyclic
nucleotide-gated channel gene, cng-3, is critical for thermotolerance in Caenorhabditis
elegans. Biochem. Biophys. Res. Commun., 325(2):525–531, 2004.
[225] Renate K Hukema, Suzanne Rademakers, Martijn PJ Dekkers, Jan Burghoorn, and
Gert Jansen. Antagonistic sensory cues generate gustatory plasticity in Caenorhabditis
elegans. EMBO J., 25(2):312–322, 2006.
[226] Nicole K Charlie, Angela M Thomure, Michael A Schade, and Kenneth G Miller. The
dunce CAMP phosphodiesterase pde-4 negatively regulates Gαs-dependent and Gαs-
independent camp pools in the Caenorhabditis elegans synaptic signaling network.
Genetics, 173(1):111–130, 2006.
[227] David M Raizen, John E Zimmerman, Matthew H Maycock, Uyen D Ta, Young-jai
You, Meera V Sundaram, and Allan I Pack. Lethargus is a Caenorhabditis elegans
sleep-like state. Nature, 451(7178):569, 2008.
[228] Julian Ceron, Jean-François Rual, Abha Chandra, Denis Dupuy, Marc Vidal, and
Sander van den Heuvel. Large-scale RNAi screens identify novel genes that interact
with the C. elegans retinoblastoma pathway as well as splicing-related components
with synMuv B activity. BMC Dev. Biol., 7(1):30, 2007.
[229] Seongseop Kim, J Amaranath Govindan, Zheng Jin Tu, and David Greenstein. Sacy-
1 dead-box helicase links the somatic control of oocyte meiotic maturation to the
sperm-to-oocyte switch and gamete maintenance in Caenorhabditis elegans. Genetics,
192(3):905–928, 2012.
[230] Caroline Schmitz, Parag Kinge, and Harald Hutter. Axon guidance genes identified in
a large-scale RNAi screen using the RNAi-hypersensitive Caenorhabditis elegans strain
nre-1 (hd20) lin-15b (hd126). Proc. Natl. Acad. Sci. U. S. A., 104(3):834–839, 2007.
154
[231] Thomas Seebeck, Geert Jan Sterk, and Hengming Ke. Phosphodiesterase inhibitors
as a new generation of antiprotozoan drugs: exploiting the benefit of enzymes that
are highly conserved between host and parasite. Future Med. Chem., 3(10):1289–1306,
2011.
[232] Inonge Gross and Jörg Durner. In search of enzymes with a role in 3′, 5′-cyclic guanosine
monophosphate metabolism in plants. Front. Plant. Sci., 7:576, 2016.
[233] Marco Conti and Joseph Beavo. Biochemistry and physiology of cyclic nucleotide
phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev.
Biochem., 76:481–511, 2007.
[234] Sharron H Francis, Mitsi A Blount, and Jackie D Corbin. Mammalian cyclic nucleotide
phosphodiesterases: molecular mechanisms and physiological functions. Physiol. Rev.,
91(2):651–690, 2011.
[235] Qing Huai, John Colicelli, and Hengming Ke. The crystal structure of AMP-
bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry,
42(45):13220–13226, 2003.
[236] Donald H Maurice, Hengming Ke, Faiyaz Ahmad, Yousheng Wang, Jay Chung, and
Vincent C Manganiello. Advances in targeting cyclic nucleotide phosphodiesterases.
Nat. Rev. Drug Discov., 13(4):290, 2014.
[237] Pasqualina D’Ursi, Sara Guariento, Gabriele Trombetti, Alessandro Orro, Elena Ci-
chero, Luciano Milanesi, Paola Fossa, and Olga Bruno. Further insights in the binding
mode of selective inhibitors to human pde4d enzyme combining docking and molecular
dynamics. Mol. Inform., 35(8-9):369–381, 2016.
[238] Jing Huang and Alexander D MacKerell Jr. CHARMM36 all-atom additive pro-
tein force field: Validation based on comparison to NMR data. J. Comput. Chem.,
34(25):2135–2145, 2013.
155
[239] Alex B Burgin, Olafur T Magnusson, Jasbir Singh, Pam Witte, Bart L Staker, Jon M
Bjornsson, Margret Thorsteinsdottir, Sigrun Hrafnsdottir, Timothy Hagen, Alex S
Kiselyov, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for
enhancing cognition with improved safety. Nat. Biotechnol., 28(1):63, 2010.
[240] Qing Huai, Yudong Liu, Sharron H Francis, Jackie D Corbin, and Hengming Ke.
Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-
1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J. Biol.
Chem., 279(13):13095–13101, 2004.
[241] Mi Eun Lee, Joseph Markowitz, Jie-Oh Lee, and Hayyoung Lee. Crystal structure of
phosphodiesterase 4D and inhibitor complex. FEBS Lett., 530(1-3):53–58, 2002.
[242] Andrew Waterhouse, Martino Bertoni, Stefan Bienert, Gabriel Studer, Gerardo Tau-
riello, Rafal Gumienny, Florian T Heer, Tjaart A P de Beer, Christine Rempfer,
Lorenza Bordoli, et al. Swiss-model: homology modelling of protein structures and
complexes. Nucleic Acids Res., 46(W1):W296–W303, 2018.
[243] Mike P Allen and Dominic J Tildesley. Computer simulation of liquids. Oxford uni-
versity press, 1989.
[244] Tom Darden, Darrin York, and Lee Pedersen. Particle mesh ewald: An N.log(N)
method for ewald sums in large systems. J. Chem. Phys., 98(12):10089–10092, 1993.
[245] Benjamin A Shoemaker, Dachuan Zhang, Ratna R Thangudu, Manoj Tyagi, Jes-
sica H Fong, Aron Marchler-Bauer, Stephen H Bryant, Thomas Madej, and Anna R
Panchenko. Inferred biomolecular interaction serverâĂŤa web server to analyze
and predict protein interacting partners and binding sites. Nucleic Acids Res.,
38(suppl_1):D518–D524, 2009.
[246] Benjamin A Shoemaker, Dachuan Zhang, Manoj Tyagi, Ratna R Thangudu, Jes-
sica H Fong, Aron Marchler-Bauer, Stephen H Bryant, Thomas Madej, and Anna R
156
Panchenko. Ibis (inferred biomolecular interaction server) reports, predicts and in-
tegrates multiple types of conserved interactions for proteins. Nucleic Acids Res.,
40(D1):D834–D840, 2011.
[247] Yu Chen and Brian K Shoichet. Molecular docking and ligand specificity in fragment-
based inhibitor discovery. Nat. Chem. Biol., 5(5):358, 2009.
[248] Chen Wang, Pan Xu, Luyu Zhang, Jing Huang, Kongkai Zhu, and Cheng Luo. Current
strategies and applications for precision drug design. Front Pharmacol., 9:787, 2018.
[249] Pratyush Tiwary, Vittorio Limongelli, Matteo Salvalaglio, and Michele Parrinello. Ki-
netics of protein–ligand unbinding: Predicting pathways, rates, and rate-limiting steps.
Proc. Natl. Acad. Sci. U. S. A., 112(5):E386–E391, 2015.
[250] Samuel Genheden and Ulf Ryde. The mm/pbsa and mm/gbsa methods to estimate




A.1 Sample Code for Free-energy reconstruction using Radial Ba-
sis Functions
The following script can be used for reconstruction of the free-energy surface (FES) as a
linear combination of Gaussian radial basis functions (see section 2.4.1.1) [141].
1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
2 % The sample script is tested for PMF reconstruction %
3 % (c) Luca Maragliano, Istituto Italiano di Tecnologia, Genoa, Italy %























27 d1 = norm(xc(:,1)-xc(:,2))
28 [ac,sigma] = reconstruct2(xc,fc);
29 %% build potential
30 n1 = size(xc,2);
31 bord=.5;









40 [xx,yy,zz] = meshgrid(linspace(xmin,xmax,100),...
41 linspace(ymin,ymax,100),linspace(zmin,zmax,100));
42 clear r2;
43 V3 = xx.*0;
44 for j=1:n1
45 r2 = (xx-xc(1,j)).^2+(yy-xc(2,j)).^2 + (zz-xc(3,j)).^2;
46 V3 = V3 + ac(j)*exp(-r2/sigma(j)^2*0.5);
47 end;
48 V3m=V3-min(V3(:));
49 %% plot potential
50 figure
51 t=0.




56 %axis([-22 18 -12 10 -10 18])
57 view([-156 16])
58 t=1



















78 function [ac,sigma] = reconstruct2(xc,fc)
79 % xc is an nd x n1 matrix with the centers coordinate:
80 % nd is the dimensionality of the free energy space,
81 % n1 is the number of centers
82 % fc is a nd x n1 matrix with the forces
83 % the outputs are: ac, the coefficients of the radial-basis fcts, and
84 % sigma, the width of the radial-basis fcts.
85 % the function also plots the relative residual and prints the condition
86 % number of the matrix A at the optimal sigma
87 nd = size(xc,1);
159
88 n1 = size(xc,2);
89 % distance between centers
90 d1 = norm(xc(:,1)-xc(:,2));
91 bb = reshape(fc’,nd*n1,1);
92 AA = zeros(n1*nd,n1);
93 % minimization loop
94 % sigmav = linspace(0.5*d1,2*d1,1e2);
95 % sigmav = linspace(5*pi,6*pi,1e1);
96 sigmav = linspace(d1,2*d1,2e2);
97 ss1 = size(sigmav,2);
98 resvrel = Inf(1,ss1);
99 B1 = xc’*xc;
100 r2 = diag(B1)*ones(1,n1)+ones(n1,1)*diag(B1)’-2*B1;
101 for i=1:ss1
102 sigma = sigmav(i);
103 sigma2 = 0.5./sigma.^2;
104 rr = exp(-r2.*sigma2);
105 for j = 1:nd
106 AA((j-1)*n1+1:j*n1,:) = (xc(j,:)’*ones(1,n1)-ones(n1,1)*xc(j
,:)).*rr;
107 end
108 AA = AA./sigma.^2;
109 if rank(AA)<n1; break; end;
110 gg = AA\bb;
111 resrelv(i) = norm(AA*gg-bb)/norm(bb);
112 resv(i) = norm(AA*gg-bb);
113 if i>1; if resrelv(i)>resrelv(i-1); break; end; end;







120 title(’residual per center |AA*gg-bb|/n1’,’FontSize’,16)
121 xlabel(’\sigma’,’FontSize’,16)
122 ylabel(’residual per center’,’FontSize’,16)
123 [i1 i2] = min(resrelv);
124 sigma = sigmav(i2);
125 %% reconstruction step
126 sigma2 = 0.5/sigma^2;
127 rr = exp(-r2*sigma2);
128 for j = 1:nd
129 AA((j-1)*n1+1:j*n1,:) = (xc(j,:)’*ones(1,n1)-ones(n1,1)*xc(j,:)).*
rr;
130 end
131 AA = AA/sigma^2;
132 % ac are the coefficients in the radial-basis representation of the free
133 % energy
134 ac = AA\bb;
135 sigma = sigma*ones(1,n1);
136 fprintf(’\n’)









The following is the input file (“meanforces_new.dat”) containing the coordinates of the
centers and the corresponding mean-force values.
1 1.470000 -2.120000 -7.710000 -9.785590 4.990049 -0.927257
2 1.470000 -2.120000 -8.280000 -9.812816 4.286304 -0.473017
3 1.560000 -2.410000 -9.890000 -6.371151 0.564879 0.349201
4 1.670000 -2.270000 -8.780000 -4.508113 1.930594 -0.806485
5 1.780000 -2.170000 -7.310000 -4.063549 1.879347 3.359805
6 1.800000 -2.210000 -9.440000 -3.680580 3.214869 -2.117216
7 1.840000 -1.670000 -5.830000 -6.623003 5.578274 3.747816
8 1.880000 -2.770000 -9.020000 -0.032609 -4.296424 0.694036
9 1.890000 -2.390000 -10.450000 -1.470600 0.430322 0.394696
10 1.890000 -2.870000 -7.610000 0.880890 -4.438182 3.351721
11 10.160000 0.380000 -5.280000 0.329397 -12.581186 5.083637
12 10.180000 2.250000 -5.310000 -0.890966 7.292744 -0.146103
13 10.210000 1.030000 -5.470000 -1.288463 -0.375553 0.266809
14 10.210000 2.750000 -5.890000 -0.472463 5.437764 -6.729431
15 10.250000 1.750000 -4.570000 -0.497051 2.693496 10.859090
16 10.320000 2.090000 -6.060000 0.531865 7.153510 -7.271102
17 10.330000 1.710000 -5.160000 -1.305893 5.445777 2.823317
18 10.360000 1.310000 -4.320000 -1.538975 -0.944368 11.377527
19 10.380000 0.900000 -6.190000 -0.067118 -1.471345 -5.396713
20 10.400000 0.270000 -6.030000 -1.254845 -9.305528 -0.620820
21 10.400000 3.840000 -5.520000 -1.538517 1.110011 -1.950121
22 10.470000 2.190000 -6.600000 -0.763081 8.472491 -8.433132
23 10.520000 1.420000 -6.180000 -0.929578 5.664027 -6.990566
24 10.530000 3.020000 -6.600000 -0.656510 2.564594 -5.712497
25 10.610000 2.920000 -5.320000 -0.558751 1.545318 0.086698
26 10.700000 1.360000 -5.350000 -0.630059 3.129134 0.481480
27 10.730000 2.560000 -4.840000 -0.295766 5.813913 5.884236
28 10.780000 0.960000 -6.870000 -0.274745 2.583686 -6.032612
29 10.790000 0.510000 -4.670000 -0.604078 -10.895482 12.771118
30 10.790000 1.000000 -5.860000 -1.229582 0.004796 -3.664434
31 10.800000 0.510000 -5.400000 -0.466494 -10.689803 1.947389
32 10.910000 -0.160000 -6.220000 -0.513956 -7.874482 -1.876247
33 10.950000 2.820000 -5.840000 -0.296766 2.573710 -5.011045
34 11.010000 2.040000 -6.080000 -0.665404 7.711624 -7.861041
35 11.020000 1.010000 -4.930000 -0.517248 -1.643624 8.777645
36 11.080000 1.460000 -6.130000 -0.271051 6.087383 -6.318860
37 11.130000 1.840000 -4.860000 -0.373715 5.104568 7.103900
38 11.180000 1.800000 -4.330000 -0.208607 2.583141 8.694338
39 11.190000 1.040000 -4.400000 -0.188699 -3.668468 12.136767
40 11.200000 3.000000 -4.150000 -0.625936 3.359043 4.409662
41 11.220000 0.650000 -6.370000 -0.324947 -3.706987 -5.135758
161
42 11.230000 0.670000 -5.740000 -0.090179 -4.240865 -0.574641
43 11.410000 0.460000 -4.650000 -0.181423 -10.398926 12.095535
44 11.420000 2.350000 -5.390000 -1.269670 7.852689 -1.725379
45 11.430000 1.370000 -4.980000 0.033519 2.122918 6.755236
46 11.500000 1.580000 -7.050000 -0.227878 7.616850 -6.348085
47 11.570000 1.310000 -6.220000 -0.112256 5.913774 -6.734546
48 11.600000 1.580000 -5.550000 -0.216202 5.784586 -2.326657
49 11.600000 1.960000 -4.030000 -0.249035 2.671545 6.284807
50 11.690000 1.880000 -4.560000 -0.120765 3.634639 9.053479
51 11.720000 0.630000 -5.560000 0.308886 -7.141562 0.668203
52 11.810000 0.560000 -6.690000 -0.013099 -4.162477 -6.105688
53 11.860000 2.000000 -6.290000 0.119091 7.982332 -7.276114
54 11.930000 0.930000 -4.470000 -0.032969 -3.756202 12.239510
55 11.930000 1.350000 -6.620000 -0.201110 4.670160 -7.090052
56 11.970000 1.100000 -4.970000 -0.309290 -1.145643 7.833637
57 11.980000 0.460000 -5.080000 -0.350485 -10.708945 6.540088
58 12.020000 2.730000 -5.770000 -0.098955 4.416381 -5.927511
59 12.080000 1.620000 -5.820000 -0.434442 6.149895 -5.374572
60 12.180000 2.170000 -5.330000 -0.993701 7.545303 -0.509524
61 12.190000 0.190000 -4.510000 -0.504289 -10.683225 11.935753
62 12.230000 0.630000 -6.110000 -0.674993 -3.808016 -3.392482
63 12.230000 3.020000 -5.070000 -0.723733 0.707082 3.381953
64 12.250000 0.330000 -5.650000 -0.225927 -12.308530 -0.174033
65 12.260000 3.780000 -5.510000 -0.832179 -0.529532 -1.538337
66 12.310000 1.130000 -6.200000 -0.592559 2.412709 -6.282849
67 12.320000 1.060000 -5.570000 -0.609169 1.395056 -1.438595
68 12.400000 0.200000 -6.610000 -0.288645 -6.167720 -5.226179
69 12.400000 1.530000 -5.140000 -1.124196 3.479462 3.749120
70 12.410000 0.720000 -4.790000 -0.562788 -7.009042 11.317314
71 12.480000 3.250000 -3.740000 -0.503941 0.605541 0.389208
72 2.020000 -1.880000 -8.320000 -2.020616 5.168058 -0.834765
73 2.020000 -2.030000 -9.960000 -1.620296 4.503261 1.162102
74 2.040000 -2.450000 -7.980000 0.073659 -0.876309 -1.257002
75 2.040000 -2.660000 -8.540000 1.127652 -4.122007 0.563482
76 2.050000 -1.690000 -6.490000 -4.047220 7.870610 0.628047
77 2.060000 -2.550000 -9.740000 0.461196 -2.254338 -1.683790
78 2.080000 -2.210000 -6.390000 -0.676476 -5.404862 2.885443
79 2.100000 -1.840000 -7.000000 -2.777419 3.180030 5.175967
80 2.100000 -1.930000 -7.660000 -1.785870 5.148049 -1.229410
81 2.150000 -1.220000 -8.520000 -4.318319 15.486063 -2.222311
82 2.170000 -1.900000 -9.020000 -1.299470 6.323809 -0.809971
83 2.320000 -3.040000 -9.810000 4.911817 -6.365213 1.211002
84 2.350000 -2.420000 -8.860000 2.637871 -3.227060 -0.664330
85 2.420000 -1.790000 -5.860000 -3.144319 1.032389 3.857516
86 2.470000 -2.990000 -7.880000 6.539072 -6.672430 0.550712
87 2.500000 -1.620000 -9.330000 -3.054592 9.481162 -2.412334
88 2.500000 -2.640000 -10.150000 3.527522 -6.034656 1.114888
89 2.540000 -3.000000 -8.740000 6.265618 -9.942799 0.130870
90 2.550000 -1.970000 -6.810000 0.439530 -2.067726 6.908680
91 2.550000 -1.970000 -9.800000 -0.940055 4.023278 0.039894
92 2.560000 -1.910000 -8.680000 -0.381733 3.782025 -0.168624
93 2.560000 -2.240000 -7.460000 0.969988 -3.825991 1.928867
94 2.600000 -2.340000 -8.400000 1.891884 -3.560201 0.438040
95 2.610000 -0.760000 -8.700000 -5.530802 14.634261 -1.594754
162
96 2.660000 -1.900000 -7.930000 -1.109495 2.146963 -1.607371
97 2.670000 -3.250000 -8.280000 3.157939 -3.486741 -1.781799
98 2.710000 -2.110000 -10.280000 0.270010 0.184418 1.445464
99 2.740000 -1.930000 -6.300000 -2.207743 -1.718878 1.570019
100 2.780000 -2.420000 -6.710000 3.678854 -4.129190 2.967938
101 2.850000 -1.730000 -7.360000 -2.375362 3.999146 0.111007
102 2.900000 -1.990000 -9.300000 -0.972644 0.563813 -1.047719
103 2.940000 -1.140000 -6.380000 -5.559317 11.024156 -1.825307
104 2.940000 -1.540000 -8.770000 -5.549079 8.218361 -0.677302
105 2.990000 -2.530000 -9.380000 4.276616 -8.264305 -0.789744
106 3.000000 -1.030000 -5.170000 -7.008680 6.814184 5.735588
107 3.010000 -2.820000 -8.790000 0.951670 -5.546646 1.371082
108 3.030000 -1.870000 -9.860000 -2.863721 1.601365 -0.521689
109 3.070000 -2.750000 -7.780000 1.635657 -4.038255 0.695380
110 3.080000 -2.260000 -7.680000 1.876295 -7.781997 0.635802
111 3.120000 -1.260000 -7.090000 -4.728191 9.068522 0.430987
112 3.130000 -1.680000 -6.790000 -0.885649 -0.628200 5.988530
113 3.130000 -2.610000 -7.260000 0.925797 -10.283233 0.693989
114 3.210000 -1.440000 -7.960000 -4.838812 6.758490 -2.426404
115 3.220000 -1.800000 -5.430000 -3.362104 -7.704335 7.602412
116 3.230000 -1.300000 -9.980000 -6.704521 9.601720 1.268847
117 3.230000 -1.550000 -10.460000 -4.596837 6.005295 0.493376
118 3.230000 -2.210000 -5.820000 -5.736266 -10.563909 7.563982
119 3.230000 -2.540000 -8.260000 3.307465 -10.315886 -0.258160
120 3.270000 -4.240000 -7.850000 -1.445826 -0.675387 4.983644
121 3.290000 -2.000000 -8.920000 0.503675 -3.282220 -0.698471
122 3.300000 -1.480000 -9.140000 -6.800216 6.508543 -0.800016
123 3.310000 -1.840000 -7.530000 -1.662242 -3.074127 2.088493
124 3.330000 -2.060000 -10.490000 0.113140 -4.688570 0.718155
125 3.380000 -2.040000 -8.160000 -0.152428 -6.648301 -0.529211
126 3.400000 -3.430000 -8.030000 -1.692701 -2.792933 -1.202766
127 3.430000 -2.630000 -10.140000 -0.738600 -6.175346 1.232766
128 3.450000 -1.510000 -5.990000 0.115159 -5.966683 7.742243
129 3.450000 -4.290000 -8.640000 0.279142 -1.377745 -1.265891
130 3.500000 -2.380000 -9.630000 3.154513 -9.911830 -1.664458
131 3.510000 -2.370000 -6.460000 2.927198 -15.818146 2.007969
132 3.510000 -3.070000 -6.260000 -3.161518 -18.433693 11.068323
133 3.520000 -1.020000 -6.770000 -3.424899 8.114120 1.784130
134 3.540000 -0.800000 -7.560000 -7.025334 9.459388 -0.289985
135 3.540000 -2.730000 -8.810000 -3.272266 -5.279181 -1.238291
136 3.550000 -1.580000 -9.640000 -2.130468 2.722263 -2.072569
137 3.550000 -2.970000 -8.140000 -3.163119 -3.457108 -0.964448
138 3.590000 -1.390000 -7.590000 -3.249656 3.947318 1.177240
139 3.610000 -2.290000 -8.580000 2.735607 -9.292341 -0.888280
140 3.630000 -0.150000 -7.410000 -7.766808 9.189951 -0.475645
141 3.640000 -0.810000 -8.380000 -7.267304 11.606289 -2.581550
142 3.650000 -1.570000 -6.470000 1.162952 -4.141665 7.503477
143 3.660000 -0.980000 -8.920000 -4.490235 9.457324 -0.109234
144 3.680000 -1.280000 -10.350000 -2.787161 6.820652 0.874688
145 3.690000 0.120000 -5.780000 -6.372637 2.239877 -0.305453
146 3.700000 -2.130000 -6.940000 1.409731 -7.795042 6.556067
147 3.760000 -2.080000 -10.040000 2.099290 -4.971352 0.903574
148 3.780000 -2.570000 -7.580000 -3.065761 -4.391506 2.295742
149 3.790000 -1.520000 -7.120000 2.604494 -0.294103 2.959327
163
150 3.790000 -2.820000 -9.520000 -3.012678 -5.863907 -1.780807
151 3.790000 -3.140000 -10.210000 -2.723597 -5.628188 0.808057
152 3.820000 -1.370000 -8.510000 0.117832 3.867569 -2.052579
153 3.820000 -4.460000 -8.210000 0.772448 -5.439717 3.618620
154 3.820000 -4.820000 -10.020000 1.015474 1.153112 0.444472
155 3.830000 -1.730000 -8.100000 2.382660 -3.871209 -1.386598
156 3.870000 -1.950000 -9.050000 -0.778882 -0.102451 -0.631741
157 3.880000 -0.440000 -6.240000 0.349090 -1.640122 -1.758444
158 3.890000 -1.010000 -5.130000 -2.813109 4.148113 5.958722
159 3.970000 -1.710000 -10.310000 4.767743 -3.070539 1.235396
160 4.000000 -1.740000 -7.560000 5.206293 -5.599441 1.658151
161 4.020000 -1.460000 -9.310000 4.442137 0.699896 -1.343906
162 4.040000 -2.440000 -8.220000 -2.390232 -4.325837 0.072488
163 4.060000 -0.830000 -7.240000 -0.403484 5.645580 3.967544
164 4.060000 -1.120000 -6.810000 3.328613 2.868491 4.076771
165 4.080000 -2.310000 -6.500000 -1.381826 -9.075440 1.049330
166 4.100000 -1.250000 -9.850000 3.599599 3.537593 0.336824
167 4.130000 -0.520000 -7.920000 -3.225067 7.669725 -3.988029
168 4.140000 -1.880000 -5.730000 -1.389061 -3.635261 5.614716
169 4.140000 -2.350000 -10.420000 -0.085269 -2.765264 0.968779
170 4.140000 -4.950000 -9.090000 1.041130 2.274613 -0.229843
171 4.150000 -1.090000 -7.750000 3.057731 4.131807 -0.640695
172 4.160000 -1.170000 -6.270000 4.723494 -1.666095 4.575410
173 4.170000 -2.600000 -8.710000 0.294758 -6.096677 -0.550167
174 4.180000 -2.590000 -9.890000 0.494912 -5.032680 0.418716
175 4.180000 -3.370000 -8.830000 1.951023 -5.788995 -1.321839
176 4.190000 -1.180000 -8.880000 4.772582 3.340467 0.007011
177 4.190000 -2.940000 -6.440000 0.285906 -8.209997 7.013270
178 4.190000 -3.600000 -6.990000 0.495233 -8.116226 4.869160
179 4.190000 0.310000 -5.920000 -5.875549 -5.888099 0.831154
180 4.190000 0.730000 -7.170000 -5.480088 8.180393 -3.603162
181 4.200000 -1.830000 -8.590000 3.647515 -1.879768 -1.340319
182 4.210000 -0.080000 -7.580000 -5.382754 7.006465 -2.415755
183 4.210000 -2.030000 -6.990000 2.688249 -3.912597 5.742791
184 4.220000 -0.530000 -8.490000 -2.488143 7.118298 -2.298807
185 4.220000 -2.420000 -9.200000 0.319968 -4.373995 -0.413001
186 4.230000 -5.100000 -10.240000 1.872499 2.316112 1.220353
187 4.240000 -1.040000 -5.610000 4.805478 -6.281026 5.954221
188 4.270000 -2.680000 -7.600000 -0.027437 -11.381655 -2.144056
189 4.270000 -3.020000 -8.060000 2.405375 -5.822452 -0.615311
190 4.290000 -1.440000 -8.250000 6.813849 -0.321762 -1.935248
191 4.290000 -1.780000 -9.630000 3.458713 0.795462 -1.249165
192 4.310000 -0.460000 -6.810000 -0.954586 2.871875 3.820897
193 4.320000 -1.510000 -7.110000 7.691676 -3.497254 4.865637
194 4.320000 0.180000 -6.550000 -1.403350 -5.783934 4.431160
195 4.330000 -2.050000 -7.820000 0.688616 -1.286833 1.513804
196 4.340000 -0.330000 -5.310000 0.268397 -3.452452 1.169911
197 4.340000 -0.960000 -10.370000 4.821383 4.327572 0.824766
198 4.380000 -1.900000 -5.110000 -0.042070 -10.142058 15.852719
199 4.380000 0.730000 -5.330000 -6.830413 0.573644 3.417525
200 4.390000 -0.580000 -5.820000 -0.806802 2.181452 -0.866439
201 4.400000 -2.100000 -6.140000 1.038072 -6.348476 2.449267
202 4.400000 -4.880000 -9.820000 2.368387 2.986602 -0.159066
203 4.420000 0.720000 -6.090000 -6.008680 3.253870 -2.514157
164
204 4.440000 0.380000 -4.930000 -4.666213 -8.625240 7.486384
205 4.460000 -0.720000 -7.590000 3.086580 3.153877 -0.737242
206 4.480000 -1.750000 -6.590000 1.308740 4.159887 -1.034718
207 4.500000 -1.510000 -10.160000 6.703095 -0.391844 1.595561
208 4.500000 -2.900000 -10.280000 4.377151 -7.758788 0.832771
209 4.510000 -2.480000 -6.970000 3.726110 -1.892715 2.051724
210 4.520000 1.200000 -7.160000 -7.566908 16.874228 -4.073073
211 4.540000 -0.900000 -6.950000 6.342940 0.016932 4.588568
212 4.570000 -2.890000 -8.860000 4.609167 -8.046249 0.561148
213 4.600000 -2.180000 -5.630000 1.735749 -12.507701 8.796243
214 4.630000 -5.300000 -9.440000 4.628955 0.755702 -0.262614
215 4.640000 -2.290000 -8.530000 3.397215 -3.900287 -0.563893
216 4.670000 -1.630000 -5.690000 2.511834 1.990933 3.175886
217 4.670000 -2.460000 -7.800000 4.120627 -6.442432 1.278630
218 4.670000 0.200000 -7.330000 -2.734028 3.678339 1.063417
219 4.680000 -0.420000 -6.270000 -0.037796 1.173538 -2.268326
220 4.680000 -1.140000 -8.700000 7.454345 2.141599 -2.258181
221 4.680000 -1.300000 -6.360000 5.297482 4.457757 -3.508386
222 4.690000 -0.260000 -7.660000 1.360590 2.313850 -2.382844
223 4.700000 -1.520000 -7.760000 1.766637 6.600609 0.940029
224 4.710000 -5.460000 -10.200000 5.508190 -1.893559 1.051645
225 4.720000 -0.910000 -5.050000 0.169857 3.918847 8.182927
226 4.720000 -2.660000 -9.470000 5.272360 -6.445159 -1.442031
227 4.720000 -2.720000 -8.270000 3.769986 -7.816313 -0.133827
228 4.750000 -1.020000 -7.930000 7.276638 1.175270 -2.425706
229 4.760000 -2.060000 -8.970000 3.356487 0.279907 -0.837866
230 4.760000 1.090000 -5.500000 -6.101597 9.359843 0.203263
231 4.800000 0.430000 -6.420000 0.467138 -4.873386 4.792695
232 4.810000 -1.190000 -7.370000 7.241381 -0.728716 3.841719
233 4.820000 0.290000 -5.750000 -1.780848 -8.969543 0.837479
234 4.830000 -1.330000 -9.520000 2.955362 11.655929 -1.018340
235 4.830000 -2.100000 -6.690000 4.741772 -2.847821 5.423159
236 4.850000 -0.320000 -7.010000 3.437222 -1.181741 4.264129
237 4.860000 0.970000 -6.130000 -3.615946 6.265728 -3.571929
238 4.880000 -2.590000 -10.120000 4.951982 -6.331773 1.560828
239 4.920000 -2.550000 -6.420000 4.253723 -14.110398 2.705759
240 4.940000 0.930000 -7.110000 -5.500820 10.785299 3.028568
241 4.950000 -1.180000 -5.420000 1.194126 6.554039 3.443597
242 4.960000 -1.930000 -7.230000 5.394983 -1.395456 3.952844
243 4.970000 -2.920000 -7.750000 6.492949 -7.132185 0.864996
244 4.980000 -2.040000 -9.800000 5.358382 0.239460 -0.313196
245 5.000000 -1.440000 -4.970000 1.933756 0.447480 15.704404
246 5.000000 -1.620000 -8.240000 6.362592 -0.586621 -1.766079
247 5.000000 0.600000 -5.180000 -1.855560 -5.553953 4.787424
248 5.020000 -2.020000 -5.890000 3.516523 -7.076170 2.975502
249 5.030000 1.460000 -7.160000 -5.047748 17.038799 -3.534401
250 5.050000 -1.390000 -8.940000 6.381571 1.575937 0.620047
251 5.070000 -0.890000 -5.920000 0.886655 9.224613 -2.262109
252 5.070000 -2.070000 -10.410000 5.444685 -1.265097 0.907437
253 5.140000 -0.550000 -5.220000 -0.858790 3.126429 2.643051
254 5.150000 0.850000 -4.730000 -1.016898 -2.063311 9.431469
255 5.160000 -0.250000 -6.150000 0.242950 2.200820 -3.348519
256 5.170000 -1.470000 -7.120000 3.543595 5.844263 0.879714
257 5.180000 -2.450000 -7.170000 7.247987 -5.202087 3.189444
165
258 5.190000 0.380000 -6.860000 -0.025898 1.250865 3.502156
259 5.200000 -0.090000 -5.570000 0.087813 -8.404875 0.473690
260 5.200000 0.520000 -6.110000 0.467435 -3.455571 -2.608300
261 5.210000 -2.150000 -9.350000 5.476206 -2.749068 -1.138429
262 5.260000 -1.230000 -6.280000 2.189622 9.663296 -2.963120
263 5.310000 0.540000 -7.630000 -1.874913 2.550372 -1.471901
264 5.330000 -0.110000 -7.510000 3.376774 -2.620245 -0.574225
265 5.340000 -2.220000 -8.420000 5.083711 -4.508308 -1.000604
266 5.370000 0.170000 -5.090000 0.232935 -9.805058 5.698012
267 5.380000 1.570000 -4.840000 -4.419427 12.692011 6.333938
268 5.400000 -1.930000 -7.850000 5.018345 -2.792842 1.909229
269 5.450000 1.030000 -5.270000 -0.577851 3.179862 2.316042
270 5.460000 0.110000 -6.470000 1.581735 -8.000470 -3.449772
271 5.480000 -1.860000 -6.220000 4.560303 -0.890183 -0.294788
272 5.520000 -0.370000 -7.090000 0.531156 -1.252364 -2.644332
273 5.520000 -2.330000 -10.350000 5.853322 -5.025993 0.854952
274 5.520000 1.510000 -5.440000 -2.230416 12.202447 -0.385406
275 5.530000 -0.960000 -7.550000 3.987823 11.770851 -3.538373
276 5.550000 -1.510000 -6.790000 4.475621 6.599496 -1.931426
277 5.550000 0.960000 -6.110000 0.789043 4.809904 -4.019577
278 5.560000 -1.630000 -8.310000 5.365530 4.559041 -1.996384
279 5.560000 -1.650000 -5.430000 3.212084 -2.608166 6.615633
280 5.570000 -1.950000 -8.850000 4.798322 -0.391977 -2.439367
281 5.640000 1.070000 -6.640000 1.207548 5.886533 -5.675743
282 5.650000 1.330000 -4.310000 -1.457491 4.520629 10.358261
283 5.660000 -2.510000 -8.050000 4.028168 -9.029806 -3.423799
284 5.710000 0.790000 -8.110000 -3.554358 2.904050 -2.298852
285 5.740000 0.240000 -8.080000 -0.721254 -4.413234 -1.459978
286 5.750000 -0.380000 -7.790000 -1.373982 -1.437502 -2.613933
287 5.750000 -1.420000 -6.080000 4.563731 5.754505 -2.253122
288 5.750000 -1.820000 -7.130000 5.698422 -1.387835 3.877744
289 5.750000 1.420000 -7.150000 -0.401374 11.007213 -3.888427
290 5.780000 -0.680000 -6.460000 -0.391152 4.965101 -3.784924
291 5.820000 0.560000 -5.630000 2.890539 -6.396539 0.541520
292 5.830000 -2.210000 -6.060000 4.781170 -11.652579 2.739130
293 5.850000 0.810000 -7.110000 2.555555 1.336511 -4.327075
294 5.860000 2.000000 -5.530000 -3.603476 14.668583 -2.166133
295 5.870000 0.140000 -4.960000 -1.419550 -9.399266 5.992914
296 5.930000 -0.380000 -5.590000 0.528337 0.490034 -1.294186
297 5.940000 1.650000 -6.150000 -1.009981 12.416338 -5.603166
298 5.950000 -1.260000 -5.540000 4.359454 4.469948 1.812648
299 5.990000 0.060000 -6.700000 3.291725 -7.901625 -4.060096
300 6.010000 -1.840000 -6.390000 5.871569 -1.725065 -1.739007
301 6.020000 0.570000 -6.260000 3.493596 -3.525321 -4.344670
302 6.020000 1.440000 -4.940000 -1.268812 7.358745 5.312328
303 6.030000 1.400000 -6.640000 -0.995089 8.623967 1.814714
304 6.060000 -1.730000 -7.900000 5.574838 0.245764 0.463545
305 6.130000 -1.300000 -6.810000 4.986794 8.583773 -3.595565
306 6.130000 -2.670000 -6.520000 4.532879 -16.382965 2.617609
307 6.130000 1.480000 -4.350000 -2.631996 4.853879 8.800497
308 6.140000 -0.570000 -7.490000 -0.952977 3.764521 -0.457009
309 6.140000 0.770000 -5.300000 0.380271 -6.085596 3.282303
310 6.190000 1.100000 -5.900000 -0.359627 3.592734 -4.143387
311 6.190000 1.250000 -8.110000 -7.029285 10.120116 -0.966697
166
312 6.230000 -1.340000 -5.050000 2.408447 -0.495421 12.519599
313 6.240000 -0.470000 -6.200000 -0.502339 2.151677 -3.715754
314 6.330000 -0.430000 -5.080000 0.280964 -0.235228 3.233716
315 6.330000 0.850000 -4.820000 -1.218289 -5.465954 7.861419
316 6.360000 -1.410000 -6.090000 3.669792 4.471261 -1.351240
317 6.360000 -1.980000 -5.870000 4.831958 -7.806591 2.895534
318 6.380000 0.900000 -7.150000 -1.442137 -0.576524 -5.142725
319 6.420000 -0.560000 -7.030000 3.069367 -2.227903 -3.250582
320 6.420000 0.630000 -5.900000 -1.046445 -5.798025 -2.383686
321 6.420000 1.570000 -5.680000 -2.960701 9.172733 -4.174515
322 6.450000 1.180000 -3.970000 -3.549352 -3.004582 10.652515
323 6.480000 -1.990000 -6.500000 4.043524 -2.847972 -1.121834
324 6.530000 0.710000 -6.570000 -0.588745 -4.027726 -5.542502
325 6.570000 -0.200000 -5.800000 1.504181 -6.073162 -1.061145
326 6.610000 -1.600000 -5.650000 5.287634 -1.337155 2.173533
327 6.620000 1.540000 -4.570000 -2.859815 3.541240 5.403079
328 6.630000 -1.090000 -6.780000 3.664742 8.018772 -3.706543
329 6.630000 1.710000 -5.240000 -3.770365 9.505173 0.621020
330 6.670000 1.100000 -5.110000 -1.049995 0.135023 3.169182
331 6.690000 0.520000 -5.060000 -0.075904 -10.513305 5.914184
332 6.810000 1.180000 -5.990000 -0.662750 2.993023 -5.205589
333 6.850000 0.840000 -4.420000 -0.099106 -7.133138 11.288634
334 6.850000 1.360000 -6.510000 -0.596096 6.408150 -6.173361
335 6.910000 1.340000 -5.520000 -0.534212 4.565864 -1.636322
336 6.910000 2.070000 -5.800000 -1.432949 9.057551 -5.034982
337 6.920000 2.570000 -5.580000 -4.829117 8.977786 -4.277987
338 7.010000 1.260000 -4.150000 0.055078 -1.672152 8.924435
339 7.050000 1.850000 -4.010000 0.046123 4.027859 7.862283
340 7.080000 -1.850000 -5.730000 3.822482 -7.600072 3.217529
341 7.100000 -0.730000 -7.070000 6.218815 8.665473 -2.926175
342 7.110000 -0.730000 -6.270000 3.795763 5.222723 -4.287915
343 7.170000 0.680000 -5.860000 1.859171 -6.265047 -2.351190
344 7.190000 0.350000 -5.350000 1.971966 -11.064725 2.725801
345 7.210000 1.670000 -7.190000 2.547221 9.167685 2.324850
346 7.320000 2.070000 -4.630000 2.390077 5.542002 4.430370
347 7.370000 1.450000 -5.200000 2.721028 5.053285 2.840806
348 7.390000 1.190000 -4.620000 3.878594 -0.887461 8.373271
349 7.440000 1.540000 -5.720000 3.241314 7.036184 -3.927956
350 7.450000 0.150000 -6.820000 5.234042 -11.940313 -5.242416
351 7.510000 1.390000 -6.380000 3.648288 5.388274 -6.766823
352 7.510000 2.470000 -5.500000 2.035588 1.841560 -2.741476
353 7.580000 1.020000 -6.000000 4.524123 -0.519741 -4.711188
354 7.630000 -1.830000 -5.690000 5.568798 -3.779837 4.768283
355 7.710000 0.890000 -4.910000 2.770515 -4.067473 7.296069
356 7.770000 2.660000 -6.110000 0.466204 -0.316426 -4.973325
357 7.810000 0.970000 -5.550000 1.861250 0.435538 -0.650927
358 7.820000 3.010000 -4.740000 -0.869983 2.620221 4.012755
359 7.850000 1.140000 -4.430000 2.293750 -1.102156 9.739676
360 7.870000 3.100000 -5.770000 2.315459 0.595940 -5.309249
361 7.930000 1.550000 -5.060000 0.771882 5.946854 5.398545
362 8.020000 2.270000 -4.920000 1.866762 3.743695 2.417959
363 8.230000 3.660000 -4.830000 -0.685348 7.291451 3.529174
364 8.320000 0.960000 -5.610000 0.484645 -2.857555 -1.676067
365 8.370000 0.620000 -6.460000 -0.238463 -5.273331 -5.725803
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366 8.430000 1.950000 -5.410000 -1.539673 8.510531 -1.092240
367 8.510000 1.030000 -4.710000 -0.949979 -3.224230 11.938912
368 8.690000 1.470000 -6.100000 -0.672348 6.303684 -6.792371
369 8.850000 2.640000 -6.260000 -2.609535 6.346974 -8.074174
370 8.940000 0.350000 -4.760000 -1.009582 -12.140244 11.065896
371 8.970000 0.760000 -5.760000 -1.365027 -4.264435 -2.156946
372 8.980000 1.380000 -4.980000 -0.956414 2.911630 6.951530
373 8.990000 0.540000 -5.260000 -2.014932 -9.671615 4.194186
374 9.070000 0.010000 -5.560000 -2.203293 -13.727834 2.322717
375 9.100000 1.170000 -6.610000 -1.846779 3.245957 -6.790586
376 9.100000 1.270000 -5.700000 -1.061001 2.991233 -2.734217
377 9.120000 2.160000 -5.350000 -1.493177 7.751459 -1.027296
378 9.160000 1.780000 -6.050000 -1.327887 9.236950 -5.988685
379 9.180000 0.960000 -7.770000 -1.268384 1.385118 0.208353
380 9.220000 0.430000 -6.300000 -2.510071 -4.167695 -4.276783
381 9.430000 0.820000 -4.780000 -1.322281 -7.393560 11.321846
382 9.440000 0.390000 -7.060000 -1.679670 -4.249693 -6.689306
383 9.490000 1.170000 -6.290000 -2.293362 3.027558 -6.488503
384 9.510000 1.730000 -5.640000 -1.915270 6.374895 -3.513869
385 9.620000 1.010000 -5.320000 -1.155763 -1.444269 2.390249
386 9.730000 0.470000 -5.870000 -0.330852 -8.231715 -2.128090
387 9.840000 1.480000 -5.050000 -0.266062 3.405301 5.359532
388 9.880000 1.720000 -6.640000 0.204631 7.355597 -7.061658
389 9.920000 2.300000 -6.770000 -1.450918 7.423427 -7.131328
390 9.940000 3.490000 -5.280000 -2.341432 2.985128 0.767734
391 9.970000 4.160000 -5.750000 -2.319189 0.357524 -2.823965
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The following output figures are generated from the script.
Figure A.1. The locations of centers are shown as blue points, and the mean-forces at each
point are shown as red arrow.
169
Figure A.2. The reconstructed 3D free energy surfaces are shown. The lower isosurfaces
with lower energy values are shown with darker colors.
170
Figure A.3. The optimization profile of σ is shown.
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A.2 Sample code for zero temperature string method (ZTS)
The minimum free-energy pathways (MFEP) can be determined using the ZTS method [149]
(see section 2.4.1.2).
1 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
2 %% Zero-temperature string method (ZTS) code %
3 % The script is only tested for string %
4 % optimization, and nothing else. %
5 % (c) Eric Vanden-Eijnden, NYU, New York, NY %





11 % max number of iterations
12 nstepmax = 2e3;
13 % frequency of plotting
14 nstepplot = 1e1;
15 % plot string every nstepplot if flag1 = 1
16 flag1 = 1;
17 % parameter used as stopping criterion
18 tol1 = 1e-7;
19 % number of images along the string (try from n1 = 3 up to n1 = 1e4)
20 n1 = 25;
21 % time-step (limited by the ODE step on line 83 & 84 but independent of n1)
22 h = 1e-4;
23 % end points of the initial string
24 % notice that they do NOT have to be at minima of V -- the method finds
25 % those automatically
26 xa = -1;
27 ya = 0.5;
28 xb = 0.7;
29 yb = 0.5;
30 % initialization
31 g1 = linspace(0,1,n1);
32 x = (xb-xa)*g1+xa;
33 y = (x-xa)*(yb-ya)/(xb-xa)+ya;
34 dx = x-circshift(x,[0 1]);
35 dy = y-circshift(y,[0 1]);
36 dx(1) = 0;
37 dy(1) = 0;
38 lxy = cumsum(sqrt(dx.^2+dy.^2));
39 lxy = lxy/lxy(n1);
40 x = interp1(lxy,x,g1);
41 y = interp1(lxy,y,g1);
42 xi = x;
43 yi = y;
44 % parameters in Mueller potential
45 aa = [-1 -1 -6.5 0.7];
46 bb = [0 0 11 0.6];
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47 cc = [-10 -10 -6.5 0.7];
48 AA = [-200 -100 -170 15];
49 XX = [1 0 -0.5 -1];
50 YY = [0 0.5 1.5 1];
51 [xx,yy] = meshgrid(-1.5:0.01:1.2,-0.2:0.01:2);
52 V1 = AA(1)*exp(aa(1)*(xx-XX(1)).^2+bb(1)*(xx-XX(1)).*(yy-YY(1))+cc(1)*(yy-YY
(1)).^2);
53 for j=2:4





















73 %% Main loop
74 for nstep=1:nstepmax
75 % calculation of the x and y-components of the force, dVx and dVy respectively
76 ee = AA(1)*exp(aa(1)*(x-XX(1)).^2+bb(1)*(x-XX(1)).*(y-YY(1))+cc(1)*(y-YY
(1)).^2);
77 dVx = (2*aa(1)*(x-XX(1))+bb(1)*(y-YY(1))).*ee;
78 dVy = (bb(1)*(x-XX(1))+2*cc(1)*(y-YY(1))).*ee;
79 for j=2:4
80 ee = AA(j)*exp(aa(j)*(x-XX(j)).^2+bb(j)*(x-XX(j)).*(y-YY(j))+cc(j)*(y-
YY(j)).^2);
81 dVx = dVx + (2*aa(j)*(x-XX(j))+bb(j)*(y-YY(j))).*ee;
82 dVy = dVy + (bb(j)*(x-XX(j))+2*cc(j)*(y-YY(j))).*ee;
83 end;
84 x0 = x;
85 y0 = y;
86 % string steps:
87 % 1. evolve
88 x = x - h*dVx;
89 y = y - h*dVy;
90 % 2. reparametrize
91 dx = x-circshift(x,[0 1]);
92 dy = y-circshift(y,[0 1]);
93 dx(1) = 0;
94 dy(1) = 0;
95 lxy = cumsum(sqrt(dx.^2+dy.^2));
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96 lxy = lxy/lxy(n1);
97 x = interp1(lxy,x,g1);
98 y = interp1(lxy,y,g1);





104 tol = (norm(x-x0)+norm(y-y0))/n1;





110 fprintf(’ZTS calculation with %d images\n’,n1)
111 if tol > tol1
112 fprintf(’The calculation failed to converge after %d iterations\n’,nstep)
113 else











125 % Energy along MEP
126 tx = circshift(x,[0 -1])-circshift(x,[0 1]);
127 ty = circshift(y,[0 -1])-circshift(y,[0 1]);
128 % potential computed as integral of projection of gradV on string tangent
129 Vz=cumtrapz(tx.*dVx + ty.*dVy);
130 Vz=0.5*Vz;
131 Vz=Vz-min(Vz);
132 ntxy = sqrt(tx.*tx+ty.*ty);
133 tx = tx./ntxy;
134 ty = ty./ntxy;
135 % err is an estimate of the error between disrectized MEP and actual one
136 % err scale as 1/n1
137 err = trapz(1-(tx.*dVx+ty.*dVy).^2./(dVx.*dVx+dVy.*dVy))/(n1-1);
138 fprintf(’Estimate of difference between discretized MEP and actual one: %f\n’,
err)
139 %
140 % Reinterpolate string with lots of points to get accurate energy along it
141 g0 = linspace(0,1,1e3);
142 x0 = interp1(lxy,x,g0);
143 y0 = interp1(lxy,y,g0);
144 ee = AA(1)*exp(aa(1)*(x0-XX(1)).^2+bb(1)*(x0-XX(1)).*(y0-YY(1))+cc(1)*(y0-YY
(1)).^2);
145 V0=ee;
146 dVx = (2*aa(1)*(x0-XX(1))+bb(1)*(y0-YY(1))).*ee;
147 dVy = (bb(1)*(x0-XX(1))+2*cc(1)*(y0-YY(1))).*ee;
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148 for j=2:4
149 ee = AA(j)*exp(aa(j)*(x0-XX(j)).^2+bb(j)*(x0-XX(j)).*(y0-YY(j))+cc(j)*(y0-
YY(j)).^2);
150 V0 = V0 + ee;
151 dVx = dVx + (2*aa(j)*(x0-XX(j))+bb(j)*(y0-YY(j))).*ee;









161 legend(’Thermodynamic integration along string’,’Exact’,’Location’,’South’)
162 legend(’boxoff’)
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The following uotpot figures are generated from the zts script.
Figure A.4. The initial string before initiation of the script.
176
Figure A.5. The final string after completion of the script.
177




B.1 Sample Code for selecting centers
The exploration of the protein interior space via TAMD results in a dense cloud of ligand
coordinates (section 2.4.1.1). I used the following script for selecting the centers within the
protein matrix for mean-force calculation.
1 #################################################################
2 ## Point Clustering (Version 3.0) ##
3 ## This script has been only tested for selecting positions of ##
4 ## ligand covering various areas of the protein by a distance ##
5 ## cut-off value. These centers could be used for mean-force ##
6 ## calculation described in chapter 3. ##
7 #################################################################
8
9 set outfile [open ox.dat w];
10 set nf [molinfo top get numframes]
11 set sel [atomselect top "segname OX"]
12 set com_list {}
13 set refcom {}
14 set newcom {}
15 set com_list2 {}
16 set chosen_frames {}
17 proc lremove {list match} {
18 set idx_list [lsearch -all $list $match]
19 foreach idx [lreverse $idx_list] {




24 for {set i 0 } { $i < $nf } { incr i } {
25 set temp_ox {}
26 $sel frame $i
27 set com_ox [measure center $sel weight mass]
28 lappend temp_ox $com_ox
29 lappend com_list $temp_ox
30 }
31 set com_list2 $com_list
32 set size [llength $com_list]
33 set uni {}
34 set k 1
35 set g 1
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36 puts "Initial total COM: $size "
37 set refcom0 {}
38 set newcom5 {}
39 set new2 {}
40 set refcom0 [lindex $com_list 0]
41 lappend uni $refcom0
42 set ref [lindex $refcom0 0]
43 for {set i 1} { $i < [llength $com_list] } { incr i} {
44 set newcom5 [lindex $com_list $i]
45 set new5 [lindex $newcom5 0]
46 set dd [vecdist $new5 $ref]
47 set g 1
48 if { $dd >= 2.5 } {
49 for {set j 0 } { $j < [llength $uni] } { incr j } {
50 set newcom [lindex $uni $j]
51 set s1 [lsearch -all $com_list $newcom]
52 set new2 [lindex $com_list $s1]
53 set new3 [lindex $new2 0]
54 set dddd [vecdist $new5 $new3]
55 if {$dddd > 0 && $dddd < 3.0 } {
56 set g 0 }
57 }
58 if {$g == 1 } {
59 lappend uni $newcom5
60 set refcom0 $newcom5




65 set refcom1 {}
66 set newcom1 {}
67 # for {set r 0 } { $r < [llength $uni] } { incr r } {
68 # set refcom [lindex $uni $r]
69 # set ref [lindex $refcom 0]
70 # for {set k 0} { $k < [llength $uni] } { incr k } {
71 # set newcom [lindex $uni $k]
72 # set new [lindex $newcom 0]
73 # set ddd [vecdist $new $ref]
74 # if {$ddd < 2.51 && $ddd > 0} {
75 # puts "$r $k $ddd \ " }
76 # }
77 # }
78 #set chosen_frames {}
79 draw delete all
80 for {set i 0 } { $i < [llength $uni] } { incr i } {
81 set refcom1 [lindex $uni $i]
82 set s [lsearch -exact $com_list2 $refcom1]
83 lappend chosen_frames $s
84 puts $outfile "$s $refcom1 \ "
85 set ref [lindex $refcom1 0]
86 # puts "$ref"
87 draw color red
88 draw sphere $ref radius 0.5
89 # animate write pdb ${s}.pdb beg $s end $s
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90 }
91 set size [llength $uni]
92 puts "Final total COM: $size "
93 close $outfile
94 puts "frames chosen are: $chosen_frames"
The following typical output data file shows how coordinates of the centers are shown in
“ox.dat”.
1 0 7.1351 85.4152 76.9845
2 156 7.0427 82.6447 75.2778
3 191 4.10029 81.7408 76.387
4 206 1.98574 82.4221 74.2702
5 211 -0.356568 84.6737 74.5849
6 247 2.60047 84.1852 71.0736
7 290 5.08997 82.5053 72.0253
8 338 3.94729 86.4296 74.0891
9 733 7.2174 85.6596 73.1914
10 2580 5.02837 87.7864 76.841
11 2728 -0.823304 81.2919 75.0923
12 2762 -1.12958 82.0141 71.8188
13 5280 -2.86603 82.4115 69.3282
14 5372 3.35803 79.5987 72.587
15 5414 2.97107 79.2217 77.5833
16 6315 7.91289 82.0163 71.0953
17 6363 10.2266 84.9011 76.4793
18 7211 -3.16977 85.1162 73.4462
19 7358 11.4153 85.3845 71.0905
20 7455 9.24379 87.798 71.7588
21 7903 8.47505 88.5709 77.1181
22 7909 6.31513 88.2072 79.6226
23 9779 -0.598473 83.0012 67.4441
24 10410 9.0344 85.1746 79.3655
25 12211 -5.08412 84.4729 70.8897
26 12220 -3.59797 87.3056 70.978
27 12290 -0.088821 86.7477 72.3108
28 12298 -3.06006 89.8068 72.6884
29 12341 -3.01366 89.6928 75.7531
30 12480 -5.77485 88.7539 68.2326
31 12898 12.6081 85.8561 78.2051
32 13693 1.18522 78.7637 75.204
33 14215 -0.810877 87.7092 75.1475
34 14429 -6.34716 88.7802 73.7231
35 14447 -8.36029 89.9232 70.7358
36 14480 -10.123 92.6985 69.7389
37 14486 -7.82316 91.0486 67.4253
38 14912 7.04897 82.8316 79.1575
39 15000 -2.01535 78.1745 82.9957
40 15002 0.43548 77.3959 81.3736
41 15071 -1.03908 76.8404 78.4965
42 15157 2.13227 74.1964 82.2809
43 15195 -0.71501 73.5197 83.2207
44 15225 -4.70946 77.7479 84.7837
45 15326 -1.78592 78.8838 86.0158
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46 15343 0.56893 77.6384 88.2306
47 15362 3.55881 77.3868 88.7032
48 15709 -3.18309 78.6372 79.9735
49 15839 1.5584 78.7178 84.0627
50 15860 2.89458 76.0987 86.0084
51 15993 -0.0992651 75.958 85.5896
52 16422 3.42125 78.6341 81.5722
53 16782 -1.61375 76.4536 74.5981
54 16789 1.50726 75.1149 73.5906
55 17207 -5.92617 79.5784 79.0649
56 17214 -7.95139 80.7052 80.9874
57 17268 -8.08941 77.5371 77.6604
58 17340 -5.80022 80.3998 83.165
59 17725 -6.94952 77.566 82.4301
60 19413 -4.72763 78.4518 88.2021
61 19475 -4.35415 80.6275 85.8048
62 19979 -6.52378 83.3175 83.6854
63 20307 -5.43351 82.4185 80.2318
64 20409 -7.71119 80.8883 85.9511
65 20695 -3.38147 73.8707 84.8278
66 20705 -4.76022 75.2638 82.0215
67 20914 0.252021 77.2081 91.2985
68 21256 -5.5409 76.0863 78.6958
69 21746 -0.272053 78.0284 71.8256
70 21756 -1.79839 75.0986 71.1601
71 21776 -0.0915667 77.1357 68.8906
72 21790 2.99189 75.6838 70.3448
73 24403 0.986457 80.5307 87.4241
74 25209 -9.63618 76.6114 80.1423
75 25221 -9.37912 79.2163 83.6128
76 25227 -9.65463 75.566 84.4429
77 25708 -9.59972 80.313 77.5849
78 25711 -12.2069 81.7913 78.0756
79 25718 -10.143 84.0751 78.0835
80 25762 -13.0779 82.0587 74.9921
81 25779 -12.054 84.5249 73.4851
82 25788 -9.05334 83.682 73.6551
83 25807 -7.94901 85.7751 76.29
84 25828 -7.8868 85.6192 79.4377
85 25841 -7.32407 87.5269 82.0868
86 25850 -4.27308 86.5287 81.0078
87 25868 -3.79369 84.1495 78.3871
88 25898 -1.34692 84.6306 80.4013
89 26697 -5.72582 72.2962 83.6206
90 27184 -1.77601 70.1802 82.7375
91 27280 -10.2919 78.37 75.3051
92 27284 -8.37523 75.7658 75.0296
93 27292 -7.24866 73.1177 76.4577
94 27673 -2.45819 74.3541 77.3623
95 27725 -11.6236 75.728 76.2037
96 27746 -8.19481 76.1339 71.4791
97 27756 -9.86193 73.1767 70.6255
98 27775 -9.97434 74.6542 67.6926
99 27783 -8.19527 73.6674 64.7872
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100 27790 -5.55023 72.5659 66.2084
101 27807 -6.28999 75.873 66.0208
102 27842 -5.88627 78.481 67.5104
103 27860 -3.21747 75.8665 68.5378
104 28443 0.903283 74.8342 89.3632
105 29289 -4.8102 74.0598 74.455
106 29368 0.854802 73.6352 70.882
107 29711 -12.2702 77.3339 82.1299
108 29915 -1.24518 79.9476 90.7084
109 30000 14.9703 93.7883 94.715
110 30001 13.7146 90.0929 93.2049
111 30094 12.8017 89.2761 90.1279
112 30173 11.2603 87.7012 88.0044
113 30210 8.00348 88.852 88.0841
114 30484 15.8416 90.9543 91.1764
115 30727 8.20999 85.9679 89.5407
116 31210 10.3387 90.5778 91.4926
117 33805 18.1487 93.1588 90.0519
118 33925 16.4352 91.4383 87.9478
119 34363 15.0601 87.0594 89.7112
120 34412 10.7545 86.6302 91.5772
121 35210 5.08066 90.0703 88.5942
122 35228 5.18456 87.7336 90.5426
123 35341 5.45502 90.6981 91.5825
124 35396 11.006 86.8117 94.9752
125 35430 10.7992 83.8352 94.1879
126 35746 13.8828 92.6993 89.1085
127 36407 13.4493 87.3994 96.8475
128 36478 10.896 89.8585 94.5575
129 36846 7.85948 87.7463 92.0737
130 37360 16.2352 90.8196 94.6945
131 38409 5.73247 88.3188 95.3002
132 38764 9.00363 88.541 85.083
133 39764 5.5124 92.4056 86.5484
134 39831 4.29214 93.023 89.9503
135 40256 4.35224 89.4817 85.5505
136 40264 3.62183 92.2582 83.6031
137 40335 3.44229 94.5511 87.4491
138 41144 17.4094 88.5241 88.3844
139 41281 5.85185 94.4184 84.1123
140 41478 3.05991 95.719 83.5125
141 41784 6.77811 92.354 82.1059
142 41841 5.2955 97.198 86.818
143 41861 8.15189 96.1233 87.371
144 41900 9.87323 98.124 89.372
145 41909 7.75953 96.6024 91.6622
146 41957 6.56776 98.4494 89.3902
147 41979 2.83732 98.934 88.2184
148 42363 11.3277 96.8024 86.7179
149 42822 3.7294 96.8739 90.24
150 42841 5.65124 98.6003 93.25
151 42863 9.12351 99.3475 92.9977
152 42909 5.87241 98.6047 96.8971
153 42930 3.9719 96.0604 96.4887
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154 42978 2.7325 99.0494 96.0453
155 43114 14.4279 88.3379 87.025
156 43484 4.96169 99.4478 84.0545
157 43498 4.03853 100.659 81.1839
158 44184 10.2113 84.003 87.8207
159 45000 14.74 84.0507 71.6804
160 45043 15.5001 80.96 73.3332
161 45192 12.5429 82.7204 73.2925
162 45715 9.96288 91.3777 71.2315
163 45746 11.4495 91.1158 67.7748
164 45763 11.745 89.9624 64.6253
165 45786 14.1821 91.7683 64.7346
166 45842 16.8772 93.6042 66.9184
167 45850 19.6844 92.9532 65.7277
168 45863 23.0417 92.0531 66.1996
169 45909 20.4208 92.3354 68.8185
170 45925 19.267 90.9382 62.6974
171 45986 19.4953 89.1783 59.7148
172 46144 17.5247 83.8643 72.8341
173 46219 11.9341 86.5122 74.0527
174 46340 11.7277 88.4249 76.5302
175 46746 12.1384 88.1819 69.2111
176 46903 16.7171 86.4872 71.1689
177 46909 15.2958 83.7865 75.7012
178 47838 14.3498 92.3488 68.7978
179 47854 17.0665 95.7922 69.8577
180 47902 23.1192 94.49 68.4883
181 48275 8.21782 89.1538 68.355
182 48328 10.3978 93.2381 73.7507
183 48342 12.5865 94.9603 75.1012
184 48379 10.2766 97.3114 75.1652
185 48398 13.2073 98.7562 73.1421
186 48426 10.3022 98.1995 71.8297
187 48479 9.54532 100.94 70.8073
188 49447 6.80723 92.3623 71.7377
189 49477 6.47318 95.6562 69.599
190 49490 6.53173 93.1849 67.7629
191 50379 8.48999 94.4875 75.961
192 50413 9.67346 96.4316 78.0274
193 51789 14.6155 88.7566 64.1894
194 51933 22.5554 89.5591 64.312
195 51976 20.7023 93.6561 62.5712
196 51982 20.8669 92.2675 59.6872
197 51991 24.056 91.9896 58.2814
198 52937 25.4646 89.6201 63.4884
199 52946 23.3845 89.8324 61.1029
200 53280 8.56636 90.1671 65.3873
201 53404 26.2739 94.7062 67.5974
202 53409 25.4519 93.1284 70.672
203 53418 27.5991 91.6226 68.9346
204 53425 27.3047 91.3423 65.4401
205 53436 30.092 90.6348 66.684
206 53479 24.8038 92.7822 63.0657
207 53486 26.4353 90.0741 60.2316
184
208 53488 28.9856 91.4444 61.1333
209 53768 4.02202 93.1006 65.746
210 53780 5.22809 94.5092 62.8748
211 53786 8.54911 92.727 62.9972
212 53981 12.162 93.0452 62.5108
213 53990 15.1121 93.2763 61.6849
214 54898 15.766 95.4148 73.7298
215 55225 4.85793 90.9854 74.1641
216 55282 5.23304 91.5737 61.9299
217 55315 9.49886 91.8281 59.9016
218 55324 9.10584 94.7849 60.7624
219 55364 14.395 95.5462 59.7567
220 55368 13.4163 92.4716 58.5636
221 55416 14.0593 96.0322 62.7901
222 55436 17.6941 92.8711 59.3607
223 55455 14.9974 95.8191 56.6137
224 55479 13.0262 98.1597 55.0293
225 55484 15.4991 97.7228 52.1518
226 55901 30.4263 93.1498 68.4496
227 55909 29.3813 92.8719 72.0127
228 55928 29.0693 87.7593 67.7686
229 55936 32.1188 88.4597 67.9656
230 55961 28.8597 88.6311 63.7859
231 56284 13.5151 90.3631 61.86
232 56409 21.7956 92.8813 72.0858
233 56414 22.1254 89.876 72.2056
234 56436 26.3882 88.2905 73.2902
235 56814 14.383 89.6632 67.1647
236 57307 17.5176 95.0115 63.7838
237 57399 26.146 88.6418 66.6097
238 57417 28.2311 89.2433 70.6998
239 57428 29.1795 85.471 65.3813
240 57486 28.141 89.0276 57.6636
241 57491 31.7401 89.1265 57.1754
242 57998 28.0457 94.3463 59.5314
243 58268 6.65527 87.1762 65.82
244 58282 7.1354 87.3422 62.0094
245 58288 10.2792 87.2154 61.7247
246 58658 16.6952 78.4282 72.2514
247 58845 12.1338 91.8763 76.0824
248 58909 11.175 92.7272 79.4656
249 58978 7.36898 95.4803 73.0651
250 59398 17.319 96.574 60.7571
251 59403 15.088 98.6497 59.2278
252 59498 13.8043 99.6462 50.3247
253 59681 15.3074 75.6769 73.0649
254 59705 15.0263 77.2339 69.612
255 59709 10.3717 76.0132 69.1277
256 59719 11.2703 79.2119 70.0091
257 59746 12.6423 77.4116 65.856
258 59756 9.98813 75.282 63.834
259 59780 9.38158 77.8198 62.2754
260 59792 13.017 74.2403 63.6795
261 59860 14.4586 74.6581 66.5257
185
262 59863 17.9848 75.7387 67.3083
263 59901 20.9957 76.6113 67.212
264 59909 19.9066 75.829 71.1131
265 59923 23.0008 74.4934 68.4037
266 59929 20.7535 72.0209 67.7305
267 59933 23.478 71.2819 69.3446
268 59982 21.2707 74.164 65.1748
269 59988 24.5697 74.6582 65.7611
270 60000 38.6844 93.357 58.0567
271 60051 40.5804 90.8549 59.4269
272 60206 36.4636 94.1357 55.9041
273 60224 35.7699 91.6259 57.8926
274 60335 33.3502 93.5191 59.5877
275 60842 41.1888 93.6283 60.8847
276 61361 42.8916 89.6518 61.5272
277 61898 43.9644 93.3944 62.9925
278 61916 42.7333 92.9752 66.0196
279 61998 44.1118 94.4425 60.1263
280 62185 39.4632 90.513 56.5748
281 62210 33.0591 93.834 56.5127
282 62275 32.1715 94.9969 53.2237
283 62331 31.9768 97.9989 52.5177
284 62342 34.2792 97.4988 54.697
285 63942 45.1992 88.1281 59.5719
286 65184 40.6073 87.745 58.7014
287 65380 41.4359 91.7454 63.3436
288 65411 43.791 89.9484 66.0217
289 65434 46.3555 88.0146 65.0996
290 65496 45.9073 89.4194 62.4605
291 65769 31.1146 95.9421 50.3899
292 65786 33.1677 96.7005 48.1053
293 65807 33.0543 99.5594 49.7603
294 65835 30.7121 101.205 52.7759
295 65862 34.3535 102.983 53.0802
296 65879 32.1505 105.11 54.4152
297 65904 35.169 106.307 52.191
298 65962 33.3459 103.347 50.108
299 65989 33.6168 105.797 47.9588
300 66296 29.2612 98.2719 48.6756
301 66479 31.196 106.126 51.2357
302 66863 43.7688 91.497 59.3224
303 67435 46.751 91.9163 60.9192
304 68226 30.2018 92.3172 56.7756
305 68289 33.6758 94.0451 46.724
306 69682 38.1888 85.831 58.3762
307 69695 36.6053 88.3853 58.8253
308 69726 33.9817 86.5053 58.563
309 69747 36.4678 89.267 55.9564
310 69756 34.3408 87.9183 53.8812
311 69780 34.8667 90.6135 50.9737
312 69868 37.7656 87.2181 53.8966
313 70173 43.2625 86.0259 57.7865
314 70180 41.6479 84.2867 59.6296
315 70185 41.1105 81.6516 58.0926
186
316 70192 38.539 82.9687 59.9469
317 70403 47.4857 91.7645 63.903
318 70448 44.6488 86.6435 62.995
319 70795 31.3777 97.633 45.8635
320 70814 34.0369 99.5849 46.3521
321 70863 39.2573 104.826 52.8019
322 70868 37.1413 103.235 50.4358
323 70898 37.7274 108.135 53.0657
324 70909 37.8061 108.634 56.3451
325 70957 41.1063 108.549 52.984
326 70980 37.8221 110.59 50.352
327 70984 40.8773 109.738 49.3581
328 70998 41.1812 111.358 46.4168
329 71350 37.7664 98.379 55.0397
330 71363 41.0268 100.018 56.3091
331 71402 41.8071 102.834 57.3825
332 71409 39.5281 100.932 58.8567
333 71447 38.178 101.423 54.2224
334 71490 41.9839 103.074 52.1858
335 71761 32.4447 85.849 55.9095
336 71780 32.9563 86.7426 51.1933
337 71788 35.7298 85.4724 51.8931
338 72727 33.2821 90.1495 60.4076
339 73279 39.9296 93.0622 54.8181
340 73341 41.8858 96.5049 61.4788
341 73783 34.8629 88.6419 48.3954
342 73805 36.9979 91.4334 48.5528
343 73842 37.7461 92.3367 51.4583
344 73863 40.9231 89.998 51.9206
345 73928 38.3432 83.8801 53.7603
346 73982 39.5339 86.1558 50.199
347 74211 30.6099 95.7225 56.5923
348 74481 29.5939 104.194 49.3172
349 74497 31.176 104.972 46.1078
350 75140 31.6289 91.2614 62.8747
351 75163 31.8913 88.234 62.3119
352 75184 30.2776 86.5345 60.1126
353 75209 24.9201 89.0394 57.7541
354 75263 25.1058 88.8183 54.7432
355 75283 26.023 88.6782 51.6782
356 75306 28.7641 89.7452 53.1146
357 75344 27.118 91.2198 55.5535
358 75482 28.017 93.5992 53.2126
359 75680 27.1967 86.7408 61.4738
360 76291 27.791 86.9577 55.4679
361 77268 22.1058 90.08 56.9053
362 78775 23.7425 91.7425 53.4331
363 78878 27.1233 94.1834 56.4755
364 80256 22.2289 88.7297 50.1237
365 80275 23.4285 90.5491 47.7484
366 80287 26.6141 90.1341 45.7716
367 80299 25.8931 92.7881 47.8424
368 80335 26.3547 94.8723 50.3131
369 80364 29.5411 92.3513 50.1328
187
370 80368 28.3792 89.5369 49.2271
371 80488 29.854 90.7421 45.0148
372 80498 29.2553 92.4854 42.3315
373 80833 26.2475 91.4852 50.5396
374 81256 21.7263 89.1577 53.3164
375 81684 27.6699 83.8427 62.7429
376 81698 24.4008 86.3436 62.5116
377 81727 22.2985 85.8972 59.6308
378 81737 23.4906 86.0971 56.6518
379 81756 22.3084 86.1951 53.8775
380 81787 24.4573 87.2692 48.6541
381 82184 27.9787 84.4605 58.4956
382 82536 28.7468 93.8865 63.0177
383 82860 30.8261 92.1178 53.6098
384 82991 28.1043 95.5177 47.2876
385 83830 27.5138 96.6518 53.3359
386 85656 30.5137 82.9544 59.3211
387 85681 27.7306 81.0812 59.3852
388 85684 28.3489 78.6527 57.3693
389 85692 24.4962 81.004 58.2003
390 85703 22.5304 83.2718 55.9334
391 85710 19.2534 86.5151 54.5126
392 85728 19.5134 84.8532 57.4599
393 85756 22.5055 85.1964 49.706
394 85776 21.2651 86.4879 46.9104
395 85781 23.2734 87.9498 45.036
396 85787 26.1244 86.9024 45.2619
397 86211 18.7137 90.3395 55.4939
398 86248 21.6722 91.7633 50.1848
399 86261 18.7958 89.0472 49.5443
400 86275 19.4712 91.1445 46.6483
401 86789 27.9465 86.0356 47.6391
402 87198 25.0303 84.5905 59.6473
403 87484 28.0525 89.3096 43.0765
404 89216 20.5036 92.6082 53.955
405 89278 23.5655 92.4472 44.774
406 89444 32.0623 93.0243 44.3804
407 89472 30.3518 95.8711 43.0343
408 89486 30.9222 94.878 40.2397
409 89491 33.5377 96.9462 40.2731
410 95673 26.0745 84.3853 55.9713
411 95710 16.4406 87.8914 53.3631
412 95728 17.0207 87.4968 56.4494
413 96755 19.8108 86.2553 50.7753
414 96867 28.255 86.5206 52.0834
415 96934 28.6661 82.782 54.0303
416 96946 26.1825 83.055 52.1309
417 99312 23.0765 93.9322 47.9197
418 100863 33.8043 91.3473 54.4324
419 102715 15.546 90.6606 55.0112
420 102999 26.6686 93.332 44.0585
421 103270 17.4372 87.3008 47.2752
422 103279 18.4729 88.8681 44.6482
423 103990 31.9126 89.9914 50.3358
188
424 104498 29.9696 101.218 47.708
425 105000 44.2066 102.155 65.9959
426 105139 46.9223 101 67.1848
427 105280 44.9848 104.24 63.2626
428 105305 46.4989 104.231 66.1887
429 105338 48.4888 104.2 68.8257
430 105360 50.259 101.593 70.9061
431 105401 53.5728 101.516 69.9864
432 105484 51.8713 102.77 67.6231
433 105715 43.7239 105.624 66.0976
434 106409 46.0492 102.293 70.0835
435 107410 52.7777 101.977 72.9777
436 107844 45.8206 106.034 68.8815
437 107916 48.8054 103.458 72.9513
438 108710 41.6658 104.541 63.6906
439 109182 42.9229 99.6262 64.6816
440 110403 53.56 104.567 69.5585
441 110498 51.4674 106.214 66.2446
442 110786 47.7289 103.485 62.0441
443 110882 51.3412 105.055 71.9384
444 110907 55.3443 104.288 72.542
445 111435 51.591 99.148 69.6598
446 112595 46.1796 100.609 64.0389
447 113291 49.2123 102.651 65.0806
448 113340 51.7085 107.21 69.7235
449 113363 56.0926 106.964 71.016
450 113413 56.4933 107.746 74.4604
451 113436 58.4697 105.03 72.1628
452 113486 57.6742 105.415 68.7294
453 113497 59.9748 106.569 66.8707
454 115156 44.6561 98.4349 67.1681
455 115215 40.2773 107.724 62.7579
456 115247 40.8529 109.301 59.7641
457 115278 40.1412 111.03 55.7638
458 115286 44.2274 110.141 55.9517
459 115307 45.2747 113.085 56.3029
460 115321 46.9275 110.435 57.4536
461 115335 46.296 114.24 58.902
462 115341 48.9619 114.711 60.617
463 115359 52.1751 114.422 60.0674
464 115363 55.9925 113.145 61.1176
465 115368 54.4061 112.42 58.598
466 115409 56.4225 113.227 64.1421
467 115424 58.6723 112.289 62.1732
468 115489 58.8803 113.656 59.4195
469 115498 58.2396 114.77 56.6617
470 115863 56.5037 102.417 69.5209
471 115936 56.2888 100.337 72.3219
472 115987 54.6659 104.268 65.9115
473 116256 40.458 106.984 56.697
474 116286 43.6556 108.904 51.4399
475 116306 44.8257 111.86 53.4335
476 116331 42.1358 113.592 55.4481
477 116404 49.1075 116.275 57.7059
189
478 116431 48.8825 112.614 56.3765
479 116480 44.1612 115.262 53.4978
480 116488 47.5714 115.898 53.7411
481 116498 46.105 116.354 50.7057
482 116907 56.4768 102.224 75.5882
483 116917 53.3798 101.624 77.1346
484 116933 55.6788 98.0079 74.7437
485 117291 45.3159 107.445 54.0051
486 117402 55.4575 116.421 61.1546
487 117409 53.7218 116.586 64.2046
488 117475 53.6401 116.47 58.2615
489 117486 55.2147 115.765 55.3992
490 117692 40.9907 102.819 66.2049
491 117781 40.5898 112.339 52.5721
492 117835 44.0065 115.856 56.4589
493 117854 47.5962 118.041 59.7813
494 117974 51.5467 117.787 56.4117
495 117984 52.5634 117.759 53.5008
496 118498 55.8243 117.147 52.3829
497 118913 50.6577 114.306 63.1101
498 118951 52.1204 113.555 56.9154
499 119238 41.9957 106.32 60.373
500 119315 47.7193 110.454 54.411
501 119418 50.7962 111.673 59.2568
502 119424 51.6589 110.281 56.6445
503 119480 50.1562 112.779 53.4196
504 119486 52.7088 111.05 51.8936
505 119912 53.4162 110.944 62.1228
506 119933 55.3974 108.84 58.2424
507 119959 54.362 111.674 55.6412
508 120000 18.953 79.5523 82.011
509 120002 22.0036 78.7428 81.2804
510 120069 20.7699 81.1297 79.2364
511 120211 16.4911 81.7329 80.2903
512 120262 19.3688 79.6948 76.9109
513 120279 20.4945 79.3009 73.6495
514 120291 22.3662 77.039 74.3727
515 120376 18.1417 76.7232 75.4285
516 120413 20.1691 77.3978 78.8793
517 120745 24.1418 80.8811 78.6827
518 120764 24.1967 82.5052 74.7373
519 120787 26.9023 83.7686 73.6383
520 120835 24.9283 86.3467 75.947
521 120863 30.1305 83.5625 75.3522
522 120909 26.9759 83.226 76.7673
523 121247 18.6207 83.9159 77.0771
524 121296 16.3345 85.7534 79.4698
525 121307 18.2223 87.7678 80.7654
526 121363 18.6982 84.5049 81.91
527 121417 13.9186 85.9697 81.5082
528 121478 15.4563 88.902 80.3228
529 121658 24.7281 76.6211 80.3658
530 122141 26.3983 79.405 80.9773
531 122158 27.5543 74.3727 80.4158
190
532 122166 25.2587 73.7715 82.4485
533 122182 23.7861 70.7096 81.3516
534 122208 22.0043 74.8598 79.6791
535 122264 24.6848 78.0655 77.7256
536 122288 28.9554 80.6778 75.2217
537 122292 28.6257 78.7502 78.3209
538 122338 28.9001 81.2923 81.5429
539 122362 31.9645 81.8943 82.187
540 122368 31.4314 81.0189 79.1994
541 122415 30.2304 82.7532 84.5578
542 122728 21.3261 77.1544 83.7643
543 122979 23.3961 85.3197 73.353
544 123673 25.2833 72.7584 78.9825
545 123762 27.3629 73.5829 76.7484
546 123780 28.9096 74.0266 74.0836
547 123786 32.271 73.2042 73.8527
548 123802 31.5367 74.1317 76.6624
549 123807 34.3934 76.9684 76.02
550 123821 34.7419 73.5767 75.8454
551 123830 35.1875 76.3217 79.1187
552 123841 36.7071 77.5257 82.0445
553 123860 40.0247 75.6943 81.6668
554 123863 42.9344 77.7425 82.8337
555 123882 38.4553 76.3057 84.7259
556 123909 42.9115 76.3875 87.5331
557 123924 44.2058 74.7622 85.13
558 123986 43.7521 76.3962 80.1336
559 124330 24.1933 81.1404 82.9413
560 124680 19.6266 75.5897 81.6119
561 124696 16.6151 74.8446 80.9911
562 124711 13.579 75.8572 79.2193
563 124727 16.9325 72.2923 82.6776
564 124752 19.101 74.1719 78.2375
565 124782 18.4213 72.7819 75.5622
566 124860 25.1572 76.5968 83.72
567 124937 28.2361 75.8027 83.1322
568 125195 22.5192 73.8388 83.887
569 125214 18.5924 79.3364 85.1297
570 125227 20.1638 75.3789 86.5236
571 125290 29.8896 76.735 80.6465
572 125363 35.3671 83.436 83.2209
573 125409 34.4127 84.1936 86.5397
574 125431 36.9498 80.4721 83.5972
575 125436 39.9858 80.5769 84.7838
576 125482 36.3664 80.8938 80.0141
577 125488 39.2943 80.0475 80.7649
578 125863 31.574 76.7378 84.1932
579 125899 29.6274 75.4902 86.2952
580 125910 31.4705 75.4849 89.0238
581 125925 31.3491 72.6293 85.5569
582 125936 34.4816 72.0094 86.588
583 126247 20.8972 82.2915 75.8689
584 126405 31.6317 83.0449 72.5863
585 126411 32.6013 82.2587 76.5508
191
586 126490 34.9999 82.7893 70.7637
587 126842 19.466 89.532 82.8651
588 126881 17.3827 91.0188 85.0443
589 126980 15.8769 91.2212 82.2961
590 127989 35.2254 83.8848 76.1612
591 128215 16.1023 78.0534 82.8708
592 128228 18.0093 73.6495 85.3294
593 128290 27.0191 73.262 84.9973
594 128306 27.2804 77.4332 86.154
595 128327 27.2788 77.0475 89.2301
596 128335 25.3414 78.6977 90.902
597 128338 28.509 79.2378 90.9366
598 128345 28.0691 76.9534 93.5888
599 128360 31.0288 74.3423 93.508
600 128363 34.8596 76.1697 92.9075
601 128399 33.7218 75.6123 96.1379
602 128410 34.9001 76.4598 99.0427
603 128433 34.5249 72.2692 97.4436
604 128470 33.0866 72.1102 94.0482
605 130184 23.9439 67.4599 80.3345
606 130196 20.5191 70.1337 82.3105
607 130225 18.3102 73.7099 88.8235
608 130236 21.5675 72.7104 87.3349
609 130341 23.4984 79.7731 86.0651
610 130370 31.2862 78.1645 86.9037
611 130410 31.2183 78.2889 92.1407
612 130427 28.3307 73.3692 89.2716
613 130436 31.7829 72.4825 90.599
614 130470 29.0479 70.5954 87.9195
615 130789 30.8362 76.9803 75.9241
616 130892 32.827 84.1408 79.9812
617 130902 35.9437 83.8916 79.9616
618 130999 34.5735 85.0187 73.0541
619 131409 30.2056 75.3662 97.1366
620 131430 29.8995 71.53 94.1349
621 131491 33.2826 74.8288 86.5458
622 131842 28.7526 88.2128 77.2808
623 131863 32.8883 89.4595 77.9321
624 131878 29.828 91.062 78.0509
625 131903 33.1767 93.5581 78.075
626 131909 31.6412 90.2136 81.2517
627 131982 31.6441 92.1283 75.5176
628 131989 33.9699 94.0072 74.7202
629 132403 37.0119 85.9903 85.4499
630 132413 35.8241 82.8704 88.8553
631 132478 33.2338 85.566 83.3277
632 132711 15.5395 78.4889 75.8464
633 132780 19.6392 79.171 70.6692
634 132786 23.2614 77.2184 70.4608
635 132825 24.7563 74.6535 71.2111
636 132842 26.8295 77.4298 71.8677
637 132858 28.6612 73.9001 70.5185
638 132864 32.6014 72.8171 69.7769
639 132876 29.6448 71.5821 72.3498
192
640 132901 35.0738 71.6998 73.0027
641 132912 33.8484 70.8564 78.6322
642 132928 33.846 69.2363 74.2766
643 132935 36.2367 67.8181 73.0238
644 132963 32.5181 69.6903 71.4375
645 132986 33.3601 71.0312 66.2788
646 132991 36.2441 71.9441 66.5981
647 133490 32.3849 75.0382 81.3756
648 133860 29.6136 85.0134 78.0958
649 133935 31.7834 86.4579 75.9626
650 133997 31.7782 88.4073 72.9392
651 134203 21.1163 69.4115 79.3805
652 134209 17.7349 69.9137 77.0093
653 134233 21.1766 70.9923 74.8239
654 134236 20.119 67.5346 75.4493
655 134246 20.4907 71.618 70.9707
656 134256 18.6703 69.1948 69.2343
657 134276 19.3189 70.4019 65.1386
658 134280 19.5323 72.7602 62.9868
659 134286 23.258 71.6708 62.8961
660 134290 25.2224 69.6034 63.8868
661 134316 26.5619 73.0335 64.0945
662 134329 26.2331 74.3662 68.2771
663 134368 29.7235 72.2161 67.4427
664 134403 33.6404 76.2365 70.2513
665 134481 31.6346 74.6404 66.2478
666 134497 34.7738 74.1346 64.0088
667 134711 15.1197 72.1864 76.9903
668 135000 29.0459 89.6405 88.3355
669 135017 29.7089 89.4147 85.4052
670 135139 32.7202 88.5042 84.8918
671 135205 28.043 90.6592 83.1813
672 135211 24.9868 89.9837 83.7963
673 135228 25.4922 88.3592 86.6472
674 135256 26.4729 87.4144 82.9137
675 135330 31.7874 91.4274 84.2028
676 135407 34.1534 88.9165 87.6539
677 136354 25.9137 91.697 86.5181
678 137848 31.1939 91.7012 88.9097
679 137982 30.8762 93.9244 86.8683
680 138307 35.0116 90.6104 81.8309
681 138338 37.7309 92.0036 82.0862
682 138350 39.5242 91.7616 84.7472
683 138363 43.184 91.5402 85.3436
684 138407 43.5204 92.8336 88.3856
685 138433 44.2816 89.5986 87.8424
686 138835 34.7847 91.8395 84.6473
687 138989 45.5002 93.1503 84.029
688 139335 23.6202 90.1418 88.4485
689 139863 37.5877 89.3288 87.1202
690 139899 36.5508 88.6826 90.3456
691 141355 40.2376 93.3599 87.6434
692 141377 41.1722 90.3503 87.6322
693 141410 44.0243 93.2672 91.3458
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694 141498 42.7751 93.6531 82.4144
695 141757 28.7347 88.4752 81.1797
696 141790 33.7175 88.0714 80.6796
697 141862 35.7372 88.9865 84.4535
698 141925 39.7277 88.9495 83.0981
699 142663 30.5177 86.0296 85.0819
700 142928 23.219 86.4031 88.1165
701 143182 24.0513 85.4065 82.8477
702 143209 22.4031 88.9085 81.5483
703 143486 42.0706 90.5368 81.0036
704 143898 46.8342 92.0132 87.1536
705 143913 47.1151 91.2019 90.4712
706 143930 47.3199 89.0836 87.9926
707 143983 47.3622 90.4546 84.2808
708 145215 25.2176 92.9834 81.6979
709 145256 25.7349 90.0135 80.5335
710 145718 26.9247 95.6636 82.1338
711 145732 27.4853 94.4994 85.8176
712 145796 25.755 97.642 86.5393
713 145803 27.8665 98.5886 88.6297
714 145838 30.2117 101.078 88.9476
715 145842 31.9797 101.073 91.4798
716 145860 33.921 97.318 92.6079
717 145863 37.0564 99.8205 92.4365
718 145868 34.9227 99.1155 90.3953
719 145879 34.1388 99.6864 95.04
720 145912 36.8513 99.2215 97.1264
721 145933 37.2424 95.258 95.125
722 146981 37.8177 90.7886 79.0639
723 147211 22.577 92.0831 85.8736
724 147220 25.0907 94.5315 88.0473
725 147260 28.3461 97.4529 85.0337
726 147278 29.0675 99.9565 82.6742
727 147288 32.2775 99.0437 81.693
728 147303 32.9286 100.165 84.7108
729 147328 35.0559 100.55 87.11
730 147341 34.8769 103.375 88.5201
731 147358 38.4842 103.808 88.4414
732 147363 42.315 102.255 89.2497
733 147368 40.8679 102.31 86.4285
734 147403 43.6443 105.568 88.9804
735 147409 42.581 103.882 92.0858
736 147436 45.7118 102.463 90.1809
737 147480 40.4706 105.29 86.2957
738 147487 42.8443 104.313 84.6272
739 147768 24.0576 95.2447 84.9896
740 147845 29.6293 98.7402 91.9923
741 148737 24.1935 89.0342 78.1453
742 149403 37.4235 91.9942 89.381
743 149412 37.3978 89.5144 93.4226
744 149722 21.1081 84.8307 84.5977
745 149791 26.9624 84.7207 84.4126
746 149841 27.9464 86.7248 87.2188
747 150063 0.773091 91.053 82.0184
194
748 150093 2.78027 88.8576 81.3657
749 150290 5.62595 87.6153 82.5326
750 150694 -1.59979 89.6136 83.316
751 150706 -1.58749 92.386 80.4727
752 150722 -3.79459 94.4117 80.688
753 150746 -3.06832 93.9142 77.109
754 151210 -4.94726 91.2632 81.5575
755 151255 -5.007 91.3878 78.4521
756 151279 -5.51102 93.1721 74.7199
757 151711 -7.35783 93.4426 80.0594
758 151788 -3.56995 92.8891 72.2841
759 151853 -4.84338 96.8489 76.031
760 151898 -2.82231 96.5366 78.6331
761 151915 -3.53869 97.7547 81.6842
762 153756 -2.86001 89.5364 79.9348
763 153873 1.45289 88.9699 84.4974
764 153965 2.90268 86.5006 85.5496
765 155780 -5.32016 96.5822 72.4123
766 155858 -0.278967 98.1172 79.0824
767 155907 0.632117 99.978 81.2631
768 155912 0.124685 99.5026 84.2533
769 155979 -4.19098 100.385 80.3043
770 155998 -2.18842 100.639 78.08
771 157182 -0.324432 87.8975 80.9699
772 157261 -7.98004 92.2618 76.571
773 157278 -7.37256 93.7743 72.3892
774 157382 -5.95177 95.9453 79.1129
775 157480 -7.26707 99.9589 79.0237
776 157980 -8.6012 97.1406 73.1437
777 160455 -2.64491 100.738 83.1272
778 160658 3.53484 85.3781 82.1067
779 160904 1.71756 100.823 78.4633
780 160998 -0.214703 101.841 76.1668
781 161778 -6.92091 96.2931 69.8813
782 161784 -5.34655 93.6329 69.0403
783 161814 -2.60049 95.9501 70.4629
784 161841 -2.7855 98.0858 73.5275
785 161861 0.000899255 96.329 72.6689
786 161903 2.01595 98.0474 71.1514
787 161978 -1.8836 98.9224 70.3448
788 161991 0.512871 100.356 69.2235
789 161998 -2.46085 100.421 67.7863
790 163508 1.26684 93.6631 85.2003
791 163717 -9.09902 95.9062 79.3308
792 163727 -10.1451 93.1266 82.2272
793 163766 -9.73341 95.3182 75.8675
794 164397 4.59494 100.043 72.5609
795 164409 4.42454 99.5809 75.6508
796 164484 3.50253 101.479 67.3089
797 164991 2.71349 102.817 74.909
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APPENDIX C
NAMD SAMPLE INPUT FILES
C.1 Sample NAMD configuration file for TAMD simulation
The following script is for a TAMD simulation using the NAMD software.
1 #NAMD CONFIG FILE FOR TAMD runs
2 # input
3 # set path /export/users/harishv/abc/tamd_dimer_3kt/
































36 # Multiple timestepping
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44 # Periodic Boundary Conditions
45 if {0} {
46 cellBasisVector1 94.549 0. 0.
47 cellBasisVector2 0. 80.798 0.
48 cellBasisVector3 0. 0. 87.958
49 cellOrigin 24.078893661499023 91.66455078125 70.47941589355469
50 }
51 wrapAll on





57 # Temperature control
58 set temperature 310
59 temperature $temperature






66 # external forces







74 #set hvcv /export/users/harishv/hvcv/
75 tclforces on
76 tclforcesscript cfacv_tclforces.tcl
77 set labelPDB label.pdb
78 set cvINP cv.inp
79 set restrINP restr.inp




C.2 Sample NAMD configuration files
In this section, I provide general input scripts for running MD simulations in NAMD using
the NPT ensemble for RGS proteins and human PDE 4.
C.2.1 RGS4 equilibration
1 # equilibration in NPT ensemble run
2 #############################################################
3 ## ADJUSTABLE PARAMETERS ##
4 #############################################################
5 set input ionized_conjugated_1agr95C
6 structure $input.psf
7 coordinates $input.pdb
8 set outputname npt
9 set temperature 310
10 #continuing a run
11 #set inputname npt.restart ;# only need to edit this in one place!
12 #binCoordinates $inputname.coor ;# coordinates from last run (binary)
13 #extendedSystem $inputname.xsc ;# cell dimensions from last run
14 firsttimestep 0
15 #############################################################






















38 # Periodic Boundary Conditions
39 if {1} {
40 cellBasisVector1 89.55800247192383 0. 0.
41 cellBasisVector2 0. 66.03299713134766 0.
42 cellBasisVector3 0. 0. 57.72800064086914









51 # Constant Temperature Control
52 langevin on ;# do langevin dynamics
53 langevinDamping 5 ;# damping coefficient (gamma) of 5/ps
54 langevinTemp $temperature
55 langevinHydrogen off ;# don’t couple langevin bath to hydrogens




















C.2.2 Human PDE 4 equilibration
1 # equilibration in NPT ensemble run
2 #############################################################
3 ## ADJUSTABLE PARAMETERS ##
4 #############################################################
5 set input ionized
6 structure ${input}_pde4ibm.psf
7 coordinates ${input}_pde4ibm.pdb
8 set outputname npt
9 set temperature 300
10 #continuing a run
11 #set inputname npt.restart ;# only need to edit this in one place!
12 #binCoordinates $inputname.coor ;# coordinates from last run (binary)
13 #extendedSystem $inputname.xsc ;# cell dimensions from last run
14 firsttimestep 0
15 #############################################################






















38 # Periodic Boundary Conditions
39 if {1} {
40 cellBasisVector1 80.03099822998047 0 0
41 cellBasisVector2 0 88.6500015258789 0
42 cellBasisVector3 0 0 80.71900177001953
43 cellOrigin 20.97156524658203 6.474047660827637 24.07125473022461
44 }
45 wrapAll on







52 # Constant Temperature Control
53 langevin on ;# do langevin dynamics
54 langevinDamping 5 ;# damping coefficient (gamma) of 5/ps
55 langevinTemp $temperature
56 langevinHydrogen off ;# don’t couple langevin bath to hydrogens
57 # Constant Pressure Control (variable volume)





















LINUX AND BASH SCRIPTS
D.1 Sample code catdcd
Catdcd functions much like the Unix "cat" command: it concatenates DCD files into a single
DCD file. You can also use catdcd to write only selected atoms to the final DCD file. Starting
with version 4.0, CatDCD is now built as part of the VMD Plugin tree, and shares the
same reader/writer with VMD. CatDCD 4.0 can read/write any of the structure/trajectory
formats that are supported by VMD by virtue of the plugin interface1.
1 CatDCD 4.0
2 catdcd -o outputfile [-otype <filetype>] [-i indexfile]
3 [-stype <filetype>] [-s structurefile]
4 [-first firstframe] [-last lastframe] [-stride stride]
5 [-<filetype>] inputfile1 [-<filetype>] inputfile2 ...
6 * EXAMPLES *
7 catdcd -num eq01.dcd eq02.dcd
8 Prints the number of frames in the two DCD files, then the total,
9 then exits.
D.2 Parallel calculations for per residue non-bonded interaction
energy
VMD has an ability for handling analysis with high computational cost using parallel calcu-
lations. The following script distributes analysis task on N number of CPUs on the Cluster.
In my thesis, I used this feature for calculating per residue non-bonded interaction energy
described in chapter 6.
1 ############################################################################
2 # (c) Hossein Mohammadiarani #









10 #SBATCH -N 1
11 #SBATCH --cpus-per-task=24
12 #SBATCH --time 240:00:00







20 module load mpi/openmpi-x86_64
21 module load vmd/vmd-1.9.2-text
22 psf=/mnt/lustre/chem-eng/mm14/120/zar_nematode_resenergy/ionized_pde4zarc.psf
23 dcd=/mnt/lustre/chem-eng/mm14/120/zar_nematode_resenergy/npt_zc.dcd
24 NumCpus=24; # the number of cpus that deployed for calculations
25 totalnf=6000; # the total length of dcd file to be analyzed




30 for j in $(seq 0 $iter )
31 do
32 start=$(( $FramesCpu * $j))
33 end=$(($FramesCpu * ($j+1)-1))
34 srun --exclusive -n 1 -c 1 -s -v vmd -e intermedcalc.vmd -
args $psf $dcd $start $end _out_$j.dat >& analysis_$j.log
&
35 echo "last job number is : $j";






SUPPORTING INFORMATION FOR STUDIES REPORTED
IN CHAPTER 3
This appendix provides additional analyses related to Chapter 3.
E.1 Supplemental Results: Testing the effect of F417Y mutation
Kubas et al. [10] have previously shown that mutating F417Y results in a decrease in the rate
of oxygen diffusion toward the G-site. To demonstrate the effect of this specific mutation
(F417Y) on oxygen diffusion along the MFEP between the Xe-site and the G-site (pathway
1-0 in Fig 3.2), I prepared three systems each for the wildtype (WT) and the mutant protein
that differed in the location of oxygen along the MFEP.
Specifically, three locations of oxygen were chosen (see Fig E.1): one corresponding to
the Xe-site (system 1), another in the proximity of residues F417/Y417 (system 2), and
the third away from the F417/Y419, but toward the G-site (system 3). The WT systems
contained 62,306 atoms and the mutant systems contained 62,307 atoms. All systems were
energy minimized and briefly equilibrated in the NPT ensemble to equilibrate the volumes
of simulation domains. I carried out mean-force calculations using 5-ns long restrained MD
simulations (following the same protocols as for all centers reported in section 2.4.1.1) for
each of the 3 oxygen locations along the same MFEP in the WT and the mutant proteins,
and integrated these mean-forces to obtain the PMFs (Fig E.1c) for oxygen diffusion from
the Xe-site toward the G-site. These results show an increase in the free-energy barrier
of 2.4 kcal/mol for oxygen diffusion along the MFEP from the Xe-site toward the G-site.
Importantly, the location of the barrier is near the side-chain of Y417, and the free-energy
values after crossing this barrier are significantly lower toward the G-site (located near point
3 along the MFEP; see Fig E.1a,b) with respect to the Xe-site (point 1 along the MFEP; see
Fig E.1a,b). The existence of a free-energy barrier for oxygen diffusion along this MFEP in
the mutant protein implies a decreased diffusion rate, as suggested by Kubas et al. [10].
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Figure E.1. The effect of F417Y mutation on the PMFs along the pathway 1-0 (see Fig
3.2) in [FeFe]-hydrogenase. (a and b) Snapshots highlighting the location of the wildtype
F417 residue and the mutant Y417 residue along the pathway 1-0 (yellow curve). Three
points (in the collective variable space) chosen to map the PMF are labeled and depicted
as blue spheres in panel a. The approximate locations of the Xe-site and the G-site are
marked by Xe and G, respectively. The H-cluster in each panel is labeled and highlighted in
a stick representation. (c) The PMF values (kcal/mol) calculated with respect to the first
point are shown for the WT protein by blue filled squares, and for the mutated protein by
black filled squares. The increase in the free-energy value of the second point closest to the
mutated residue is showing a higher energy-barrier of oxygen transition around Y417 toward
the H-cluster in the mutated protein.
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Figure E.2. Energy barriers (kcal/mol) between local minima in the 3D PMF map (Figure
3.2 in the main article). The value on the entry i j is the free energy barrier when going from
local minimum i to local minimum j. The empty cells indicate negligible energy barriers
or minima pairs that are not connected. The G-site and the Xe-site are shown by local
minimum 0, and local minimum 1, respectively (Figure 3.2b).
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Figure E.3. Histogram of the standard deviation of each mean-force over the last 10% for
all centers of O2 in [FeFe]-hydrogenase. The convergence of mean-force values for all centers
are represented as a delta function at the origin.
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Figure E.4. Histogram of the standard deviation of each mean-force over the last 10% of
each mean-force simulation. Data are from mean-force simulations for all 635 unique centers
of CO in [FeFe]-hydrogenase (This figure was created by my co-author Yong Liu [3]).
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Figure E.5. Major energy barriers (kcal/mol) along MFEPs between minima pairs (MFEPs
are shown in Fig. 3.3) . The value on the entry i j is the free energy barrier of the rate-
limiting step from the local minima i to the local minima j (This figure was created by my
co-author Yong Liu [3]).
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Figure E.6. Continuation of major energy barriers (kcal/mol) along MFEPs between min-
ima pairs from Fig E.5 (This figure was created by my co-author Yong Liu [3]).
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APPENDIX F
SUPPORTING INFORMATION FOR STUDIES REPORTED
IN CHAPTER 4
This appendix provides additional figures related to Chapter 4.
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Figure F.1: The traces of root-mean-squared-deviation (RMSD) vs. simulation time (µs) for
4 helices in the α4-α7 helical bundle of RGS4 are shown from two independent simulation
runs (Run1, panel a; Run2, panel b) for complexes of RGS4 with TDZD compounds 1 (cyan
trace), 2 (green trace), and 3 (magenta trace). The black traces show data for an apo-RGS4
simulation from our previous work [13].
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Figure F.2: Same data as in Fig. F.1 are shown for Model 2.
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Figure F.3: The traces of buried surface area (BSA) between the α5-α6 helices and the rest
of RGS4 vs. simulation time (µs) are shown from two independent simulation runs for each
Model (Models 1 and 2). The BSA traces are shown for three TDZD compounds (cyan,
green, and magenta traces) and from a simulation of apo-RGS4 (black traces). The dotted
horizontal line in each panel highlights the BSA-value in the crystal structure of RGS4 (PDB:
1AGR).
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Figure F.4: Snapshots at various time-points for conformational evolution of complexes of
non-TDZD compounds 4 (panel a) and 5 (panel b) with RGS4 (Model 1). In each panel,
snapshots from three independent simulation runs are shown for each compound. Coloring
and labeling schemes are identical to initial states shown in Fig. 4.3.
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Figure F.5: Snapshots at various time-points for conformational evolution of complexes of
non-TDZD compounds 4 (panel a) and 5 (panel b) with RGS4 (Model 2). Coloring and
labeling schemes are similar to Fig. F.4.
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Figure F.6: The traces of buried surface area (BSA) between the α5-α6 helices and the rest of
RGS4 vs. simulation time (µs) are shown from three independent simulation runs for Model
1. The BSA traces are shown for two non-TDZD compounds (magenta and yellow traces)
and from a simulation of apo-RGS4 (black traces). The dotted horizontal line in each panel
highlights the BSA-value in the crystal structure of RGS4 (PDB: 1AGR). The symbols (×)
on the BSA traces mark the locations of time-points in Run3 of each compound (panel c)
after which compounds diffuse out of the binding pocket.
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Figure F.7: The RMSD data similar to Fig. F.1 are shown for non-TDZD compounds 4 and
5 from three independent simulations. The red symbol (×) marks the locations of time-
points in Run3 of each compound after which compounds diffuse out of the binding pocket
(see snapshots in Fig. F.4).
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Figure F.8: The histograms of RMSD-averages computed based upon data from each run in
Fig. F.7 are shown.
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APPENDIX G
SUPPORTING INFORMATION FOR STUDIES REPORTED
IN CHAPTER 5
This appendix provides additional figures related to Chapter 5.
Figure G.1. The traces of root-mean-squared-deviation (RMSD) vs. simulation time (µs)
for (a) RGS4 D90L, (b) RGS8 E84L, and (c) RGS19 L118D.Two independent simulation runs
for each structure are presented, and the wild-type runs are presented from our previous work
[13].
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Figure G.2. The salt-bridge interaction within the α4-α7 bundle of helices in single-cysteine
structures of RGS4, RGS8, and RGS19 from MD simulations and potency of CCG-50014
inhibition of single-cysteine RGS proteins from our previous work [13] (This figure was
created by my co-author Vincent Shaw).
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APPENDIX H
SUPPORTING INFORMATION FOR STUDIES REPORTED
IN CHAPTER 6
This appendix provides additional figures related to Chapter 6.
Figure H.1. The nonbonded interaction energy analysis between residues in the inhibitor
binding pocket of PDE4D and C. elegans PDE4 for the first simulation run. See Fig. 6.1a
and 6.1b for depictions of the binding pocket and the 32 residues analyzed with bound (a)
IBMX, (b) zardaverine, and (c) roflumilast. Amino acid residues in blue text denote residues
that differ between human and C. elegans PDE4 sequences.
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Figure H.2. The nonbonded interaction energy analysis between residues in the inhibitor
binding pocket of PDE4D and C. elegans PDE4 for the second simulation run. (a) IBMX,
(b) zardaverine, and (c) roflumilast. Amino acid residues in blue text denote residues that
differ between human and C. elegans PDE4.
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Figure H.3. Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of Q369/Q282 (red
dashed line, labeled 2) and the O6 oxygen of IBMX bound to human PDE4D or C. elegans
PDE4 obtained from two independent MD simulation runs, (a) run 1 and (b) run 2.
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Figure H.4. Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of Q369/Q282 (red
dashed line, labeled 2) and the O4 oxygen of zardaverine bound to human PDE4D or C.
elegans PDE4 obtained from two independent MD simulation runs, (a) run 1 and (b) run 2.
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Figure H.5. Interatomic distances between C4 atom of F506(human)/O atom on the side
chain of Y253(C. elegans) (blue dashed line, labeled 1) or the Nδ atom of Q369/Q282 (red
dashed line, labeled 2) and the O4 oxygen of roflumilast bound to human PDE4D or C.
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Figure I.1. Shown is the journal cover image [17] related to work described in chapter 4
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